


Covid-19 Literature Update



A CURATED SELECTION AND OVERVIEW OF COVID-19 PUBLICATIONS

Update August 10=7 - August 23, 2020,

Dr. Peter J. Lansberg MD, PhD

Weekly COVID-19 Literature Update

will keep you up-to-date with all recent PubMed publications
categorized by relevant topics

COVID-19 publications - Week 34 2020 712 Publications

PubMed based Covid-19 weekly literature update

For those interested in receiving weekly updates
click [here](#)

For questions and requests for topics to add send an e-mail
lansberg@gmail.com

Reliable on-line resources for Covid 19

[WHO](#)

[Daily dashbord](#)

[Country Guidance](#)

[Travel restriction](#)

[Covid Counter](#)

[Covid forecasts](#)

[CDC](#)

[AHA](#)

[ESC](#)

[EMA](#)

[Evidence EPPI](#)

[Wikipedia](#)

[Cardionerds - COVID-19](#)

[Genomic epidemiology](#)

[Oxygenation Ventilation toolkit](#)

[Cochrane](#)

[BMJ](#)

[The Lancet](#)

[New England Journal of Medicine](#)

[JAMA](#)

[Cell](#)

[Science](#)

[Oxford Universtiy Press](#)

[Cambridge Univeristy Press](#)

[Springer Nature](#)

[Elsevier](#)

[Wiley](#)

[PLOS](#)

[LitCovid NIH-NLM](#)

[SSRN \(Pre-prints\)](#)

[German \(ICU\) bed capacity](#)

[COVID reference \(Steinhauser Verlag\)](#)

[COVID-19 Projections tracker](#)

[AAN - Neurology resources](#)

[COVID-19 resources \(Harvard\)](#)

[COVID-19 resources \(McMasters\)](#)

[COVID-19 resources \(NHLBI\)](#)

[COVID-19 resources \(MEDSCAPE\)](#)

[COVID-19 Diabetes \(JDRF\)](#)

[COVID-19 TELEMEDICINE \(BMJ\)](#)

[Global Causes of death \(Johns Hopkins\)](#)

[COVID-19 calculators \(Medscape\)](#)

Guidelines

[NICE Guidelines Covid-19](#)

[Korean CDC Covid-19 guidelines](#)

[Flattening the curve - Korea](#)

[IDSA COVID-19 Guidelines](#)

[Airway Management Clinical Practice Guidelines \(SIAARTI/EAMS, 2020\)](#)

[ESICM Ventilation Guidelines](#)

[Performing Procedures on Patients With Known or Suspected COVID-19 \(ASA, 2020\)](#)

[OSHA Guidance on Preparing the Workplace for COVID-19 \(2020\)](#)

[Policy for Sterilizers, Disinfectant Devices, and Air Purifiers \(FDA, 2020\)](#)

[Breast Cancer Patient Triage Guidelines \(CPBCC, 2020\)](#)

[clinical guidance for adult Belgian patients with suspected or confirmed COVID-19](#)

[National Covid-19 Testing Action Plan \(Rockefeller Foundation\)](#)

[ASE issues Echo-cardiography guidance](#)

Trials & Registries

[CAPACITY European registry COVID 19 patients](#)

[WHO launches global megatrial](#)

[FDA launches Convalescent plasma trial](#)

[Lets Beat Covid-19 Survey to help plan hospital services](#)

[COVID IBD registry](#)

[Google mobility reports per country COVID 19](#)

[World's largest trial of potential coronavirus treatments rolled out across the UK](#)

[Pregnancy Registry \(US\)](#)

[ICNARC report on COVID-19 in critical care - NHS April 24](#)

[COVID-19 Human Genetics - Biobanks](#)

[COVID19 settings of transmission database](#)

Mainstream Media

[New York Times - Corona update](#)

[The CDC was pressured by the White House to exclude asymptomatic people](#)
[In Germany, early results of school reopenings](#)
[What if the First Coronavirus Vaccines Aren't the Best?](#)
[One Meeting in Boston Seeded Tens of Thousands of Infections, Study Finds](#)
[Why Does the Coronavirus Hit Men Harder? A New Clue](#)
[Exercise May Boost Your Vaccine Response](#)
[Coronavirus Vaccine Tracker](#)
[Coronavirus Drug and Treatment Tracker](#)

Washington Post - Corona update

[U.S. reports more than 1,000 coronavirus deaths in a day](#)
[Only a tiny fraction of the U.S. population has coronavirus antibodies,](#)
[Researchers design reusable face mask said to be as effective as N95 respirator](#)
[America is running short on masks, gowns and gloves. Again.](#)
[People are turning to celebrities and social media for medical advice](#)
[How tiny Uruguay has avoided the worst of the coronavirus](#)

Guardian - Corona update

[world map: which countries have the most coronavirus cases/deaths?](#)
[Why do Covid fatalities remain low when infection numbers are rising?](#)
[Coronavirus reinfection – what it actually means, and why you shouldn't panic](#)
[Over 1,000 US health workers died of Covid-19. Many were immigrants](#)
[Obesity increases risk of Covid-19 death by 48%, study finds](#)

Key Articles

- 1. Not just antibodies: B cells and T cells mediate immunity to COVID-19.**
[Nat. Rev. Immunol. 2020; Cox RJ, Brokstad KA.](#)
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32839569>
- 2. Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.** [J Am Heart Assoc](#)
2020:e017736Chen C, Wang F, Chen P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32807002>
- 3. Anticoagulant treatment in COVID-19: a narrative review.** [J. Thromb. Thrombolysis](#) 2020;1-7Carfora V, Spiniello G, Ricciolino R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32809158>
- 4. Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms.** [J Neurol Sci](#) 2020; 418:117090Neumann B, Schmidbauer ML, Dimitriadis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805440>
- 5. Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.** [Cell](#) 2020; Schulte-Schrepping J, Reusch N, Paclik D *et al.*

<http://www.ncbi.nlm.nih.gov/pubmed/?term=32810438>

6. **Implications of AB0 blood group in hypertensive patients with covid-19.** BMC Cardiovasc. Disord. 2020; 20:373Sardu C, Marfella R, Maggi P *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32799852>
 7. **Biosensors: frontiers in rapid detection of COVID-19.** 3 Biotech 2020; 10:385Samson R, Navale GR, Dharne MS.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32818132>
 8. **Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.** Indian Pacing Electrophysiol J 2020; Pranata R, Huang I, Raharjo SB.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32814094>
 9. **Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) - anatomic pathology perspective on current knowledge.** Diagn. Pathol. 2020; 15:103Mohanty SK, Satapathy A, Naidu MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799894>
 10. **Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.** Scott. Med. J. 2020:36933020949219Megaly M, Glogoza M.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32807019>
 11. **The cholesterol metabolite 27-hydroxycholesterol inhibits SARS-CoV-2 and is markedly decreased in COVID-19 patients.** Redox Biol 2020; 36:101682Marcello A, Civra A, Milan Bonotto R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32810737>
 12. **COVID-19: Questions and answers from infectiology.** Deutsche Medizinische Wochenschrift 2020; 145:1051-1056Khatamzas E, Rothe C, Kroidl I.
 13. **COVID-19 Vaccine: A comprehensive status report.** Virus Res. 2020:198114Kaur SP, Gupta V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800805>
 14. **Hydroxychloroquine for treatment of non-severe COVID-19 patients; systematic review and meta-analysis of controlled clinical trials.** J Med Virol 2020; Elsayah HK, Elsokary MA, Elrazzaz MG, ElShafey AH.
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32808712>
 15. **Call to Action: SARS-CoV-2 and Cerebrovascular Disorders (CASCADE).** J. Stroke Cerebrovasc. Dis. 2020; 29:104938Abootalebi S, Aertker BM, Andalibi MS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807412>
-

Basic Science (38 articles)

1. **Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.** *ACS Nano* 2020; Qiao B, Olvera de la Cruz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806067>
2. **Mechanistic insights into SARS-CoV-2 epidemic via revealing the features of SARS-CoV-2 coding proteins and host responses upon its infection.** *Bioinformatics* 2020; Qin S, Xia X, Shi X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805023>
3. **Caveolae and Lipid Rafts in Endothelium: Valuable Organelles for Multiple Functions.** *Biomolecules* 2020; 10Filippini A, D'Alessio A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825713>
4. **Host-membrane interacting interface of the SARS coronavirus envelope protein: Immense functional potential of C-terminal domain.** *Biophys. Chem.* 2020; 266:106452Mukherjee S, Bhattacharyya D, Bhunia A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818817>
5. **The Cellular basis of the loss of smell in 2019-nCoV-infected individuals.** *Brief. Bioinform.* 2020; Gupta K, Mohanty SK, Mittal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810867>
6. **Structure-Based Drug Design of an Inhibitor of the SARS-CoV-2 (COVID-19) Main Protease Using Free Software: A Tutorial for Students and Scientists.** *ChemRxiv* 2020; Zhang S, Krumberger M, Morris MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817929>
7. **Unpuzzling COVID-19: tissue-related signaling pathways associated with SARS-CoV-2 infection and transmission.** *Clin Sci (Lond)* 2020; 134:2137-2160Battagello DS, Dragunas G, Klein MO *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820801>
8. **Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials against COVID-19: An in-silico Evaluation.** *Comb. Chem. High Throughput Screen.* 2020; Gorla US, Rao GK, Kulandaivelu US *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819226>
9. **Molecular Docking and Virtual Screening based prediction of drugs for COVID-19.** *Comb. Chem. High Throughput Screen.* 2020; Talluri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798373>
10. **Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein.** *Comput. Biol. Med.* 2020; 124:103967Rakib A, Sami SA, Mimi NJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32828069>
11. **The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19.** *Daru* 2020; Ashraf MA, Sherafat A, Pourdast A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803688>
12. **Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds.** *Eur. J. Med. Chem.* 2020; 206:112702Liu P, Liu H, Sun Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798789>
13. **The development of Coronavirus 3C-Like protease (3CL(pro)) inhibitors from 2010 to 2020.** *Eur. J. Med. Chem.* 2020; 206:112711Liu Y, Liang C, Xin L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810751>
14. **Emerging strategies on in silico drug development against COVID-19: challenges and opportunities.** *Eur. J. Pharm. Sci.* 2020:105522Yadav M, Dhagat S, Eswari JS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827661>
15. **Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine-promising therapeutic strategy for SARS-CoV-2 treatment.** *Expert Opin Drug Deliv* 2020; Ansari MA, Almatroudi A, Alzohairy MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820694>
16. **Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.** *F1000Res* 2020; 9:576Barh D, Tiwari S, Silva Andrade B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802318>
17. **Unravelling host-pathogen interactions: ceRNA network in SARS-CoV-2 infection (COVID-19).** *Gene* 2020:145057Arora S, Singh P, Dohare R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805314>
18. **Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin.** *Heliyon* 2020; 6:e04647Ejuh GW, Fonkem C, Tadjouteu Assatse Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802983>
19. **Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz.** *Heliyon* 2020; 6:e04642Jordaan MA, Ebenezer O, Damoyi N, Shapi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802982>
20. **Searching potential antiviral candidates for the treatment of the 2019 novel coronavirus based on DFT calculations and molecular docking.** *Heliyon* 2020; 6:e04640Sagaama A, Brandan SA, Ben Issa T, Issaoui N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802981>
21. **Dengue serology in Indonesian COVID-19 patients: Coinfection or serological overlap?** *IDCases* 2020; 22:e00927Kembuan GJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802747>
22. **Translation of genomic epidemiology of infectious pathogens: Enhancing African genomics hubs for outbreaks.** *Int J Infect Dis* 2020; Oboh MA, Omoleke SA, Ajibola O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800861>
23. **Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications.** *Int J Mol Sci* 2020; 21Farsalinos K, Eliopoulos E, Leonidas DD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823591>
24. **Deciphering SARS-CoV-2 Virologic and Immunologic Features.** *Int J Mol Sci* 2020; 21Lebeau G, Vagner D, Frumence É *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824753>
25. **In silico molecular investigations of pyridine N-Oxide compounds as potential inhibitors of SARS-CoV-2: 3D QSAR, molecular docking modeling, and ADMET screening.** *J Biomol Struct Dyn* 2020:1-11Ghaleb A, Aouidate A, Ayouchia HBE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799761>
26. **An in-silico evaluation of dietary components for structural inhibition of SARS-Cov-2 main protease.** *J Biomol Struct Dyn* 2020:1-7Pandey AK, Verma S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811367>
27. **SARS-CoV-2 exhibits intra-host genomic plasticity and low-frequency polymorphic quasispecies.** *J Clin Virol* 2020; 131:104585Karamitros T, Papadopoulou G, Bousali M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818852>
28. **SARS-CoV-2 growth, furin-cleavage-site adaptation and neutralization using serum from acutely infected hospitalized COVID-19 patients.** *J. Gen. Virol.* 2020; Klimstra WB, Tilston-Lunel NL, Nambulli S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821033>
29. **Genes encoding ACE2, TMPRSS2 and related proteins mediating SARS-CoV-2 viral entry are upregulated with age in human cardiomyocytes.** *J. Mol. Cell. Cardiol.* 2020; Robinson EL, Alkass K,

- Bergmann O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818486>
30. **Genome-wide computational prediction of miRNAs in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) revealed target genes involved in pulmonary vasculature and antiviral innate immunity.** *Mol Biol Res Commun* 2020; 9:83-91 Saini S, Saini A, Thakur CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802902>
 31. **Putative SARS-CoV-2 M(pro) Inhibitors from an In-House Library of Natural and Nature-Inspired Products: A Virtual Screening and Molecular Docking Study.** *Molecules* 2020; 25 Mazzini S, Musso L, Dallavalle S, Artali R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824454>
 32. **SARS-CoV-2 ORF8 and SARS-CoV ORF8ab: Genomic Divergence and Functional Convergence.** *Pathogens* 2020; 9 Mohammad S, Bouchama A, Mohammad Alharbi B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825438>
 33. **Broad host range of SARS-CoV-2 predicted by comparative and structural analysis of ACE2 in vertebrates.** *Proc Natl Acad Sci U S A* 2020; Damas J, Hughes GM, Keough KC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826334>
 34. **IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.** *Proc Natl Acad Sci U S A* 2020; Kang S, Tanaka T, Inoue H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826331>
 35. **ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review.** *Rep Biochem Mol Biol* 2020; 9:97-105 Mostafa-Hedeab G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821757>
 36. **Intranasal exposure of African green monkeys to SARS-CoV-2 results in acute phase pneumonia with shedding and lung injury still present in the early convalescence phase.** *Virology* 2020; 17:125 Cross RW, Agans KN, Prasad AN *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811514>
 37. **No evidence for distinct types in the evolution of SARS-CoV-2.** *Virus Evol* 2020; 6:veaa034 MacLean OA, Orton RJ, Singer JB, Robertson DL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817804>
 38. **Of Mice and Men: The Coronavirus MHV and Mouse Models as a Translational Approach to Understand SARS-CoV-2.** *Viruses* 2020; 12 Körner RW, Majjouti M, Alcazar MAA, Mahabir E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806708>

Biomarkers - Genetics (66 articles)

1. **Biosensors: frontiers in rapid detection of COVID-19.** *3 Biotech* 2020; 10:385 Samson R, Navale GR, Dharne MS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818132>
2. **A 3D-printed nasopharyngeal swab for COVID-19 diagnostic testing.** *3D Print Med* 2020; 6:21 Ford J, Goldstein T, Trahan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803531>
3. **Elevated Lactate Dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19.** *Aging (Albany NY)* 2020; 12 Li C, Ye J, Chen Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805722>
4. **Analytical and Clinical Evaluation of the Automated Elecsys Anti-SARS-CoV-2 Antibody Assay on the Roche cobas e602 Analyzer.** *Am J Clin Pathol* 2020; Chan CW, Parker K, Tesic V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814955>
5. **Humoral Immune Response to SARS-CoV-2.** *Am J Clin Pathol* 2020; Herroelen PH, Martens GA, De Smet D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808976>
6. **Adjusting Coronavirus Prevalence Estimates for Laboratory Test Kit Error.** *Am. J. Epidemiol.* 2020; Sempos CT, Tian L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803245>
7. **The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature.** *Am. J. Hum. Genet.* 2020; LoPresti M, Beck DB, Duggal P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814065>
8. **Prolonged Persistence of PCR-detectable Virus During an Outbreak of SARS-CoV-2 in an Inpatient Geriatric Psychiatry Unit in King County, Washington.** *Am. J. Infect. Control* 2020; Corcorran MA, Olin S, Rani G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827597>
9. **Non-Specific Laboratory Tests in Patients with COVID-19.** *Ann. Clin. Lab. Sci.* 2020; 50:528-535 Borai A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826251>
10. **Changes in serum virus-specific IgM/IgG antibody in asymptomatic and discharged patients with reoccurring positive COVID-19 nucleic acid test (RPNAT).** *Ann. Med.* 2020:1-14 Liu J, Lian R, Zhang G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808808>
11. **Fighting the COVID-19 pandemic: onsite mass workplace testing for COVID-19 in the Republic of Korea.** *Ann Occup Environ Med* 2020; 32:e22 Seo E, Mun E, Kim W, Lee C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802338>
12. **Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers.** *Arch Pathol Lab Med* 2020; Tjendra Y, Al Mana AF, Espejo AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818235>
13. **Safety considerations in the bioanalytical laboratories handling specimens from coronavirus disease 2019 patients.** *Bioanalysis* 2020; Chen Z, Sikorski TW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820941>
14. **PCR past, present and future.** *Biotechniques* 2020; Zhu H, Zhang H, Xu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815744>
15. **Implications of AB0 blood group in hypertensive patients with covid-19.** *BMC Cardiovasc. Disord.* 2020; 20:373 Sardu C, Marfella R, Maggi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799852>
16. **COVID-19 and haemoglobin oxygen affinity: some clarity?** *Br. J. Haematol.* 2020; Shattock MJ, Daniel Y, Hunt BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805061>
17. **Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.** *Cell* 2020; Schulte-Schrepping J, Reusch N, Paclik D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810438>
18. **Elevated Calprotectin and Abnormal Myeloid Cell Subsets Discriminate Severe from Mild COVID-19.** *Cell* 2020; Silvin A, Chapuis N, Dunsmore G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810439>
19. **Routine laboratory blood tests predict SARS-CoV-2 infection using machine learning.** *Clin Chem* 2020; Yang HS, Hou Y, Vasovic LV *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821907>
20. **Laboratory Findings in COVID-19 Diagnosis and Prognosis.** *Clin Chim Acta* 2020; Pourbagheri-Sigaroodi A, Bashash D, Fateh F, Abolghasemi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798514>

21. **Epidemiological, virological and serological features of COVID-19 cases in people living with HIV in Wuhan City: A population-based cohort study.** *Clin Infect Dis* 2020; Huang J, Xie N, Hu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803216>
22. **Epidemiology, outcomes and associated factors of COVID-19 RT-PCR confirmed cases in the San Pedro Sula Metropolitan Area, Honduras.** *Clin Infect Dis* 2020; Zuniga-Moya JC, Norwood DA, Romero Reyes LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803236>
23. **Epidemiological and clinical characteristics of SARS-CoV-2 infections at a testing site in Berlin, Germany, March and April 2020 - A cross-sectional study.** *Clin Microbiol Infect* 2020; Maechler F, Gertler M, Hermes J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827715>
24. **Nucleic Acid Testing for Coronavirus Disease 2019: Demand, Research Progression, and Perspective.** *Crit Rev Anal Chem* 2020:1-12 Zhang S, Su X, Wang J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813575>
25. **SARS-CoV-2: Symptoms-based testing is not enough.** *Deutsche Medizinische Wochenschrift* 2020; 145:958-959 Krome S.
26. **Anti SARS-CoV-2 antibodies monitoring in a group of residents in a long term care facility during COVID-19 pandemic peak.** *Diagnosis (Berl)* 2020; Carta M, Bragagnolo L, Tramarin A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827394>
27. **EDTA-Anticoagulated Whole Blood for SARS-CoV-2 Antibody Testing by Electrochemiluminescence Immunoassay (ECLIA) and Enzyme-Linked Immunosorbent Assay (ELISA).** *Diagnostics (Basel)* 2020; 10Kovac M, Risch L, Thiel S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823852>
28. **Proposal of De Novo Antigen Test for COVID-19: Ultrasensitive Detection of Spike Proteins of SARS-CoV-2.** *Diagnostics (Basel)* 2020; 10Kyosei Y, Namba M, Yamura S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823866>
29. **The Model for Early COvid-19 Recognition (MECOR) Score: A Proof-of-Concept for a Simple and Low-Cost Tool to Recognize a Possible Viral Etiology in Community-Acquired Pneumonia Patients during COVID-19 Outbreak.** *Diagnostics (Basel)* 2020; 10Sambataro G, Giuffrè M, Sambataro D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825763>
30. **Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes.** *EMBO Mol Med* 2020:e202013038 Alzaid F, Julla JB, Diedisheim M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816392>
31. **Accurate Serology for SARS-CoV-2 and common Human Coronaviruses using a Multiplex Approach.** *Emerg Microbes Infect* 2020:1-24 van Tol S, Mögling R, Li W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819220>
32. **Evaluation of three immunochromatographic tests for rapid detection of antibodies against SARS-CoV-2.** *Eur J Clin Microbiol Infect Dis* 2020:1-9 Guedez-López GV, Alguacil-Guillén M, González-Donapetry P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808111>
33. **Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis.** *Eur. J. Epidemiol.* 2020; Taneri PE, Gómez-Ochoa SA, Llanaj E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816244>
34. **Evaluation of the automated cartridge-based ARIES SARS-CoV-2 Assay (RUO) against automated Cepheid Xpert Xpress SARS-CoV-2 PCR as gold standard.** *Eur. J. Microbiol. Immunol. (Bp)* 2020; Tanida K, Koste L, Koenig C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804668>
35. **COVID-19: fighting the invisible enemy with microRNA.** *Expert Rev. Anti Infect. Ther.* 2020; Chauhan N, Jaggi M, Chauhan SC, Yallapu MM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814446>
36. **Evaluation of the Ion AmpliSeq SARS-CoV-2 Research Panel by Massive Parallel Sequencing.** *Genes (Basel)* 2020; 11Alessandrini F, Caucci S, Onofri V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806776>
37. **Whole Genome Sequencing of SARS-CoV-2: Adapting Illumina Protocols for Quick and Accurate Outbreak Investigation during a Pandemic.** *Genes (Basel)* 2020; 11Pillay S, Giandhari J, Tegally H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824573>
38. **Building the National SARS-CoV-2 Laboratory Diagnostic Capacity in Taiwan.** *Health Secur* 2020; Yang JR, Liu MT, Huang HI *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822227>
39. **COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study.** *Immun. Ageing* 2020; 17:22 Jurado A, Martín MC, Abad-Molina C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802142>
40. **Gargle lavage as a viable alternative to swab for detection of SARS-CoV-2.** *Indian J Med Res* 2020; Mittal A, Gupta A, Kumar S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820725>
41. **Difference in Biomarkers Between COVID-19 Patients and Other Pulmonary Infection Patients.** *Infect Drug Resist* 2020; 13:2609-2615 Dai J, Du Y, Gao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801798>
42. **Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review.** *Infect Drug Resist* 2020; 13:2657-2665 Russo A, Minichini C, Starace M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801804>
43. **A highly specific and sensitive serological assay detects SARS-CoV-2 antibody levels in COVID-19 patients that correlate with neutralization.** *Infection* 2020:1-8 Peterhoff D, Glück V, Vogel M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827125>
44. **Risk factors for positive and negative COVID-19 tests: a cautious and in-depth analysis of UK biobank data.** *Int J Epidemiol* 2020; Chadeau-Hyam M, Bodinier B, Elliott J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814959>
45. **Comparison of Automated SARS-CoV-2 Antigen Test for COVID-19 Infection with Quantitative RT-PCR using 313 Nasopharyngeal Swabs Including from 7 Serially Followed Patients.** *Int J Infect Dis* 2020; Hirotsu Y, Maejima M, Shibusawa M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800855>
46. **Pooling of SARS-CoV-2 samples to increase molecular testing throughput.** *J Clin Virol* 2020; 131:104570 Perchetti GA, Sullivan KW, Pepper G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805524>
47. **Performance evaluation of serological assays to determine the immunoglobulin status in SARS-CoV-2 infected patients.** *J Clin Virol* 2020; 131:104589 Wechselberger C, Süßner S, Doppler S, Bernhard D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810840>
48. **Usefulness of bronchoalveolar lavage in suspect covid-19 repeatedly negative swab test and interstitial lung disease.** *J Glob Antimicrob Resist* 2020; Vannucci J, Ruberto F, Diso D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810641>

49. **Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID-19.** *J Infect Dis* 2020; Guervilly C, Burtsey S, Sabatier F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812049>
50. **Clinical Characteristics of COVID-19: Clinical Dynamics of Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection Detected by Early Active Surveillance.** *J Korean Med Sci* 2020; 35:e297Suh HJ, Kim DH, Heo EY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808513>
51. **A Case of Gastrointestinal-Predominant COVID-19 Demonstrates Value of Stool PCR Test.** *J Med Virol* 2020; Khoury NC, Russi TJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816305>
52. **Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients.** *J. Mol. Cell. Cardiol.* 2020; 147:74-87Li C, Jiang J, Wang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827510>
53. **Genes encoding ACE2, TMPRSS2 and related proteins mediating SARS-CoV-2 viral entry are upregulated with age in human cardiomyocytes.** *J. Mol. Cell. Cardiol.* 2020; Robinson EL, Alkass K, Bergmann O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818486>
54. **Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms.** *J Neurol Sci* 2020; 418:117090Neumann B, Schmidbauer ML, Dimitriadis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805440>
55. **The Urgency of Conducting Serological Studies for COVID-19.** *J Res Health Sci* 2020; 20:e00479Moradi G, Mostafavi E, Haghdoost AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814701>
56. **Universal laboratory testing for SARS-CoV-2 in hyperacute stroke during the COVID-19 pandemic.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:105061Barlinn K, Siepman T, Pallesen LP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807466>
57. **Rapid, large-scale, and effective detection of COVID-19 via non-adaptive testing.** *J. Theor. Biol.* 2020:110450Täufer M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814072>
58. **Investigation of a family cluster outbreak of COVID-19 indicates the necessity of CT screening for asymptomatic family members in close contact with confirmed patients.** *J Thorac Dis* 2020; 12:3673-3681Liu Z, Wu Q, Zou Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802446>
59. **SARS-CoV-2 Detection for Diagnosis Purposes in the Setting of a Molecular Biology Research Lab.** *Methods Protoc* 2020; 3Coupeau D, Burton N, Lejeune N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824827>
60. **Levels of the TNF-Related Cytokine LIGHT Increase in Hospitalized COVID-19 Patients with Cytokine Release Syndrome and ARDS.** *mSphere* 2020; 5Perlin DS, Zafir-Lavie I, Roadcap L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817460>
61. **Vitamin D Insufficiency and Deficiency and Mortality from Respiratory Diseases in a Cohort of Older Adults: Potential for Limiting the Death Toll during and beyond the COVID-19 Pandemic?** *Nutrients* 2020; 12Brenner H, Hollecsek B, Schöttker B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824839>
62. **Is growth hormone insufficiency the missing link between obesity, male gender, age and COVID-19 severity?** *Obesity (Silver Spring)*, 2020; Lubrano C, Masi D, Risi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808459>
63. **Clinical Sensitivity of Severe Acute Respiratory Syndrome Coronavirus 2 Nucleic Acid Amplification Tests for Diagnosing Coronavirus Disease 2019.** *Open Forum Infect Dis* 2020; 7:ofaa315Ridgway JP, Pisano J, Landon E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818146>
64. **The cholesterol metabolite 27-hydroxycholesterol inhibits SARS-CoV-2 and is markedly decreased in COVID-19 patients.** *Redox Biol* 2020; 36:101682Mancello A, Civra A, Milan Bonotto R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810737>
65. **Utility of the neutrophil-to-lymphocyte ratio and C-reactive protein level for coronavirus disease 2019 (COVID-19).** *Scand. J. Clin. Lab. Invest.* 2020:1-5Yufei Y, Mingli L, Xuejiao L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804580>
66. **iSCAN: An RT-LAMP-coupled CRISPR-Cas12 module for rapid, sensitive detection of SARS-CoV-2.** *Virus Res* 2020; 288:198129Ali Z, Aman R, Mahas A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822689>

Children (22 articles)

1. **Emerging health challenges for children with physical disabilities and their parents during the COVID-19 pandemic: the ECHO French survey.** *Ann. Phys. Rehabil. Med.* 2020; Cacioppo M, Bouvier S, Bailly R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818674>
2. **Was child abuse underdetected during the COVID-19 lockdown?** *Arch. Pediatr.* 2020; Caron F, Plancq MC, Tourneux P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807622>
3. **Caring for children and adolescents with type 1 diabetes mellitus: italian society for pediatric and adolescent diabetes (ISPED) Statements during COVID-19 pandemia.** *Diabetes Res Clin Pract* 2020:108372d'Annunzio G, Maffei C, Cherubini V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827594>
4. **Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach.** *Eur. J. Pediatr.* 2020; Sperotto F, Friedman KG, Son MBF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803422>
5. **The Coronavirus Disease 2019 (COVID-19) in Children: A Study in an Iranian Children's Referral Hospital.** *Infect Drug Resist* 2020; 13:2649-2655Mahmoudi S, Mehdizadeh M, Shervin Badv R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801803>
6. **SARS-CoV-2 Infection in Children in Southern Italy: A Descriptive Case Series.** *Int J Environ Res Public Health* 2020; 17Loconsole D, Caselli D, Centrone F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825563>
7. **Fever with Rash is One of the First Presentations of COVID-19 in Children: A Case Report.** *Int Med Case Rep J* 2020; 13:335-340Navaeifar MR, Poudineh Ghazaghi M, Shahbaznejad L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821174>
8. **COVID-19 Outbreak Among Adolescents at an Inpatient Behavioral Health Hospital.** *J. Adolesc. Health* 2020; Krass P, Zimbrick-Rogers C, Iheagwara C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798098>
9. **Bridging the Needs of Adolescent Diabetes Care During Coronavirus Disease 2019: A Nurse-Led Telehealth Initiative.** *J. Adolesc. Health* 2020; Lim ST, Yap F, Chin X.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798101>
10. **Pediatric Asthma Healthcare Utilization, Viral Testing, and Air Pollution Changes during the COVID-19 Pandemic.** *J Allergy Clin Immunol Pract* 2020; Taquechel K, Diwadkar AR, Sayed S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827728>
 11. **Including Children with Developmental Disabilities in the Equation During this COVID-19 Pandemic.** *J. Autism Dev. Disord.* 2020; Aishworiya R, Kang YQ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816170>
 12. **Novel coronavirus disease 2019 (COVID-19) outbreak in children in Iran: Atypical CT manifestations and mortality risk of severe COVID-19 infection.** *J Microbiol Immunol Infect* 2020; Mamishi S, Heydari H, Aziz-Ahari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814650>
 13. **Severe diabetic ketoacidosis and coronavirus disease 2019 (COVID-19) infection in a teenage patient with newly diagnosed diabetes.** *J. Pediatr. Endocrinol. Metab.* 2020; Rabizadeh S, Hajmiri M, Rajab A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809963>
 14. **Paediatric activities and adherence to vaccinations during the COVID-19 epidemic period in Tuscany, Italy: a survey of paediatricians.** *J. Prev. Med. Hyg.* 2020; 61:E125-e129 Bechini A, Garamella G, Giammarco B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802994>
 15. **[Encephalitis associated with COVID-19 in a 13-year-old girl: A case report].** *Medwave* 2020; 20:e7984 Conto-Palomino NM, Cabrera-Bueno ML, Vargas-Ponce KG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804920>
 16. **COVID-19 - What does a paediatrician need to know?** *Paediatr. Respir. Rev.* 2020; Robinson J, Freire D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798115>
 17. **The pervasive relevance of COVID-19 within routine paediatric palliative care consultations during the pandemic: A conversation analytic study.** *Palliat. Med.* 2020;269216320950089 Ekberg K, Weinglass L, Ekberg S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799739>
 18. **[Impact of the COVID-19 pandemic on emergency department: Early findings from a hospital in Madrid].** *An Pediatr (Barc)* 2020; Molina Gutiérrez M, Ruiz Domínguez JA, Bueno Barriocanal M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800720>
 19. **Transverse Myelitis in a Child With COVID-19.** *Pediatr. Neurol.* 2020; 112:5-6 Kaur H, Mason JA, Bajracharya M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823138>
 20. **Impact of Social Isolation due to the COVID-19 Pandemic in Patients with Pediatric Disorders: Rehabilitation Perspectives From a Developing Country.** *Phys Ther* 2020; Meireles ALF, de Meireles LCF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805029>
 21. **Sexual and gender minority adolescents must be prioritised during the global COVID-19 public health response.** *Sex Reprod Health Matters* 2020; 28:1804717 DeMulder J, Kraus-Perrotta C, Zaidi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799759>
 22. **Lockdown and adolescent mental health: reflections from a child and adolescent psychotherapist.** *Wellcome Open Res* 2020; 5:132 Catty J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802965>
 23. **[COVID-19: treatment strategies of German-speaking pediatric rheumatologists : Results of an online survey].** *Z. Rheumatol.* 2020;1-8 Janda A, Schuetz C, Heeg M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809050>

Clinical Features (25 articles)

1. **Similarities in Cutaneous Histopathological Patterns between COVID-19-positive and COVID-19 High-risk Patients with Skin Dermatoses.** *Acta Derm. Venereol.* 2020; Gianotti R, Coggi A, Boggio F, Fellegara G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812055>
2. **Epidemiology and clinical characteristics of 43 COVID-19 patients in Weifang, China.** *Ann Palliat Med* 2020; Wang Q, Zheng S, Tan W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819125>
3. **Clinical characteristics and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance database analysis.** *Bjog* 2020; Takemoto MLS, Menezes MO, Andreucci CB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799381>
4. **How Do Presenting Symptoms and Outcomes Differ by Race/Ethnicity Among Hospitalized Patients with COVID-19 Infection? Experience in Massachusetts.** *Clin Infect Dis* 2020; McCarty TR, Hathorn KE, Redd WD *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827436>
5. **Epidemiological and clinical characteristics of SARS-CoV-2 infections at a testing site in Berlin, Germany, March and April 2020 - A cross-sectional study.** *Clin Microbiol Infect* 2020; Maechler F, Gertler M, Hermes J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827715>
6. **Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy.** *Clin Microbiol Infect* 2020; Vena A, Giacobbe DR, Di Biagio A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810610>
7. **Chilblains in COVID-19 Infection.** *Cureus* 2020; 12:e9245 Mohan V, Lind R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821591>
8. **Hospital Course of a Man With Viral Pneumonia Caused by COVID-19.** *Cureus* 2020; 12:e9261 Solomon M, Ganti L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821607>
9. **Neuroradiologic manifestations of COVID-19: what the emergency radiologist needs to know.** *Emerg Radiol* 2020;1-9 Goldberg MF, Goldberg MF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822060>
10. **Epidemiological & clinical characteristics & early outcome of COVID-19 patients in a tertiary care teaching hospital in India: A preliminary analysis.** *Indian J Med Res* 2020; Kayina CA, Haritha D, Soni L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811801>
11. **Clinical characteristics of diarrhea in 90 cases with COVID-19: A descriptive study.** *Int. Emerg. Nurs.* 2020; 52:100912 Xiao Y, Huang S, Yan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827932>
12. **Fever with Rash is One of the First Presentations of COVID-19 in Children: A Case Report.** *Int Med Case Rep J* 2020; 13:335-340 Navaeifar MR, Poudineh Ghazaghi M, Shahbaznejad L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821174>
13. **Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study.** *Intensive Care Med* 2020; Xie J, Wu W, Li S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816098>
14. **Clinical Profiles in Renal Patients with COVID-19.** *J Clin Med* 2020; 9Arenas MD, Crespo M, Pérez-Sáez MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824683>

15. **COVID-19 in critically ill patients in North Brabant, the Netherlands: Patient characteristics and outcomes.** *J Crit Care* 2020; 60:111-115Aleva FE, van Mourik L, Broeders M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799179>
16. **COVID-19-related cutaneous manifestations associated with multiple drug sensitization as shown by lymphocyte transformation test.** *J Eur Acad Dermatol Venereol* 2020; Hayakawa J, Takakura H, Mizukawa Y, Shiohara T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810920>
17. **Medical Features of COVID-19 and Influenza Infection: A Comparative Study in Paris, France.** *J Infect* 2020; Faury H, Courboulès C, Payen M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798533>
18. **COVID-19-Associated Critical Illness-Report of the First 300 Patients Admitted to Intensive Care Units at a New York City Medical Center.** *J Intensive Care Med* 2020; 35:963-970Chand S, Kapoor S, Orsi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812834>
19. **Clinical Characteristics of COVID-19: Clinical Dynamics of Mild Severe Acute Respiratory Syndrome Coronavirus 2 Infection Detected by Early Active Surveillance.** *J Korean Med Sci* 2020; 35:e297Suh HJ, Kim DH, Heo EY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808513>
20. **Considerations on oral manifestations of COVID-19.** *J Med Virol* 2020; de Sousa F, Paradella TC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827318>
21. **Reversible cerebral vasoconstriction syndrome and dissection in the setting of COVID-19 infection.** *J Stroke Cerebrovasc Dis* 2020; 29:105011Dakay K, Kaur G, Gulko E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807426>
22. **High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards.** *J Thromb. Thrombolysis* 2020:1-5Le Jeune S, Suhl J, Benainous R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812199>
23. **Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.** *Mult Scler Relat Disord* 2020; 45:102452De Angelis M, Petracca M, Lanzillo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823148>
24. **Main symptoms in patients presenting in the COVID-19 period.** *Scott. Med. J.* 2020:36933020949253Çalica Utku A, Budak G, Karabay O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807018>
25. **COVID-19 Infection and Cardiac Arrhythmias.** *Trends Cardiovasc. Med* 2020; Manolis AS, Manolis AA, Manolis TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814095>

CNS (19 articles)

1. **The Cellular basis of the loss of smell in 2019-nCoV-infected individuals.** *Brief. Bioinform.* 2020; Gupta K, Mohanty SK, Mittal A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810867>
2. **COVID-19 and the central nervous system.** *Clin. Neurol. Neurosurg.* 2020; 198:106116Alomari SO, Abou-Mrad Z, Bydon A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32828027>
3. **COVID-19: A neurological point-of-view.** *Deutsche Medizinische Wochenschrift* 2020; 145:1074-1079Simon OJ, Timmermann L.
4. **Counseling of people with epilepsy via telemedicine: Experiences at a German tertiary epilepsy center during the COVID-19 pandemic.** *Epilepsy Behav.* 2020; 112:107298von Wrede R, Moskau-Hartmann S, Baumgartner T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801068>
5. **Neurological Aspects of Coronavirus Infectious Disease 2019 (COVID-19).** *Innov. Clin. Neurosci.* 2020; 17:13-15Butala N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802586>
6. **Resilience of Alzheimer's Disease to COVID-19.** *J. Alzheimers Dis.* 2020; Li J, Long X, Huang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804094>
7. **The Interrelation of Neurological and Psychological Symptoms of COVID-19: Risks and Remedies.** *J Clin Med* 2020; 9Nami M, Gadad BS, Chong L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823540>
8. **Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic.** *J. Neurol.* 2020; Costamagna G, Abati E, Bresolin N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804279>
9. **Neurological involvement associated with COVID-19 infection in children.** *J Neurol Sci* 2020; 418:117096Chen TH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823135>
10. **Cerebrospinal fluid findings in COVID-19 patients with neurological symptoms.** *J Neurol Sci* 2020; 418:117090Neumann B, Schmidbauer ML, Dimitriadis K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805440>
11. **Special considerations in the assessment of catastrophic brain injury and determination of brain death in patients with SARS-CoV-2.** *J Neurol Sci* 2020; 417:117087Valdes E, Agarwal S, Carroll E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798855>
12. **Novel Outreach Program and Practical Strategies for Patients with Parkinsonism in the COVID-19 Pandemic.** *J Parkinsons Dis.* 2020; Sennott B, Woo K, Hess S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804103>
13. **[Encephalitis associated with COVID-19 in a 13-year-old girl: A case report].** *Medwave* 2020; 20:e7984Conto-Palomino NM, Cabrera-Bueno ML, Vargas-Ponce KG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804920>
14. **Covid-19 and Parkinsonism: A non-post-encephalitic case.** *Mov Disord* 2020; Faber I, Brandão PRP, Menegatti F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815213>
15. **Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.** *Mult Scler Relat Disord* 2020; 45:102452De Angelis M, Petracca M, Lanzillo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823148>
16. **An Integrated Care Strategy for the Follow-up of Patients With COVID-19-Associated Chemosensory Dysfunction.** *Otolaryngol Head Neck Surg* 2020:194599820950716Locatello LG, Maggiore G, Bruno C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806993>
17. **Predictors of COVID-19 outcome in Parkinson's disease.** *Parkinsonism Relat. Disord.* 2020; 78:134-137Fasano A, Elia AE, Dallochio C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827969>
18. **Transverse Myelitis in a Child With COVID-19.** *Pediatr. Neurol.* 2020; 112:5-6Kaur H, Mason JA, Bajracharya M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823138>
19. **Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach.** *Ther. Clin. Risk Manag.* 2020;

Coagulation (17 articles)

1. **Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience.** *Ann. Hematol.* 2020;1-6Hanif A, Khan S, Mantri N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808105>
2. **Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial.** *Clin. Trials* 2020;1740774520943846Houston BL, Lawler PR, Goligher EC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815416>
3. **Acute Limb Ischemia in COVID-19 Disease: A Mysterious Coagulopathy.** *Cureus* 2020; 12:e9167Anwar S, Acharya S, Shahih S, Khabut A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802604>
4. **COVID-19 from the Perspective of Haematology and Haemostaseology.** *Deutsche Medizinische Wochenschrift* 2020; 145:1044-1050Spiekermann K, Subklewe M, Hildebrandt M *et al.*
5. **COVID-19-associated aortic arch thrombus.** *Eur J Cardiothorac Surg* 2020; Mosbahi S, Heinisch PP, Schoenhoff FS, Berger DC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820319>
6. **A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19.** *Int J Infect Dis* 2020; Lu YF, Pan LY, Zhang WW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798659>
7. **Hemoperfusion as a Supportive Treatment in a COVID-19 Patient with Late Pulmonary Thromboembolism: A Case Report.** *Int Med Case Rep J* 2020; 13:341-345Moradi H, Abbasi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821175>
8. **Severe arterial thromboembolism in patients with Covid-19.** *J Crit Care* 2020; 60:106-110Lameijer JRC, van Houte J, van Berckel MMG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799178>
9. **Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients.** *J. Mol. Cell. Cardiol.* 2020; 147:74-87Li C, Jiang J, Wang F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827510>
10. **Anticoagulant treatment in COVID-19: a narrative review.** *J. Thromb. Thrombolysis* 2020;1-7Carfora V, Spiniello G, Ricciolino R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809158>
11. **High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards.** *J. Thromb. Thrombolysis* 2020;1-5Le Jeune S, Suhl J, Benainous R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812199>
12. **Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound?** *J Ultrasound* 2020;1-9Ierardi AM, Coppola A, Fusco S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809207>
13. **Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group.** *Med Clin (Barc)* 2020; Zalba Marcos S, Antelo ML, Galbete A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814635>
14. **Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19.** *Thromb Res* 2020; 196:11-14Huang CT, Hsu SY, Chang KW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810772>
15. **The reversed halo sign: Considerations in the context of the COVID-19 pandemic.** *Thromb Res* 2020; 195:228-230Marchiori E, Nobre LF, Hochegger B, Zanetti G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799128>
16. **Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit.** *Thromb Res* 2020; 196:1-3Vlot EA, Van den Dool EJ, Hackeng CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805623>
17. **Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:724Busani S, Tosi M, Mighali P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807241>

Complications (48 articles)

1. **Spontaneous pneumomediastinum in a male adult with COVID-19 pneumonia.** *Am J Emerg Med* 2020; Janssen J, Kamps MJA, Joosten TMB, Barten DG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800430>
2. **Spontaneous hemopneumothorax in a patient with COVID-19: A case report.** *Am J Emerg Med* 2020; Long A, Grimaldo F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800431>
3. **COVID-19 Intubation Safety: A Multidisciplinary, Rapid-Cycle Model of Improvement.** *Am. J. Med. Qual.* 2020;1062860620949141Tronnier A, Mulcahy CF, Pierce A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806935>
4. **Reply to: On Happy Hypoxia and on Sadly Ignored Acute Vascular Distress Syndrome in COVID-19 Patients.** *Am J Respir Crit Care Med* 2020; Tobin MJ, Laghi F, Jubran A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813546>
5. **ARDS in COVID-19: Do All These Patients Definitely Require Intubation and Mechanical Ventilation?** *Am J Respir Crit Care Med* 2020; Yaroshetskiy AI, Avdeev SN, Konanykhin VD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809841>
6. **A fatal case of COVID-19 in a patient with common variable immunodeficiency.** *Ann. Allergy. Asthma. Immunol.* 2020; Mullur J, Wang A, Feldweg A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818593>
7. **Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience.** *Ann. Hematol.* 2020;1-6Hanif A, Khan S, Mantri N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808105>
8. **Severe Clostridium difficile colitis as potential late complication associated with COVID-19.** *Ann. R. Coll. Surg. Engl.* 2020:e1-e4Páramo-Zunzunegui J, Ortega-Fernández I, Calvo-Espino P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803988>

9. **Mechanistic insights into SARS-CoV-2 epidemic via revealing the features of SARS-CoV-2 coding proteins and host responses upon its infection.** *Bioinformatics* 2020; Qin S, Xia X, Shi X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805023>
10. **Considerations for target oxygen saturation in COVID-19 patients: are we under-shooting?** *BMC Med* 2020; 18:260 Shenoy N, Luchtel R, Gulani P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814566>
11. **Noninvasive ventilation for COVID-19-associated acute hypoxaemic respiratory failure: experience from a single centre.** *Br J Anaesth* 2020; Sivaloganathan AA, Nasim-Mohi M, Brown MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811662>
12. **COVID-19 and haemoglobin oxygen affinity: some clarity?** *Br. J. Haematol.* 2020; Shattock MJ, Daniel Y, Hunt BJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805061>
13. **Tolerability and safety of awake prone positioning COVID-19 patients with severe hypoxemic respiratory failure.** *Can J Anaesth* 2020; Solverson K, Weatherald J, Parhar KKS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803468>
14. **Severe COVID-19 Is Marked by a Dysregulated Myeloid Cell Compartment.** *Cell* 2020; Schulte-Schrepping J, Reusch N, Paclik D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810438>
15. **Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial.** *Clin. Trials* 2020:1740774520943846 Houston BL, Lawler PR, Goligher EC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815416>
16. **Above and beyond: biofilm and the ongoing search for strategies to reduce ventilator-associated pneumonia (VAP).** *Crit Care* 2020; 24:510 Sakano T, Bittner EA, Chang MG, Berra L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811553>
17. **Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey.** *Crit Care* 2020; 24:516 Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825837>
18. **Acute Limb Ischemia in COVID-19 Disease: A Mysterious Coagulopathy.** *Cureus* 2020; 12:e9167 Anwar S, Acharya S, Shahih S, Khabut A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802604>
19. **COVID-19 Induced Acute Pancreatitis: A Case Report and Literature Review.** *Cureus* 2020; 12:e9169 Kataria S, Sharif A, Ur Rehman A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802606>
20. **An Atypical Presentation of Fulminant Myocarditis Secondary to COVID-19 Infection.** *Cureus* 2020; 12:e9179 Richard I, Robinson B, Dawson A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802614>
21. **Acute Kidney Injury in COVID-19 Pneumonia: A Single-Center Experience in Bahrain.** *Cureus* 2020; 12:e9693 Taher A, Alalwan AA, Naser N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802627>
22. **COVID-19: The Intensive Care Point-of-View.** *Deutsche Medizinische Wochenschrift* 2020; 145:1057-1062 Stecher SS, Stemmler HJ, Eichenauer D *et al.*
23. **Evolving oxygenation management reasoning in COVID-19.** *Diagnosis (Berl)* 2020; Liu S, Sweeney C, Srisarajivakul-Klein N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827395>
24. **Rhabdomyolysis as Potential Late Complication Associated with COVID-19.** *Emerg Infect Dis* 2020; 26:2297-2298 He YC, Chen F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818421>
25. **Risks and features of secondary infections in severe and critical ill COVID-19 patients.** *Emerg Microbes Infect* 2020:1-45 Zhang H, Zhang Y, Wu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815458>
26. **COVID-19-associated aortic arch thrombus.** *Eur J Cardiothorac Surg* 2020; Mosbahi S, Heinisch PP, Schoenhoff FS, Berger DC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820319>
27. **Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.** *Hypertens. Res.* 2020; Matsuzawa Y, Ogawa H, Kimura K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820236>
28. **Poor outcomes in patients with cirrhosis and Corona Virus Disease-19.** *Indian J. Gastroenterol.* 2020; Shalimar, Elhence A, Vaishnav M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803716>
29. **Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.** *Int J Infect Dis* 2020; Klopfenstein T, Zayet S, Lohse A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798660>
30. **Hemoperfusion as a Supportive Treatment in a COVID-19 Patient with Late Pulmonary Thromboembolism: A Case Report.** *Int Med Case Rep J* 2020; 13:341-345 Moradi H, Abbasi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821175>
31. **Clinical characteristics and outcomes of critically ill patients with novel coronavirus infectious disease (COVID-19) in China: a retrospective multicenter study.** *Intensive Care Med* 2020; Xie J, Wu W, Li S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816098>
32. **COVID-19 in critically ill patients in North Brabant, the Netherlands: Patient characteristics and outcomes.** *J Crit Care* 2020; 60:111-115 Aleva FE, van Mourik L, Broeders M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799179>
33. **Severe arterial thromboembolism in patients with Covid-19.** *J Crit Care* 2020; 60:106-110 Lameijer JRC, van Houte J, van Berckel MMG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799178>
34. **Meta-trial of awake prone positioning with nasal high flow therapy: Invitation to join a pandemic collaborative research effort.** *J Crit Care* 2020; 60:140-142 Li J, Pavlov I, Laffey JG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799184>
35. **Toxic epidermal necrolysis and co-existent SARS-CoV-2 (COVID-19) treated with Intravenous Immunglobulin: "Killing 2 birds with one stone".** *J Eur Acad Dermatol Venereol* 2020; Saha M, D'Cruz A, Paul N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805059>
36. **COVID-19-Associated Critical Illness-Report of the First 300 Patients Admitted to Intensive Care Units at a New York City Medical Center.** *J. Intensive Care Med.* 2020; 35:963-970 Chand S, Kapoor S, Orsi D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812834>
37. **Special considerations in the assessment of catastrophic brain injury and determination of brain death in patients with SARS-CoV-2.** *J Neurol Sci* 2020; 417:117087 Valdes E, Agarwal S, Carroll E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798855>
38. **Severe diabetic ketoacidosis and coronavirus disease 2019 (COVID-19) infection in a teenage patient with newly diagnosed diabetes.** *J. Pediatr. Endocrinol. Metab.* 2020; Rabizadeh S, Hajmiri M, Rajab A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809963>
39. **Bilateral posterior cerebral artery territory infarction in a SARS-Cov-2 infected patient: discussion about an unusual case.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:105095 Bonardel C, Bonnerot M, Ludwig M

- et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807489>
40. [Encephalitis associated with COVID-19 in a 13-year-old girl: A case report]. *Medwave* 2020; 20:e7984Conto-Palomino NM, Cabrera-Bueno ML, Vargas-Ponce KG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804920>
 41. Hypermetabolism in critically ill patients with COVID-19 and the effects of hypothermia: A case series. *Metabol Open* 2020; 7:100046Yu PJ, Cassiere H, Bocchieri K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808941>
 42. COVID-19 suspicion revealed to be fat embolism syndrome. *Pan Afr. Med. J.* 2020; 36:104Mazouz S, Aissaoui O, Fehdi MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821315>
 43. A GAS-POWERED, PATIENT-RESPONSIVE AUTOMATIC RESUSCITATOR FOR USE IN ACUTE RESPIRATORY FAILURE: A BENCH AND EXPERIMENTAL STUDY. *Respir. Care* 2020; Jonkman AH, Katira BH, Schreiber A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817445>
 44. Chest physiotherapy: an important adjuvant in critically ill mechanically ventilated patients with COVID-19. *Respir. Physiol. Neurobiol.* 2020:103529Battaglini D, Robba C, Caiffa S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818606>
 45. The reversed halo sign: Considerations in the context of the COVID-19 pandemic. *Thromb Res* 2020; 195:228-230Marchiori E, Nobre LF, Hochegger B, Zanetti G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799128>
 46. Risk of Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 by Transfusion: A Literature Review. *Transfusion* 2020; Leblanc JF, Germain M, Delage G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798237>
 47. Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial. *Trials* 2020; 21:724Busani S, Tosi M, Mighali P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807241>
 48. Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial. *Trials* 2020; 21:717Villar J, Añón JM, Ferrando C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799933>

Cured – Recovered (3 articles)

1. Changes in serum virus-specific IgM/IgG antibody in asymptomatic and discharged patients with reoccurring positive COVID-19 nucleic acid test (RPNAT). *Ann. Med.* 2020:1-14Liu J, Lian R, Zhang G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808808>
2. Rehabilitation of patients with COVID-19. *Expert Rev. Respir. Med.* 2020; Sun T, Guo L, Tian F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799694>
3. Analysis of Risk Factors on Readmission Cases of COVID-19 in the Republic of Korea: Using Nationwide Health Claims Data. *Int J Environ Res Public Health* 2020; 17Jeon WH, Seon JY, Park SY, Oh IH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806775>

Cardiovascular disease (57 articles)

1. Thrombotic complications and anticoagulation in COVID-19 pneumonia: a New York City hospital experience. *Ann. Hematol.* 2020:1-6Hanif A, Khan S, Mantri N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808105>
2. Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review. *Ann Med Surg (Lond)* 2020; 57:236-243Napoli C, Tritto I, Benincasa G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802325>
3. Interplay of COVID-19 and cardiovascular diseases in Africa: an observational snapshot. *Clin Res Cardiol* 2020:1-9Chakafana G, Mutithu D, Hoewelmann J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809116>
4. Acute Limb Ischemia in COVID-19 Disease: A Mysterious Coagulopathy. *Cureus* 2020; 12:e9167Anwar S, Acharya S, Shahib S, Khabut A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802604>
5. An Atypical Presentation of Fulminant Myocarditis Secondary to COVID-19 Infection. *Cureus* 2020; 12:e9179Richard I, Robinson B, Dawson A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802614>
6. COVID-19: a cardiological point-of-view. *Deutsche Medizinische Wochenschrift* 2020; 145:1063-1067Weckbach LT, Kellnar A, Stremmel C *et al.*
7. COVID-19 and the impact of cardiovascular comorbidities. *Deutsche medizinische Wochenschrift (1946)* 2020; 145:1157-1160Seoudy H, Frey N.
8. Risk of stroke in hospitalized SARS-CoV-2 infected patients: A multinational study. *EBioMedicine* 2020; 59:102939Shahjouei S, Naderi S, Li J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818804>
9. COVID-19-associated aortic arch thrombus. *Eur J Cardiothorac Surg* 2020; Mosbahi S, Heinisch PP, Schoenhoff FS, Berger DC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820319>
10. Temporal trends in decompensated heart failure and outcomes during COVID-19: A multisite report from heart failure referral centres in London. *Eur J Heart Fail* 2020; Cannata A, Bromage DI, Rind IA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809274>
11. Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach. *Eur. J. Pediatr.* 2020; Sperotto F, Friedman KG, Son MBF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803422>
12. A case of novel coronavirus (COVID-19)-induced viral myocarditis mimicking a Takotsubo cardiomyopathy. *HeartRhythm Case Rep* 2020; 6:473-476Khalid Y, Dasu N, Dasu K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817822>
13. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study. *Hypertens. Res.* 2020; Matsuzawa Y, Ogawa H, Kimura K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820236>
14. Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis. *Indian Pacing Electrophysiol J* 2020; Pranata R, Huang I, Raharjo SB.

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814094>
15. **Reply to "SARS-CoV-2-associated Takotsubo is not necessarily triggered by the infection".** *Int J Cardiol Heart Vasc* 2020; 30:100613Sattar Y, Ullah W, Almas T, Alraies MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802937>
 16. **Evaluation of biventricular function in patients with COVID-19 using speckle tracking echocardiography.** *Int J Cardiovasc Imaging* 2020; Baycan OF, Barman HA, Atici A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803484>
 17. **A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19.** *Int J Infect Dis* 2020; Lu YF, Pan LY, Zhang WW *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798659>
 18. **Hemoperfusion as a Supportive Treatment in a COVID-19 Patient with Late Pulmonary Thromboembolism: A Case Report.** *Int Med Case Rep J* 2020; 13:341-345Moradi H, Abbasi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821175>
 19. **COVID-19-Specific Strategies for the Treatment of ST-Segment Elevation Myocardial Infarction in China.** *J Am Coll Cardiol* 2020; Ranard LS, Parikh SA, Kirtane AJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807587>
 20. **Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.** *J Am Heart Assoc* 2020:e017736Chen C, Wang F, Chen P *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807002>
 21. **Clinical Characteristics and Risk Factors of Cardiac Involvement in COVID-19.** *J Am Heart Assoc* 2020:e016807Xu H, Hou K, Xu R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806998>
 22. **Impact of COVID-19 outbreak on physical activity of patients with implantable cardioverter defibrillators.** *J. Card. Fail.* 2020; Malanchini G, Malacrida M, Ferrari P *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827643>
 23. **Increased cardiovascular death rates in a COVID-19 low prevalence area.** *J. Clin. Hypertens. (Greenwich)* 2020; Del Pinto R, Ferri C, Mammarella L *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815667>
 24. **Ischemic Stroke among the Symptoms Caused by the COVID-19 Infection.** *J Clin Med* 2020; 9Szelenberger R, Saluk-Bijak J, Bijak M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825182>
 25. **Value of electrocardiography in coronavirus disease 2019 (COVID-19).** *J. Electrocardiol.* 2020; 62:39-45Haseeb S, Gul EE, Çinier G *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805546>
 26. **Comment on "ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank" by Kuo et al.** *J Gerontol A Biol Sci Med Sci* 2020; Nikogosov DA, Shevlyakov AD, Baranova AV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803253>
 27. **Where have our patients gone? The impact of COVID-19 on stroke imaging and intervention at an Australian stroke centre.** *J. Med. Imaging Radiat. Oncol.* 2020; Amukotuwa SA, Bammer R, Maingard J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820616>
 28. **Longitudinal correlation of biomarkers of cardiac injury, inflammation, and coagulation to outcome in hospitalized COVID-19 patients.** *J. Mol. Cell. Cardiol.* 2020; 147:74-87Li C, Jiang J, Wang F *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827510>
 29. **Genes encoding ACE2, TMPRSS2 and related proteins mediating SARS-CoV-2 viral entry are upregulated with age in human cardiomyocytes.** *J. Mol. Cell. Cardiol.* 2020; Robinson EL, Alkass K, Bergmann O *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818486>
 30. **Call to Action: SARS-CoV-2 and Cerebrovascular Disorders (CASCADE).** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104938Abootalebi S, Aertker BM, Andalibi MS *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807412>
 31. **Acute stroke care in a New York City comprehensive stroke center during the COVID-19 pandemic.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:105068Agarwal S, Scher E, Rossan-Raghuath N *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807471>
 32. **Universal laboratory testing for SARS-CoV-2 in hyperacute stroke during the COVID-19 pandemic.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:105061Barlinn K, Siepmann T, Pallesen LP *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807466>
 33. **Bilateral posterior cerebral artery territory infarction in a SARS-Cov-2 infected patient: discussion about an unusual case.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:105095Bonardel C, Bonnerot M, Ludwig M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807489>
 34. **Acute stroke care algorithm in a private tertiary hospital in the Philippines during the COVID-19 pandemic: A third world country experience.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:105059Co COC, Yu JRT, Macrohon-Valdez MC *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807464>
 35. **Reversible cerebral vasoconstriction syndrome and dissection in the setting of COVID-19 infection.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:105011Dakay K, Kaur G, Gulko E *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807426>
 36. **A protocol for acute stroke unit care during the COVID-19 pandemic.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:105009De Silva DA, Tan IF, Thilarajah S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807424>
 37. **Subarachnoid hemorrhage guidance in the era of the COVID-19 pandemic - An opinion to mitigate exposure and conserve personal protective equipment.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:105010Nguyen TN, Jadhav AP, Dasenbrock HH *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807425>
 38. **Unprotected stroke management in an undiagnosed case of Severe Acute Respiratory Syndrome Coronavirus 2 infection.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104981Papi C, Spagni G, Alexandre A *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807416>
 39. **Hemorrhagic stroke in setting of severe COVID-19 infection requiring Extracorporeal Membrane Oxygenation (ECMO).** *J. Stroke Cerebrovasc. Dis.* 2020; 29:105016Zahid MJ, Baig A, Galvez-Jimenez N, Martinez N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807431>
 40. **Low stroke incidence in the TEMPiS telestroke network during COVID-19 pandemic - effect of lockdown on thrombolysis and thrombectomy.** *J Telemed Telecare* 2020:1357633x20943327Schlachetzki F, Theek C, Hubert ND *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811274>
 41. **High prevalence of early asymptomatic venous thromboembolism in anticoagulated COVID-19 patients hospitalized in general wards.** *J. Thromb. Thrombolysis* 2020:1-5Le Jeune S, Suhl J, Benainous R *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812199>

42. **Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound?** *J Ultrasound* 2020;1-9Ilerardi AM, Coppola A, Fusco S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809207>
43. **Shifting Paradigms in Cardiovascular Therapeutic Strategies During the COVID-19 Era.** *JACC Cardiovasc Interv* 2020; 13:1949-1950Kornowski R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819484>
44. **Strategies for Successful Catheterization Laboratory Recovery From the COVID-19 Pandemic.** *JACC Cardiovasc Interv* 2020; 13:1951-1957Poulin MF, Pinto DS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819485>
45. **Guidance for Rebooting Electrophysiology Through the COVID-19 Pandemic From the Heart Rhythm Society and the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology: Endorsed by the American College of Cardiology.** *JACC Clin Electrophysiol* 2020; 6:1053-1066Lakkireddy DR, Chung MK, Deering TF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819525>
46. **Coronavirus pandemic: COVID-19 increases risk of stroke.** *MMW-Fortschritte der Medizin* 2020; 162:29Diener HC.
47. **Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19?** *Mol. Med.* 2020; 26:80Namsolleck P, Moll GN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807075>
48. **Cross-Talk Between Key Players in Patients with COVID-19 and Ischemic Stroke: A Review on Neurobiological Insight of the Pandemic.** *Mol. Neurobiol.* 2020:1-8Kaushik P, Kaushik M, Parveen S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813238>
49. **Acutely altered mental status as the main clinical presentation of multiple strokes in critically ill patients with COVID-19.** *Neurol Sci* 2020:1-4Díaz-Pérez C, Ramos C, López-Cruz A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808174>
50. **A COVID-19-pandémia hatása az akut ischaemiás stroke ellátásra. A járulékos egészségügyi veszteségek retrospektív, egycentrumos felmérése (A COVID-19-pandémia orvosszakmai kérdései).** *Orv. Hetil.* 2020; 161:1395-1399Böjti PP, Stang R, Gunda B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804669>
51. **[Effects of COVID-19 pandemic on acute ischemic stroke care. A single-centre retrospective analysis of medical collateral damage].** *Orv. Hetil.* 2020; 161:1395-1399Böjti PP, Stang R, Gunda B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804669>
52. **Brady-arrhythmias in Patients with COVID-19: Marker of Poor Prognosis?** *Pacing Clin. Electrophysiol.* 2020; Chinitz JS, Goyal R, Harding M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820823>
53. **Intensive care and anesthetic management of patients with brugada syndrome and COVID-19 infection.** *Pacing Clin. Electrophysiol.* 2020; Dendramis G, Brugada P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815174>
54. **Prevention and Treatment Strategies for the Cardiology Department of a Non-COVID-19 Designated Hospital in the Post-Epidemic Period.** *Risk Manag. Healthc. Policy* 2020; 13:979-987Fan Q, Chen X, Lin Y, Wang Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801972>
55. **Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.** *Scott. Med. J.* 2020:36933020949219Megaly M, Glogoza M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807019>
56. **Anti Xa activity after high dose LMWH thrombosis prophylaxis in covid 19 patients at the intensive care unit.** *Thromb Res* 2020; 196:1-3Vlot EA, Van den Dool EJ, Hackeng CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805623>
57. **COVID-19 Infection and Cardiac Arrhythmias.** *Trends Cardiovasc. Med.* 2020; Manolis AS, Manolis AA, Manolis TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814095>

DM-MS-Obesity (12 articles)

1. **The relationship between diabetes and clinical outcomes in COVID-19: a single-center retrospective analysis.** *Acta Diabetol* 2020; Fox T, Ruddiman K, Lo KB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804317>
2. **Diabetes Mellitus is Associated with Severe Infection and Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis.** *Arch Med Res* 2020; Shang L, Shao M, Guo Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811670>
3. **Fast-track pathway for diabetic foot ulceration during COVID-19 crisis: a document from International Diabetic Foot Care Group and D-Foot International.** *Diabetes Metab Res Rev* 2020:e3396Meloni M, Bouillet B, Ahluwalia R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804425>
4. **Fast-track pathway for diabetic foot ulceration during COVID-19 crisis: A document from International Diabetic Foot Care Group and D-Foot International.** *Diabetes Metab Res Rev* 2020:e3396Meloni M, Bouillet B, Ahluwalia R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804425>
5. **Diabetes and Covid-19: An interplay difficult to dissect.** *Diabetes Metab Res Rev* 2020:e3387Napoli R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818297>
6. **Caring for children and adolescents with type 1 diabetes mellitus: italian society for pediatric and adolescent diabetes (ISPED) Statements during COVID-19 pandemic.** *Diabetes Res Clin Pract* 2020:108372d'Annunzio G, Maffei C, Cherubini V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827594>
7. **Blood glucose levels and COVID-19. Reply to Sardu C, D'Onofrio N, Balestrieri ML et al [letter] and Lepper PM, Bals R, Jüni P et al [letter].** *Diabetologia* 2020; Cariou B, Hadjadj S, Wargny M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816095>
8. **Monocytopenia, monocyte morphological anomalies and hyperinflammation characterise severe COVID-19 in type 2 diabetes.** *EMBO Mol Med* 2020:e202013038Alzaid F, Julla JB, Diedisheim M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816392>
9. **Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics.** *Int J Mol Sci* 2020; 21Ritter A, Kreis NN, Louwen F, Yuan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806722>
10. **Bridging the Needs of Adolescent Diabetes Care During Coronavirus Disease 2019: A Nurse-Led Telehealth Initiative.** *J. Adolesc. Health* 2020; Lim ST, Yap F, Chin X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798101>

11. **Severe diabetic ketoacidosis and coronavirus disease 2019 (COVID-19) infection in a teenage patient with newly diagnosed diabetes.** *J. Pediatr. Endocrinol. Metab.* 2020; Rabizadeh S, Hajmiri M, Rajab A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809963>
12. **Are people with uncontrolled diabetes mellitus at high risk of reinfections with COVID-19?** *Prim. Care Diabetes* 2020; Pal R, Banerjee M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800450>

Education and training and science (40 articles)

1. **Simulations and Virtual Learning Supporting Clinical Education During the COVID 19 Pandemic.** *Adv Med Educ Pract* 2020; 11:513-516 Tabatabai S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821192>
2. **COVID-19 pandemic preparation: using simulation for systems-based learning to prepare the largest healthcare workforce and system in Canada.** *Adv Simul (Lond)* 2020; 5:22 Dubé M, Kaba A, Cronin T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821441>
3. **Virtual Imaging Trials for Coronavirus Disease (COVID-19).** *AJR Am J Roentgenol* 2020; 1-7 Abadi E, Paul Segars W, Chalian H, Samei E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822224>
4. **Remote Anatomic Pathology Medical Student Education in Washington State.** *Am J Clin Pathol* 2020; Parker EU, Chang O, Koch L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815530>
5. **Stay calm and focus on the learning outcomes: Tools for taking biophysical chemistry online.** *Biochem Mol Biol Educ* 2020; Ballester M, Van Hoozen B, Sikora AK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798314>
6. **Maxillofacial education in the time of COVID-19: the West Midlands experience.** *Br. J. Oral Maxillofac. Surg.* 2020; Elledge R, Williams R, Fowell C, Green J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807595>
7. **Structure-Based Drug Design of an Inhibitor of the SARS-CoV-2 (COVID-19) Main Protease Using Free Software: A Tutorial for Students and Scientists.** *ChemRxiv* 2020; Zhang S, Krumberger M, Morris MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817929>
8. **Prevention Knowledge and Its Practice Towards COVID-19 Among General Population of Saudi Arabia: A Gender-based Perspective.** *Curr. Pharm. Des.* 2020; Alshammary F, Siddiqui AA, Amin J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811408>
9. **Considerations for stakeholder engagement and COVID-19 related clinical trials' conduct in sub-Saharan Africa.** *Dev World Bioeth* 2020; Folayan MO, Brown B, Haire B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798320>
10. **Coronavirus disease (COVID-19) outbreak and phase 1 trials: should we consider a specific patient management?** *Eur. J. Cancer* 2020; 137:235-239 Postel-Vinay S, Massard C, Soria JC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805640>
11. **Indoor air quality at school and students' performance: Recommendations of the UNESCO Chair on Health Education and Sustainable Development & the Italian Society of Environmental Medicine (SIMA).** *Health Promot Perspect* 2020; 10:169-174 Pulimeno M, Piscitelli P, Colazzo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802752>
12. **Simulated Video Consultations as a Learning Tool in Undergraduate Nursing: Students' Perceptions.** *Healthcare (Basel)* 2020; 8: Jiménez-Rodríguez D, Arroigante O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825269>
13. **Investigating and evaluating evidence of the behavioural determinants of adherence to social distancing measures - A protocol for a scoping review of COVID-19 research.** *HRB Open Res* 2020; 3:46 Noone C, Warner N, Byrne M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803123>
14. **COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study.** *Immun. Ageing* 2020; 17:22 Jurado A, Martín MC, Abad-Molina C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802142>
15. **Impact of a Brief Educational Intervention on Knowledge, Perceived Knowledge, Perceived Safety, and Resilience of the Public During COVID-19 Crisis.** *Int J Environ Res Public Health* 2020; 17: Kaim A, Jaffe E, Siman-Tov M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824591>
16. **The Relationship between the COVID-19 Pandemic and Nursing Students' Sense of Belonging: The Experiences and Nursing Education Management of Pre-Service Nursing Professionals.** *Int J Environ Res Public Health* 2020; 17: Santos LMD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806697>
17. **The impact of the COVID-19 pandemic on fellowship training: A national survey of pediatric otolaryngology fellowship directors.** *Int J Pediatr Otorhinolaryngol* 2020; 136:110217 Johnson J, Chung MT, Stathakios J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32797806>
18. **Investigating effects of healthcare simulation on personal strengths and organizational impacts for healthcare workers during COVID-19 pandemic: A cross-sectional study.** *Integr Med Res* 2020; 9:100476 Cheung VK, So EH, Ng GW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802743>
19. **Bibliometric analysis of researches on traditional Chinese medicine for coronavirus disease 2019 (COVID-19).** *Integr Med Res* 2020; 9:100490 Yang KL, Jin XY, Gao Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802744>
20. **COVID-19 impact and virtual medical education.** *J Adv Med Educ Prof* 2020; 8:140-143 Tabatabai S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802908>
21. **Remote Learning for Medical Student-Level Dermatology During the COVID-19 Pandemic.** *J Am Acad Dermatol* 2020; Patel PM, Tsui CL, Varma A, Levitt J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798574>
22. **The Early Influence and Effects of the Coronavirus Disease 2019 (COVID-19) Pandemic on Resident Education and Adaptations.** *J Am Coll Radiol* 2020; Chertoff JD, Zazour JG, Morgan DE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818485>
23. **Perspectives on COVID-19 from Singapore: Impact on ESKD Care and Medical Education.** *J Am Soc Nephrol* 2020; Coffman TM, Chan CM, Choong LH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817117>
24. **The impacts of the COVID-19 pandemic on the teaching of dentistry in Brazil.** *J. Dent. Educ.* 2020; Spanemberg JC, Simões CC, Cardoso JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813876>
25. **Interprofessional education during the COVID-19 pandemic: finding the good in a bad situation.** *J Interprof Care* 2020; 1-14 Jones TA, Vidal G, Taylor C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811228>
26. **Leveraging media and health communication strategies to overcome the COVID-19 infodemic.** *J Public Health Policy* 2020; 1-11 Mheidly N, Fares J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826935>

27. **Effect of COVID-19 on Surgical Training Across the United States: A National Survey of General Surgery Residents.** *J Surg Educ* 2020; Aziz H, James T, Remulla D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798154>
28. **Medical Student Assessment in the Time of COVID-19.** *J Surg Educ* 2020; Prigoff J, Hunter M, Nowygrod R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819868>
29. **Knowledge of Health Care Professionals and Medical Students Regarding Covid-19 in a Tertiary Care Hospital in Nepal.** *JNMA J. Nepal Med. Assoc.* 2020; 58:480-486 Neupane HC, Shrestha N, Adhikari S *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827009>
30. **A UK perspective on the effect of the COVID-19 pandemic on medical student career perceptions.** *Med. Educ. Online* 2020; 25:1810968Elsawy F, Malik RB, Kazi M, Ladan Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815785>
31. **Coronials: Nurses who graduated during the COVID-19 pandemic. Will they be better nurses?** *Nurse Educ. Today* 2020; 94:104536 Monforte-Royo C, Fuster P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801065>
32. **Quality of online information for the general public on COVID-19.** *Patient Educ. Couns.* 2020; Jayasinghe R, Ranasinghe S, Jayarajah U, Seneviratne S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800422>
33. **Evaluation of knowledge, attitudes, and clinical education of dental students about COVID-19 pandemic.** *PeerJ* 2020; 8:e9575 Ataş O, Talo Yildirim T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821538>
34. **Zwischen Traum und Trauma - Aufbau und Betrieb einer Kohortenstation für Patient_innen mit COVID-19 in einem Akutspital.** *Pflege* 2020; 33:247-255 Rabes C, Bläuer C, Büche V *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811329>
35. **Creating COVID-19 alternate care site trainings for interprofessional teams.** *Public Health Nurs.* 2020; S BH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808285>
36. **The scientific production during 2009 swine flu pandemic and 2019/2020 COVID-19 pandemic.** *Pulmonology* 2020; Carvalho TA, Lima TM, Melani VF *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800782>
37. **Letter from Singapore: The clinical and research response to COVID-19.** *Respirology* 2020; Chotirmall SH, Wang LF, Abisheganaden JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808426>
38. **Conducting research during the COVID-19 pandemic.** *Semin. Perinatol.* 2020:151287 Mourad M, Bousleiman S, Wapner R, Gyamfi-Bannerman C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807490>
39. **Democratizing Access to Neurosurgical Medical Education: National Efforts in a Medical Student Training Camp During COVID-19.** *World Neurosurg* 2020; Thum DiCesare JA, Segar DJ, Donoho D *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827739>
40. **COVID-19's Impact on Neurosurgical Training in Southeast Asia.** *World Neurosurg* 2020; Wittayanakorn N, Weng Nga VD, Sobana M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805466>

Elderly (11 articles)

1. **The impact of delirium on outcomes for older adults hospitalised with COVID-19.** *Age Ageing* 2020; Marengoni A, Zucchelli A, Grande G *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821901>
2. **Virtual Geriatric Clinics and the COVID-19 Catalyst: A Rapid Review.** *Age Ageing* 2020; Murphy RP, Dennehy KA, Costello MM *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821909>
3. **COVID-19: risk accumulation among biologically and socially vulnerable older populations.** *Ageing Res Rev* 2020:101149 Calderón-Larrañaga A, Dekhtyar S, Vetrano DL *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818650>
4. **Applying active learning in a virtual classroom such as a molecular biology escape room.** *Biochem Mol Biol Educ* 2020; Alonso G, Schroeder KT. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812701>
5. **COVID-19: a geriatric point-of-view.** *Deutsche Medizinische Wochenschrift* 2020; 145:1039-1043 Sieber C.
6. **Age Moderates Perceived COVID-19 Disruption on Well-being.** *Gerontologist* 2020; Knepple Carney A, Graf AS, Hudson G, Wilson E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808660>
7. **The Age-Related Risk of Severe Outcomes Due to COVID-19 Infection: A Rapid Review, Meta-Analysis, and Meta-Regression.** *Int J Environ Res Public Health* 2020; 17:Romero Starke K, Petereit-Haack G, Schubert M *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824596>
8. **Influencing Factors of Understanding COVID-19 Risks and Coping Behaviors among the Elderly Population.** *Int J Environ Res Public Health* 2020; 17:Sun Z, Yang B, Zhang R, Cheng X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823740>
9. **Novel Solutions for Dermatologic Care of Geriatric Patients and the Role of the Dermatology House Call.** *J Am Acad Dermatol* 2020; Lipner SR, Ouchida K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798576>
10. **Is Exposure to Epidemic Associated with Older Adults' Health Behavior? Evidence from China's 2002-2004 SARS Outbreak.** *J. Gerontol. B Psychol. Sci. Soc. Sci.* 2020; Zou H, Wen S, Xu H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827210>
11. **Healthcare Concerns of Older Adults during the COVID-19 Outbreak in Low- and Middle-Income Countries: Lessons for Health Policy and Social Work.** *J Gerontol Soc Work* 2020:1-7 Arthur-Holmes F, Akaadom MKA, Agyemang-Duah W *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808585>

Epidemiology (55 articles)

1. **Investigation on the impacts of COVID-19 quarantine on society and environment: Preventive measures and supportive technologies.** *3 Biotech* 2020; 10:393 Kumaravel SK, Subramani RK, Jayaraj Sivakumar TK *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821645>
2. **Implementation and Process of a COVID-19 Contact Tracing Initiative: Leveraging Health Professional Students to Extend the Workforce During a Pandemic.** *Am. J. Infect. Control* 2020; Koetter P, Pelton M, Gonzalo J *et al*. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798633>

3. **Fighting the COVID-19 pandemic: onsite mass workplace testing for COVID-19 in the Republic of Korea.** *Ann Occup Environ Med* 2020; 32:e22Seo E, Mun E, Kim W, Lee C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802338>
4. **Epidemiology and clinical characteristics of 43 COVID-19 patients in Weifang, China.** *Ann Palliat Med* 2020; Wang Q, Zheng S, Tan W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819125>
5. **Response to COVID-19 in Bangladesh: Strategies to Resist the Growing Trend of COVID-19 in a Less Restricted Situation.** *Asia Pac. J. Public Health* 2020;1010539520951689Chowdhury SR, Sunna TC, Sanjoy S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814435>
6. **Mathematical Parameters of the COVID-19 Epidemic in Brazil and Evaluation of the Impact of Different Public Health Measures.** *Biology (Basel)* 2020; 9Cotta RM, Naveira-Cotta CP, Magal P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806613>
7. **Inverted Covariate Effects for First versus Mutated Second Wave Covid-19: High Temperature Spread Biased for Young.** *Biology (Basel)* 2020; 9Seligmann H, Iggui S, Rachdi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823981>
8. **The effect of travel restrictions on the geographical spread of COVID-19 between large cities in China: a modelling study.** *BMC Med* 2020; 18:259Quilty BJ, Diamond C, Liu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814572>
9. **Forecast predictions for the COVID-19 pandemic in Brazil by statistical modeling using the Weibull distribution for daily new cases and deaths.** *Braz. J. Microbiol.* 2020; Moreau VH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809115>
10. **Epidemiological, virological and serological features of COVID-19 cases in people living with HIV in Wuhan City: A population-based cohort study.** *Clin Infect Dis* 2020; Huang J, Xie N, Hu X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803216>
11. **Prevalence of SARS-CoV-2 asymptomatic infections in two large academic health systems in Wisconsin.** *Clin Infect Dis* 2020; Rivera F, Safdar N, Ledebner N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812030>
12. **Insights on COVID-19 epidemiology from a historic cruise ship quarantine.** *Clin Infect Dis* 2020; Yamagishi T, Doi Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798226>
13. **Epidemiology, outcomes and associated factors of COVID-19 RT-PCR confirmed cases in the San Pedro Sula Metropolitan Area, Honduras.** *Clin Infect Dis* 2020; Zuniga-Moya JC, Norwood DA, Romero Reyes LE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803236>
14. **Epidemiological and clinical characteristics of SARS-CoV-2 infections at a testing site in Berlin, Germany, March and April 2020 - A cross-sectional study.** *Clin Microbiol Infect* 2020; Maechler F, Gertler M, Hermes J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827715>
15. **SARS-CoV-2: Symptoms-based testing is not enough.** *Deutsche Medizinische Wochenschrift* 2020; 145:958-959Krome S.
16. **Epidemiology of COVID-19 Outbreak on Cruise Ship Quarantined at Yokohama, Japan, February 2020.** *Emerg Infect Dis* 2020; 26. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822290>
17. **Asymptomatic Transmission of SARS-CoV-2 on Evacuation Flight.** *Emerg Infect Dis* 2020; 26Bae SH, Shin H, Koo HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822289>
18. **The Pandemic Predominantly Hits Poor Neighbourhoods? SARS-CoV-2 Infections and Covid-19 Fatalities in German Districts.** *Eur. J. Public Health* 2020; Plümpert T, Neumayer E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818263>
19. **Three infection clusters related with potential pre-symptomatic transmission of coronavirus disease (COVID-19), Shanghai, China, January to February 2020.** *Euro Surveill* 2020; 25Gong X, Xiao W, Cui Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820715>
20. **COVID -19 corollary: the changing role of a hospital epidemiologist in the new world.** *Expert Rev. Anti Infect. Ther.* 2020; Chopra T, Levy P, Tillotson G, Sobel J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799575>
21. **COVID-19 pandemic and Rohingya refugees in Bangladesh: What are the major concerns?** *Glob Public Health* 2020;1-4Banik R, Rahman M, Hossain MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816647>
22. **Communicating health crisis: a content analysis of global media framing of COVID-19.** *Health Promot Perspect* 2020; 10:257-269Ogbodo JN, Onwe EC, Chukwu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802763>
23. **Prediction of COVID-19 Outbreaks Using Google Trends in India: A Retrospective Analysis.** *Healthc Inform Res* 2020; 26:175-184Venkatesh U, Gandhi PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819035>
24. **Investigating and evaluating evidence of the behavioural determinants of adherence to social distancing measures - A protocol for a scoping review of COVID-19 research.** *HRB Open Res* 2020; 3:46Noone C, Warner N, Byrne M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803123>
25. **Global burden of coronavirus disease 2019 outbreak: Situational analysis and review.** *Hum. Antibodies* 2020; Gebru AA, Tessema TB, Milki MT *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804122>
26. **A preliminary study on contact tracing & transmission chain in a cluster of 17 cases of severe acute respiratory syndrome coronavirus 2 infection in Basti, Uttar Pradesh, India.** *Indian J Med Res* 2020; Kant R, Zaman K, Shankar P, Yadav R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811800>
27. **Epidemiological & clinical characteristics & early outcome of COVID-19 patients in a tertiary care teaching hospital in India: A preliminary analysis.** *Indian J Med Res* 2020; Kayina CA, Haritha D, Soni L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811801>
28. **China's practice to prevent and control COVID-19 in the context of large population movement.** *Infect Dis Poverty* 2020; 9:115Xu TL, Ao MY, Zhou X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814591>
29. **The epidemiological burden of and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis.** *Infection* 2020;1-21Mahumud RA, Kamara JK, Renzaho AMN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813220>
30. **Space-Time Patterns, Change, and Propagation of COVID-19 Risk Relative to the Intervention Scenarios in Bangladesh.** *Int J Environ Res Public Health* 2020; 17Masrur A, Yu M, Luo W, Dewan A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824030>

31. **Unspoken inequality: how COVID-19 has exacerbated existing vulnerabilities of asylum-seekers, refugees, and undocumented migrants in South Africa.** *Int J Equity Health* 2020; 19:141Mukumbang FC, Ambe AN, Adebiji BO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819364>
32. **Estimating the impact of physical distancing measures in containing COVID-19: an empirical analysis.** *Int J Infect Dis* 2020; Koh WC, Naing L, Wong J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800859>
33. **The Costs of an Expanded Screening Criteria for COVID-19: A Modelling Study.** *Int J Infect Dis* 2020; Lim JT, Dickens BL, Cook AR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800857>
34. **Translation of genomic epidemiology of infectious pathogens: Enhancing African genomics hubs for outbreaks.** *Int J Infect Dis* 2020; Oboh MA, Omoleke SA, Ajibola O *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800861>
35. **A reflection on the anti-epidemic response of COVID-19 from the perspective of disaster management.** *Int J Nurs Sci* 2020; 7:382-385Chan DW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817863>
36. **Experiencing Social Isolation (Even in the Era of COVID-19 Pandemic Lockdown): Teachings Through Arts from Adolescents with Cancer.** *J Adolesc Young Adult Oncol* 2020; Ferrari A, Pagani Bagliacca E, Veneroni L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809889>
37. **Reactions to COVID-19: Differential predictors of distress, avoidance, and disregard for social distancing.** *J Affect Disord* 2020; 277:94-98Taylor S, Landry CA, Paluszek MM, Asmundson GJG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799109>
38. **Examining the impact of COVID-19 in ethnically diverse families with young children with intellectual and developmental disabilities.** *J Intellect Disabil Res* 2020; Neece C, McIntyre LL, Fenning R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808424>
39. **Years of Life Lost Attributable to COVID-19 in High-incidence Countries.** *J Korean Med Sci* 2020; 35:e300Oh IH, Ock M, Jang SY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808515>
40. **Behavioural manipulation - key to the successful global spread of the new Coronavirus SARS-CoV-2?** *J Med Virol* 2020; Bouayed J, Bohn T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813286>
41. **The preventive strategies of COVID-19 pandemic in Saudi Arabia.** *J Microbiol Immunol Infect* 2020; Nurunnabi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807687>
42. **Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19).** *J. Mol. Med. (Berl.)* 2020;1-15Olwenyi OA, Dyavar SR, Acharya A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808094>
43. **Changing epidemiology of SARS-CoV in the context of COVID-19 pandemic.** *J. Prev. Med. Hyg.* 2020; 61:E130-e136Bhattacharya S, Basu P, Poddar S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802995>
44. **Safe Villages during the 1918-1919 influenza pandemic in Spain and Portugal.** *J. Prev. Med. Hyg.* 2020; 61:E137-e142Erkoreka A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802996>
45. **Potential for inter-state spread of Covid-19 from Arizona, USA: Analysis of mobile device-location and commercial flight data.** *J Travel Med* 2020; Waits A, Au NH, Thomas-Bachli A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822473>
46. **Management Strategies for People Experiencing Sheltered Homelessness during the COVID-19 Pandemic: Clinical Outcomes and Costs.** *medRxiv* 2020; Freedberg KA, Baggett TP, Scott JA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817967>
47. **The prevalence rate of anti-SARS-CoV-2-IgG is 1.2% – Screening in asymptomatic outpatients in Germany (Northrhine-Westfalia).** *MMW-Fortschritte der Medizin* 2020; 162:44-46Herrmann BL.
48. **School Nursing and Public Health: The Case for School Nurse Investigators and Contact Tracing Monitors of COVID-19 Patients in Massachusetts.** *NASN Sch. Nurse* 2020;1942602x20950670Flaherty EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806994>
49. **Leveraging best practices: protecting sub-Saharan African prison detainees amid COVID-19.** *Pan Afr. Med. J.* 2020; 36:121Chireh B, Essien SK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821332>
50. **Air quality improvement during triple-lockdown in the coastal city of Kannur, Kerala to combat Covid-19 transmission.** *PeerJ* 2020; 8:e9642Resmi CT, Nishanth T, Satheesh Kumar MK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821548>
51. **The effect of big-city news on rural America during the COVID-19 pandemic.** *Proc Natl Acad Sci U S A* 2020; Kim E, Shepherd ME, Clinton JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820075>
52. **Understanding transmission and intervention for the COVID-19 pandemic in the United States.** *Sci Total Environ* 2020; 748:141560Li Y, Zhang R, Zhao J, Molina MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798884>
53. **Sexual and gender minority adolescents must be prioritised during the global COVID-19 public health response.** *Sex Reprod Health Matters* 2020; 28:1804717DeMulder J, Kraus-Perrotta C, Zaidi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799759>
54. **Daily surveillance of COVID-19 using the prospective space-time scan statistic in the United States.** *Spat Spatiotemporal Epidemiol* 2020; 34:100354Hohl A, Delmelle EM, Desjardins MR, Lan Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807396>
55. **Protocol: Leveraging a demographic and health surveillance system for Covid-19 Surveillance in rural KwaZulu-Natal.** *Wellcome Open Res* 2020; 5:109Siedner MJ, Harling G, Derache A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802963>

Gastro-enterology (18 articles)

1. **Management of Gastrointestinal Endoscopy Unit during Post Covid-19 Endemic Outbreak: A Report from Wuhan Epicenter.** *Am. J. Infect. Control* 2020; Cao L, Guo Q, Chen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798632>
2. **The Course of SARS-COV2 Infection Was Not Severe in a Crohn's Patient Who Administered Maintenance Anti-TNF Therapy Overlapping the Early Pre-Symptomatic Period of Infection.** *Antibodies (Base)* 2020; 9Okeke F, Mone A, Swaminath A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824122>
3. **Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue.** *Arch. Toxicol.* 2020;1-5Saheb Sharif-Askari N, Saheb Sharif-Askari F, Mdkhana B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808185>

4. **Risk of COVID-19 in celiac disease patients.** *Autoimmun Rev* 2020:102639Zingone F, D'Odorico A, Lorenzon G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801048>
5. **COVID-19 Induced Acute Pancreatitis: A Case Report and Literature Review.** *Cureus* 2020; 12:e9169Kataria S, Sharif A, Ur Rehman A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802606>
6. **COVID-19 from a gastroenterological perspective.** *Deutsche Medizinische Wochenschrift* 2020; 145:1033-1038Schulz C, Mayerle J, Stubbe HC *et al.*
7. **Adoption of Multi-society Guidelines Facilitates Value-Based Reduction in Screening and Surveillance Colonoscopy Volume During COVID-19 Pandemic.** *Dig. Dis. Sci.* 2020; Xiao AH, Chang SY, Stevoff CG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803460>
8. **COVID-19 extrapulmonary illness - special gastrointestinal and hepatic considerations.** *Dis. Mon.* 2020:101064Perisetti A, Gajendran M, Mann R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807535>
9. **Poor outcomes in patients with cirrhosis and Corona Virus Disease-19.** *Indian J. Gastroenterol.* 2020; Shalimar, Elhence A, Vaishnav M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803716>
10. **Management of Immune-Related Colitis During the COVID-19 Pandemic.** *Inflamm. Bowel Dis.* 2020; Amin R, Thomas AS, Khurana S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812047>
11. **Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures.** *Inflamm. Bowel Dis.* 2020; Taxonera C, Alba C, Olivares D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812035>
12. **Clinical characteristics of diarrhea in 90 cases with COVID-19: A descriptive study.** *Int. Emerg. Nurs.* 2020; 52:100912Xiao Y, Huang S, Yan L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827932>
13. **COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature.** *Int Med Case Rep J* 2020; 13:317-321Niknam R, Malek-Hosseini SA, Hashemieh SS, Dehghani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801943>
14. **Guidelines Adaptation to the COVID-19 Outbreak for the Management of Hepatocellular Carcinoma.** *J. Laparoendosc. Adv. Surg. Tech. A* 2020; Santambrogio R, Farina G, D'Alessandro V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810426>
15. **A Case of Gastrointestinal-Predominant COVID-19 Demonstrates Value of Stool PCR Test.** *J Med Virol* 2020; Khoury NC, Russi TJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816305>
16. **Gastrointestinal and Hepatic Manifestations of COVID-19: Evolving Recognition and Need for Increased Understanding in Vulnerable Populations.** *J. Natl. Med. Assoc.* 2020; Garland V, Kumar AB, Borum ML. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807512>
17. **COVID-19 and Inflammatory Bowel Disease: Patient Knowledge and Perceptions in a Single Center Survey.** *Medicina (Kaunas)* 2020; 56Spagnuolo R, Larussa T, Iannelli C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823727>
18. **Risk Reduction of COVID-19 Pandemic in Pakistan.** *Soc Work Public Health* 2020:1-12Shoaib M, Abdullah F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811345>

Guidelines (12 articles)

1. **Australian College of Critical Care Nurses and Australasian College for Infection Prevention and Control position statement on facilitating next-of-kin presence for patients dying from coronavirus disease 2019 (COVID-19) in the intensive care unit.** *Aust. Crit. Care* 2020; Bloomer MJ, Bouchoucha S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826150>
2. **COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making.** *Biochim Biophys Acta Rev Cancer* 2020:188412Larson C, Oronsky B, Goyal S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827582>
3. **Fast-track pathway for diabetic foot ulceration during COVID-19 crisis: a document from International Diabetic Foot Care Group and D-Foot International.** *Diabetes Metab Res Rev* 2020:e3396Meloni M, Bouillet B, Ahluwalia R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804425>
4. **Adoption of Multi-society Guidelines Facilitates Value-Based Reduction in Screening and Surveillance Colonoscopy Volume During COVID-19 Pandemic.** *Dig. Dis. Sci.* 2020; Xiao AH, Chang SY, Stevoff CG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803460>
5. **Key Guidelines in Developing a Pre-Emptive COVID-19 Vaccination Uptake Promotion Strategy.** *Int J Environ Res Public Health* 2020; 17French J, Deshpande S, Evans W, Obregon R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823775>
6. **Persian medicine recommendations for the prevention of pandemics related to the respiratory system: a narrative literature review.** *Integr Med Res* 2021; 10:100483Iranzadasl M, Karimi Y, Moadeli F, Pasalar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802742>
7. **Anesthesia for Patients Undergoing Anesthesia for Elective Thoracic Surgery During the COVID-19 Pandemic: A Consensus Statement From the Israeli Society of Anesthesiologists.** *J Cardiothorac Vasc Anesth* 2020; Shaylor R, Verenkin V, Matot I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798170>
8. **Guidelines Adaptation to the COVID-19 Outbreak for the Management of Hepatocellular Carcinoma.** *J. Laparoendosc. Adv. Surg. Tech. A* 2020; Santambrogio R, Farina G, D'Alessandro V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810426>
9. **Subarachnoid hemorrhage guidance in the era of the COVID-19 pandemic - An opinion to mitigate exposure and conserve personal protective equipment.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:105010Nguyen TN, Jadhav AP, Dasenbrock HH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807425>
10. **Guidance for Rebooting Electrophysiology Through the COVID-19 Pandemic From the Heart Rhythm Society and the American Heart Association Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology: Endorsed by the American College of Cardiology.** *JACC Clin Electrophysiol* 2020; 6:1053-1066Lakkireddy DR, Chung MK, Deering TF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819525>
11. **ESOPRS recommendations for oculoplastic surgeons during the COVID-19 pandemic: a challenge for the future.** *Orbit* 2020:1-3Quaranta-Leoni FM, Paridaens D, Verity D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808834>
12. **Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection.** *Colombian Association of Rheumatology. Reumatol. Clin.* 2020;

Imaging (20 articles)

1. **Virtual Imaging Trials for Coronavirus Disease (COVID-19).** *AJR Am J Roentgenol* 2020;1-7Abadi E, Paul Segars W, Chalian H, Samei E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822224>
2. **Could Spectral CT Have a Potential Benefit in Coronavirus Disease (COVID-19)?** *AJR Am J Roentgenol* 2020;1-6Daoud B, Cazejust J, Tavolaro S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822225>
3. **Echocardiographic characteristics of patients with SARS-CoV-2 infection.** *Clin Res Cardiol* 2020; Stöbe S, Richter S, Seige M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803387>
4. **Pulmonary Sonography in Patients with Suspected COVID-19 - Step-by-Step.** *Deutsche Medizinische Wochenschrift* 2020; 145:1100-1104Schmid B, Hornuß D, Feuerstein D *et al.*
5. **CT abnormalities evocative of lung infection are associated with lower (18)F-FDG uptake in confirmed COVID-19 patients.** *Eur J Nucl Med Mol Imaging* 2020;1-5Bahloul A, Boursier C, Jeulin H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808079>
6. **Changes in lung ultrasound of symptomatic healthcare professionals with COVID-19 pneumonia and their association with clinical findings.** *J. Clin. Ultrasound* 2020; Mafort TT, Lopes AJ, da Costa CH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827163>
7. **Where have our patients gone? The impact of COVID-19 on stroke imaging and intervention at an Australian stroke centre.** *J. Med. Imaging Radiat. Oncol.* 2020; Amukotuwa SA, Bammer R, Maingard J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820616>
8. **COVID-19 Pandemic - considerations and challenges for the management of medical imaging departments in Queensland.** *J Med Radiat Sci* 2020; Eastgate P, Neep MJ, Steffens T, Westerink A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827241>
9. **Novel coronavirus disease 2019 (COVID-19) outbreak in children in Iran: Atypical CT manifestations and mortality risk of severe COVID-19 infection.** *J Microbiol Immunol Infect* 2020; Mamishi S, Heydari H, Aziz-Ahari A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814650>
10. **Investigation of a family cluster outbreak of COVID-19 indicates the necessity of CT screening for asymptomatic family members in close contact with confirmed patients.** *J Thorac Dis* 2020; 12:3673-3681Liu Z, Wu Q, Zou Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802446>
11. **Early detection of deep vein thrombosis in patients with coronavirus disease 2019: who to screen and who not to with Doppler ultrasound?** *J Ultrasound* 2020;1-9Ierardi AM, Coppola A, Fusco S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809207>
12. **Lung Ultrasound for COVID-19 Patchy Pneumonia: Extended or Limited Evaluations?** *J Ultrasound Med* 2020; Smargiassi A, Soldati G, Torri E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815618>
13. **Detection of coronavirus disease from X-ray images using deep learning and transfer learning algorithms.** *J Xray Sci Technol* 2020; Albahli S, Albattah W. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804113>
14. **A retrospective study of the initial chest CT imaging findings in 50 COVID-19 patients stratified by gender and age.** *J Xray Sci Technol* 2020; Gu Q, Ouyang X, Xie A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804112>
15. **Multimodality imaging of coronavirus disease 2019 (COVID-19): a pictorial essay.** *Pol J Radiol* 2020; 85:e387-e393Afolabi BI, Idowu BM, Onigbinde SO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817773>
16. **COVID-19 severity scoring systems in radiological imaging - a review.** *Pol J Radiol* 2020; 85:e361-e368Wasilewski PG, Mruk B, Mazur S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817769>
17. **The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research.** *SLAS Technol* 2020:2472630320950248Tan AS, Nerurkar SN, Tan WCC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808850>
18. **The reversed halo sign: Considerations in the context of the COVID-19 pandemic.** *Thromb Res* 2020; 195:228-230Marchiori E, Nobre LF, Hochegger B, Zanetti G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799128>
19. **Lung Ultrasound May Support Diagnosis and Monitoring of COVID-19 Pneumonia.** *Ultrasound Med. Biol.* 2020; Allinovi M, Parise A, Giacalone M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807570>
20. **Lung Ultrasound Findings Are Associated with Mortality and Need for Intensive Care Admission in COVID-19 Patients Evaluated in the Emergency Department.** *Ultrasound Med. Biol.* 2020; Bonadia N, Carnicelli A, Piano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798003>

Immune response (12 articles)

1. **Humoral Immune Response to SARS-CoV-2.** *Am J Clin Pathol* 2020; Herroelen PH, Martens GA, De Smet D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808976>
2. **Changes in serum virus-specific IgM/IgG antibody in asymptomatic and discharged patients with reoccurring positive COVID-19 nucleic acid test (RPNAT).** *Ann. Med.* 2020:1-14Liu J, Lian R, Zhang G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808808>
3. **Unravelling host-pathogen interactions: ceRNA network in SARS-CoV-2 infection (COVID-19).** *Gene* 2020:145057Arora S, Singh P, Dohare R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805314>
4. **Role of Monocytes/Macrophages in Covid-19 Pathogenesis: Implications for Therapy.** *Infect Drug Resist* 2020; 13:2485-2493Gómez-Rial J, Rivero-Calle I, Salas A, Martínón-Torres F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801787>
5. **Reply to "SARS-CoV-2-associated Takotsubo is not necessarily triggered by the infection".** *Int J Cardiol Heart Vasc* 2020; 30:100613Sattar Y, Ullah W, Almas T, Alraies MC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802937>
6. **Deciphering SARS-CoV-2 Virologic and Immunologic Features.** *Int J Mol Sci* 2020; 21Lebeau G, Vagner D, Frumence É *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824753>

7. **Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: A prospective longitudinal study.** *J Clin Virol* 2020; 130:104575 Fill Malfertheiner S, Brandstetter S, Roth S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805631>
8. **Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19).** *J. Mol. Med. (Berl.)* 2020;1-15 Olwenyi OA, Dyavar SR, Acharya A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808094>
9. **Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group.** *Med Clin (Barc)* 2020; Zalba Marcos S, Antelo ML, Galbete A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814635>
10. **Not just antibodies: B cells and T cells mediate immunity to COVID-19.** *Nat. Rev. Immunol.* 2020; Cox RJ, Brokstad KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32839569>
11. **IL-6 trans-signaling induces plasminogen activator inhibitor-1 from vascular endothelial cells in cytokine release syndrome.** *Proc Natl Acad Sci U S A* 2020; Kang S, Tanaka T, Inoue H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826331>
12. **The Virological, Immunological, and Imaging Approaches for COVID-19 Diagnosis and Research.** *SLAS Technol* 2020:2472630320950248 Tan AS, Nerurkar SN, Tan WCC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808850>

Management miscellaneous diseases (83 articles)

1. **Strategic implementation of dental infection control in resource-poor jurisdictions during COVID-19 pandemic: a perspective from South Africa.** *Acta Odontol. Scand.* 2020;1-4 Bignaut E, Nemitandani S, Samaranayake L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809910>
2. **Dental medicine and COVID-19 pandemic.** *Acta Stomatol. Croat.* 2020; 54:118-120 Brkić H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801369>
3. **The effect of emergency surgery on acute abdomen patients with COVID-19 pneumonia: a retrospective observational study.** *Aging (Albany NY)* 2020; 12Zhao N, Wu L, Cheng Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805726>
4. **EMS dispatch center activity during the COVID-19 containment.** *Am J Emerg Med* 2020; Penverne Y, Jenvrin J, Montassier E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826107>
5. **Otolaryngology Match 2020-21: Survey of Prospective Applicants in the Setting of COVID-19.** *Ann. Otol. Rhinol. Laryngol.* 2020:3489420952470 Izreig S, Torabi SJ, Kasle DA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814437>
6. **Emerging health challenges for children with physical disabilities and their parents during the COVID-19 pandemic: the ECHO French survey.** *Ann. Phys. Rehabil. Med.* 2020; Cacioppo M, Bouvier S, Bailly R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818674>
7. **Timing and Tips for Total Hip Arthroplasty in a Critically Ill Patient With Coronavirus Disease 2019 and a Femoral Neck Fracture.** *Arthroplast Today* 2020; 6:566-570 Kaidi AC, Held MB, Boddapati V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802926>
8. **Coronavirus disease 2019 and laparoscopic surgery in resource-limited settings.** *Asian J Endosc Surg* 2020; Bhattacharjee HK, Chaliyadan S, Verma E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808489>
9. **COVID-19 and Cancer: A guide with suggested COVID-19 rule-out criteria to support clinical decision-making.** *Biochim Biophys Acta Rev Cancer* 2020:188412 Larson C, Oronsky B, Goyal S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827582>
10. **The aggressive surgical treatment and outcome of a colon cancer patient with COVID-19 in Wuhan, China.** *BMC Gastroenterol.* 2020; 20:269 Gao J, Yang M, Liu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799796>
11. **The impact of COVID-19 on cervicofacial infection of dental aetiology.** *Br. J. Oral Maxillofac. Surg.* 2020; Politi I, McParland E, Smith R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811723>
12. **Management of early breast cancer during the COVID-19 pandemic in Brazil.** *Breast Cancer Res. Treat.* 2020; Cavalcante FP, Novita GG, Millen EC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803637>
13. **Surgical Management Strategy for Breast Cancer Patients During the COVID-19 Outbreak.** *Cancer Manag. Res.* 2020; 12:6053-6058 Liu Y, Wang J, Tang Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801857>
14. **Treatment of Gastric Cancer Patients During COVID-19 Pandemic: The West is More Vulnerable.** *Cancer Manag. Res.* 2020; 12:6467-6476 Polkowski WP, Sędlak K, Rawicz-Pruszyński K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801886>
15. **COVID-19 and Oncology: Service transformation during pandemic.** *Cancer Med* 2020; Leung MST, Lin SG, Chow J, Harky A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810386>
16. **Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer.** *Cancers (Basel)* 2020; 12Cattrini C, Bersanelli M, Latocca MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824674>
17. **Health-Related Quality of Life and Experiences of Sarcoma Patients during the COVID-19 Pandemic.** *Cancers (Basel)* 2020; 12Younger E, Smrke A, Lidington E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823999>
18. **Impact of SARS-COV-2 pandemic on elective and emergency surgery in a university hospital.** *Cir Esp* 2020; Maldonado-Marcos E, Caula-Freixa C, Planellas-Giné P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819710>
19. **Drive-Through Model for Anticoagulation Clinics During the COVID-19 Pandemic.** *Clin. Appl. Thromb. Hemost.* 2020; 26:1076029620947476 Rezaei Bookani K, Minga I, Chander M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822220>
20. **"Stay home stay safe?" Systemic inflammation in subjects undergoing routine hematology tests during the lockdown period of COVID-19.** *Clin Chem Lab Med* 2020; Tona F, Plebani M, Gregori D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809951>
21. **The UPMC Hillman Cancer Center Approach to the Management of Colorectal Cancer During the COVID-19 Pandemic Era.** *Clin. Colorectal Cancer* 2020; Lee JJ, Chu E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811719>

22. **Awareness, Perceptions, and Attitude Regarding Coronavirus Disease 2019 (COVID-19) Among Ophthalmologists in Jordan: Cross-Sectional Online Survey.** *Clin. Ophthalmol.* 2020; 14:2195-2202Jammal HM, Alqudah NM, Khader Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801630>
23. **Preserving Vision in the COVID-19 Pandemic: Focus on Health Equity.** *Clin. Ophthalmol.* 2020; 14:2073-2077Mike EV, Laroche D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801615>
24. **Breast Cancer Surgery During the COVID-19 Pandemic Peak in the UK: Operative Outcomes.** *Cureus* 2020; 12:e9280MacInnes EG, Piper J, Tait C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821623>
25. **How severe is the effect of the coronavirus pandemic on the department of surgery of a university hospital? : An analysis of the first 7 weeks.** *Der Chirurg; Zeitschrift für alle Gebiete der operativen Medizen* 2020; von Dercks N, Seehofer D, Steinert M *et al.*
26. **Adoption of Multi-society Guidelines Facilitates Value-Based Reduction in Screening and Surveillance Colonoscopy Volume During COVID-19 Pandemic.** *Dig. Dis. Sci.* 2020; Xiao AH, Chang SY, Stevoff CG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803460>
27. **Delivering esophago-gastric cancer care during the COVID-19 pandemic in the United Kingdom: a surgical perspective.** *Dis. Esophagus* 2020; Wahed S, Chmelo J, Navidi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816020>
28. **Impact of the COVID-19 epidemic on ENT surgical volume.** *Eur. Ann. Otorhinolaryngol. Head Neck Dis.* 2020; Hervochon R, Atallah S, Levivien S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807696>
29. **Face to face with COVID-19: highlights of challenges encountered in various ENT practices across the Czech Republic (a national survey).** *Eur Arch Otorhinolaryngol* 2020;1-6Guha A, Plzak J, Chovanec M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813168>
30. **COVID-19 and eating disorders during confinement: Analysis of factors associated with resilience and aggravation of symptoms.** *Eur Eat Disord Rev* 2020; Baenas I, Caravaca-Sanz E, Granero R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815293>
31. **Breast cancer surgery after the COVID-19 pandemic.** *Future Oncol* 2020; Tsang-Wright F, Tasoulis MK, Roche N, MacNeill F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815421>
32. **Management of Immune-Related Colitis During the COVID-19 Pandemic.** *Inflamm. Bowel Dis.* 2020; Amin R, Thomas AS, Khurana S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812047>
33. **Innovation in IBD Care During the COVID-19 Pandemic: Results of a Cross-Sectional Survey on Patient-Reported Experience Measures.** *Inflamm. Bowel Dis.* 2020; Taxonera C, Alba C, Olivares D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812035>
34. **Managing medicines in the time of COVID-19: implications for community-dwelling people with dementia.** *Int J Clin Pharm* 2020; Barry HE, Hughes CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803555>
35. **Melanoma diagnosis at the time of COVID-19.** *Int. J. Dermatol.* 2020; Longo C, Pampena R, Fossati B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808276>
36. **Separating the wheat from the chaff-COVID-19 in a German emergency department: a case-control study.** *Int. J. Emerg. Med.* 2020; 13:44Fistera D, Pabst D, Härtl A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819266>
37. **Dental Health Services Response to COVID-19 in Norway.** *Int J Environ Res Public Health* 2020; 17Stangvaltaite-Mouhat L, Uhlen MM, Skudutyte-Rysstad R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806769>
38. **Drastic Reduction Inpatient Visits to the Emergency Department in a Hospital in Israel During the COVID-19 Outbreak, Compared to the H1N1 2009.** *Int J Health Policy Manag* 2020; Basis F, Zeidani H, Hussein K, Hareli S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801218>
39. **Management of urology during COVID-19 pandemic: a perspective from Sichuan Province, China.** *Int J Surg* 2020; Feng D, Liu S, Bai Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798760>
40. **Hemoperfusion as a Supportive Treatment in a COVID-19 Patient with Late Pulmonary Thromboembolism: A Case Report.** *Int Med Case Rep J* 2020; 13:341-345Moradi H, Abbasi S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821175>
41. **COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature.** *Int Med Case Rep J* 2020; 13:317-321Niknam R, Malek-Hosseini SA, Hashemieh SS, Dehghani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801943>
42. **Operating room efficiency and timing during coronavirus disease 2019 outbreak in a referral orthopaedic hospital in Northern Italy.** *Int. Orthop.* 2020; Andreato M, Faraldi M, Bucci E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803358>
43. **Allergic disorders and susceptibility to and severity of COVID-19: a nationwide cohort study.** *J Allergy Clin Immunol* 2020; Yang JM, Koh HY, Moon SY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810517>
44. **Novel Solutions for Dermatologic Care of Geriatric Patients and the Role of the Dermatology House Call.** *J Am Acad Dermatol* 2020; Lipner SR, Ouchida K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798576>
45. **Public Perceptions of Resuming Elective Surgery During the COVID-19 Pandemic.** *J. Arthroplasty* 2020; Moverman MA, Puzzitiello RN, Pagani NR *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807565>
46. **Anesthesia for Patients Undergoing Anesthesia for Elective Thoracic Surgery During the COVID-19 Pandemic: A Consensus Statement From the Israeli Society of Anesthesiologists.** *J Cardiothorac Vasc Anesth* 2020; Shaylor R, Verenkin V, Matot I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798170>
47. **Impact of the SARS-CoV2 pandemic dissemination on the management of neuroendocrine neoplasia in Italy: a report from the Italian Association for Neuroendocrine Tumors (Itanet).** *J. Endocrinol. Invest.* 2020; Panzuto F, Maccauro M, Campana D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803662>
48. **Resuming of endodontic practices in COVID-19 hardest-hit area of China: A Web-based Survey.** *J Endod* 2020; Yu J, Hua F, Shen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818564>
49. **Toxic epidermal necrolysis and co-existent SARS-CoV-2 (COVID-19) treated with Intravenous Immunoglobulin: "Killing 2 birds with one stone".** *J Eur Acad Dermatol Venereol* 2020; Saha M, D'Cruz A, Paul N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805059>
50. **Guidelines Adaptation to the COVID-19 Outbreak for the Management of Hepatocellular Carcinoma.** *J. Laparoendosc. Adv. Surg. Tech. A* 2020; Santambrogio R, Farina G, D'Alessandro V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810426>

51. **Management Strategies for Cancer Patients in the Time of COVID-19 Pandemic.** *J. Maxillofac. Oral Surg.* 2020; 19:473-474 Gupta A, Sharma P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801547>
52. **Re: Maxillofacial Surgery and COVID-19, the Pandemic!** *J. Maxillofac. Oral Surg.* 2020; 19:475-476 Jayasuriya NSS, Perera IR, Ratnapreya S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801548>
53. **Immuno-epidemiology and pathophysiology of coronavirus disease 2019 (COVID-19).** *J. Mol. Med. (Berl.)* 2020; 1-15 Olwenyi OA, Dyavar SR, Acharya A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808094>
54. **Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic.** *J. Neurol.* 2020; Costamagna G, Abati E, Bresolin N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804279>
55. **Novel Outreach Program and Practical Strategies for Patients with Parkinsonism in the COVID-19 Pandemic.** *J. Parkinsons Dis.* 2020; Sennott B, Woo K, Hess S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804103>
56. **Community Pharmacy and COVID-19-The Unsung Heroes on Our High Streets.** *J Patient Exp* 2020; 7:282-284 Parkhurst C, Singh Purewal G, Donyai P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821780>
57. **Adaptation of a Gamma Knife Icon stereotactic radiosurgery program in the face of the COVID-19 pandemic.** *J Radiosurg SBRT* 2020; 7:5-10 Wegner RE, Horne ZD, Xu L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802573>
58. **Cancer patients and coronavirus disease 2019: evidence in context.** *J Transl Med* 2020; 18:315 Barba M, Krasniqi E, Ciliberto G, Vici P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799883>
59. **The Impact of Covid 19 on an Irish Vascular Unit's Service.** *J. Vasc. Surg.* 2020; Connolly M, Ahmed Z, Aly S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798571>
60. **COVID Era "Essential Surgery" Dialysis Access Management Considerations.** *J. Vasc. Surg.* 2020; Kirksey L, Vacharajani T, Droz NM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798572>
61. **Shifting Paradigms in Cardiovascular Therapeutic Strategies During the COVID-19 Era.** *JACC Cardiovasc Interv* 2020; 13:1949-1950 Kornowski R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819484>
62. **Preparation for the next COVID-19 wave: The European Hip Society and European Knee Associates recommendations.** *Knee Surg, Sports Traumatol. Arthrosc.* 2020; Donell ST, Thaler M, Budhiparama NC *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803277>
63. **Recommendations for resuming elective hip and knee arthroplasty in the setting of the SARS-CoV-2 pandemic: the European Hip Society and European Knee Associates Survey of Members.** *Knee Surg, Sports Traumatol. Arthrosc.* 2020; 1-7 Kort NP, Barrena EG, Bédard M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809121>
64. **Implementation of an operational concept in an ENT clinic in the context of the SARS-CoV-2 pandemic.** *Laryngo- Rhino- Otologie* 2020; 99:552-560 Weiss R, Loth A, Guderian D *et al.*
65. **Head and neck radiotherapy amid the COVID-19 pandemic: practice recommendations of the Italian Association of Radiotherapy and Clinical Oncology (AIRO).** *Med. Oncol.* 2020; 37:85 Alterio D, Volpe S, Bacigalupo A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808089>
66. **COVID-19: IFSO LAC Recommendations for the Resumption of Elective Bariatric Surgery.** *Obes. Surg.* 2020; 1-10 Behrens E, Poggi L, Aparicio S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827292>
67. **Intensive care and anesthetic management of patients with brugada syndrome and COVID-19 infection.** *Pacing Clin. Electrophysiol.* 2020; Dendramis G, Brugada P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815174>
68. **Preparedness among dental professionals towards COVID-19 in India.** *Pan Afr. Med. J.* 2020; 36:108 Singh KT, Mishra G, Shukla AK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821319>
69. **[Impact of the COVID-19 pandemic on emergency department: Early findings from a hospital in Madrid].** *An Pediatr (Barc)* 2020; Molina Gutiérrez M, Ruiz Domínguez JA, Bueno Barriocanal M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800720>
70. **Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review.** *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2020; 110070 Mallet J, Dubertret C, Le Strat Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800868>
71. **Recommendations on the management of adult patients with rheumatic diseases in the context of SARS-CoV-2/COVID-19 infection. Colombian Association of Rheumatology.** *Reumatol. Clin.* 2020; Saldarriaga Rivera LM, Fernández Ávila D, Bautista Molano W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800760>
72. **Prevention and Treatment Strategies for the Cardiology Department of a Non-COVID-19 Designated Hospital in the Post-Epidemic Period.** *Risk Manag. Healthc. Policy* 2020; 13:979-987 Fan Q, Chen X, Lin Y, Wang Z. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801972>
73. **[Interdisciplinary multimodal pain therapy under the protective measures of the COVID-19 pandemic : Analysis and progress report].** *Schmerz* 2020; Luchting B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820359>
74. **Management strategy for cancer patients in the context of the COVID-19 epidemic.** *Semin. Oncol.* 2020; Izmailov A, Beylerli O, Pavlov V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811667>
75. **Current effect of COVID-19 global pandemic on the professional and life profiles of the Egyptian spine surgeons.** *Sicot j* 2020; 6:31 Khattab MF, Abou-Madawi AM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819456>
76. **Dental services during the COVID-19 pandemic: A tertiary care hospital experience.** *Spec. Care Dentist.* 2020; Umer F, Motiwala M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815633>
77. **Oncology patients' perceptions of and experiences with COVID-19.** *Support. Care Cancer* 2020; 1-10 Miaskowski C, Paul SM, Snowberg K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809060>
78. **COVID-19 and surgery: A thematic analysis of unintended consequences on performance, practice and surgical training.** *Surgeon* 2020; Whelehan DF, Connelly TM, Ridgway PF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807661>
79. **Managing Disease-Modifying Therapies and Breakthrough Activity in Multiple Sclerosis Patients During the COVID-19 Pandemic: Toward an Optimized Approach.** *Ther. Clin. Risk Manag.* 2020; 16:651-662 Hamdy SM, Abdel-Naseer M, Shehata HS *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801722>
80. **Oral and maxillofacial surgical services amid COVID-19 pandemic: perspective from Tanzania.** *Trop Med Health* 2020; 48:70 Sohal KS, Simon ENM, Kalyanyama B, Moshly JR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818021>

81. **The Effects of Lockdown During the SARS-CoV-2 Pandemic on Neuro-Trauma Related Hospital Admissions.** *World Neurosurg* 2020; Figueroa JM, Boddu J, Kader M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822955>
82. **Sheltered Neurosurgery during COVID-19: The Emory Experience.** *World Neurosurg* 2020; Saad H, Alawieh A, Oyesiku N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827748>
83. **[Effects on the integrated treatment of colorectal cancer patients during COVID-19 epidemic in China: a cross-sectional study].** *Zhonghua Wei Chang Wai Ke Za Zhi* 2020; 23:795-800 Yang Y, Gao ZY, Chen YK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810953>

Management (48 articles)

1. **Hesperidin and SARS-CoV-2: New Light on the Healthy Function of Citrus Fruits.** *Antioxidants (Basel)* 2020; 9Bellavite P, Donzelli A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823497>
2. **Role of probiotics to combat viral infections with emphasis on COVID-19.** *Appl. Microbiol. Biotechnol.* 2020;1-16Sundararaman A, Ray M, Ravindra PV, Halami PM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813065>
3. **Beta-adrenergic Blockers as a Potential Treatment for COVID-19 Patients.** *Bioessays* 2020:e2000094Vasanthakumar N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815593>
4. **Melatonin's Impact on Antioxidative and Anti-Inflammatory Reprogramming in Homeostasis and Disease.** *Biomolecules* 2020; 10Chitimus DM, Popescu MR, Voiculescu SE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825327>
5. **Improving the impact of non-pharmaceutical interventions during COVID-19: examining the factors that influence engagement and the impact on individuals.** *BMC Infect. Dis.* 2020; 20:607Seale H, Dyer CEF, Abdi I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807087>
6. **Considerations for target oxygen saturation in COVID-19 patients: are we under-shooting?** *BMC Med* 2020; 18:260Shenoy N, Luchtel R, Gulani P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814566>
7. **Noninvasive ventilation for COVID-19-associated acute hypoxaemic respiratory failure: experience from a single centre.** *Br J Anaesth* 2020; Sivaloganathan AA, Nasim-Mohi M, Brown MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811662>
8. **Prescribing in COVID-19 patients: Should we take into account inflammation?** *Br. J. Clin. Pharmacol.* 2020; Marzolini C, Battegay M, Sendi P, Back DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820554>
9. **Nutritional status of micronutrients as a possible and modifiable risk factor for COVID-19: a UK perspective.** *Br. J. Nutr.* 2020;1-27Richardson DP, Lovegrove JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815493>
10. **Tolerability and safety of awake prone positioning COVID-19 patients with severe hypoxemic respiratory failure.** *Can J Anaesth* 2020; Solverson K, Weatherald J, Parhar KKS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803468>
11. **Empiric Antibacterial Therapy and Community-onset Bacterial Co-infection in Patients Hospitalized with COVID-19: A Multi-Hospital Cohort Study.** *Clin Infect Dis* 2020; Vaughn VM, Gandhi T, Petty LA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820807>
12. **Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy.** *Clin Microbiol Infect* 2020; Vena A, Giacobbe DR, Di Biagio A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810610>
13. **Above and beyond: biofilm and the ongoing search for strategies to reduce ventilator-associated pneumonia (VAP).** *Crit Care* 2020; 24:510Sakano T, Bittner EA, Chang MG, Berra L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811553>
14. **A combinational approach to restore cytokine balance and to inhibit virus growth may promote patient recovery in severe COVID-19 cases.** *Cytokine* 2020; 136:155228Mahmud-AI-Rafat A, Muzammal Haque Asim M, Taylor-Robinson AW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822911>
15. **COVID-19 Triage: Who is an inpatient? The Essen triage model.** *Deutsche Medizinische Wochenschrift* 2020; 145:E87-E92Fistera D, Risse J, Manegold R *et al.*
16. **COVID-19: Questions and answers from infectiology.** *Deutsche Medizinische Wochenschrift* 2020; 145:1051-1056Khatamzas E, Rothe C, Kroidl I.
17. **Evolving oxygenation management reasoning in COVID-19.** *Diagnosis (Berl)* 2020; Liu S, Sweeney C, Srisarajvakul-Klein N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827395>
18. **Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach.** *Eur. J. Pediatr.* 2020; Sperotto F, Friedman KG, Son MBF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803422>
19. **Emerging therapeutics for the management of COVID 19.** *Expert Opin Emerg Drugs* 2020; Debnath S, Srivastava R, Omri A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799566>
20. **Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.** *Hypertens. Res.* 2020; Matsuzawa Y, Ogawa H, Kimura K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820236>
21. **The Relationship between the COVID-19 Pandemic and Nursing Students' Sense of Belonging: The Experiences and Nursing Education Management of Pre-Service Nursing Professionals.** *Int J Environ Res Public Health* 2020; 17Santos LMD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806697>
22. **Could nasal irrigation and oral rinse reduce the risk for COVID-19 infection?** *Int. J. Immunopathol. Pharmacol.* 2020; 34:2058738420941757Casale M, Rinaldi V, Sabatino L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799596>
23. **Vitamin D can be effective on the prevention of COVID-19 complications: A narrative review on molecular aspects.** *Int. J. Vitam. Nutr. Res.* 2020;1-13Shiravi AA, Saadatkish M, Abdollahi Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811354>
24. **Persian medicine recommendations for the prevention of pandemics related to the respiratory system: a narrative literature review.** *Integr Med Res* 2021; 10:100483Iranzadasl M, Karimi Y, Moadeli F, Pasalar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802742>
25. **Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.** *J Am Heart Assoc* 2020:e017736Chen C, Wang F, Chen P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807002>

26. **Nurses' experiences regarding shift patterns in isolation wards during the COVID-19 pandemic in China: A qualitative study.** *J. Clin. Nurs.* 2020; Gao X, Jiang L, Hu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810919>
27. **COVID-19 and team-based healthcare: The essentiality of theory-driven research.** *J Interprof Care* 2020;1-7Michalec B, Lamb G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811223>
28. **The preventive strategies of COVID-19 pandemic in Saudi Arabia.** *J Microbiol Immunol Infect* 2020; Nurunnabi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807687>
29. **Knowledge, Attitude, and Practice During the COVID-19 Pandemic: A Review.** *J Multidiscip Healthc* 2020; 13:727-733Puspitasari IM, Yusuf L, Sinuraya RK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801735>
30. **COVID-19-related stigma and perceived stress among dialysis staff.** *J Nephrol* 2020; Uvais NA, Aziz F, Hafeeq B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804354>
31. **Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges.** *Life Sci* 2020;118275Parvathaneni V, Gupta V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818545>
32. **Can Bioactive Lipid Arachidonic Acid Prevent and Ameliorate COVID-19?** *Medicina (Kaunas)* 2020; 56Das UN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825011>
33. **The immunomodulatory effects of probiotics on respiratory viral infections: A hint for COVID-19 treatment?** *Microb. Pathog.* 2020:104452Mahooti M, Miri SM, Abdolalipour E, Ghaemi A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818576>
34. **Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: Two cases and implications for clinical practice.** *Mult Scler Relat Disord* 2020; 45:102452De Angelis M, Petracca M, Lanzillo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823148>
35. **Vitamin D Insufficiency and Deficiency and Mortality from Respiratory Diseases in a Cohort of Older Adults: Potential for Limiting the Death Toll during and beyond the COVID-19 Pandemic?** *Nutrients* 2020; 12Brenner H, Holleczeck B, Schöttker B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824839>
36. **The pervasive relevance of COVID-19 within routine paediatric palliative care consultations during the pandemic: A conversation analytic study.** *Palliat. Med.* 2020:269216320950089Ekberg K, Weinglass L, Ekberg S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799739>
37. **Wahrnehmungen von Pflegenden im Bereich der Intensivpflege während der COVID-19-Pandemie.** *Pflege* 2020; 33:229-236Begerow A, Michaelis U, Gaidys U. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811326>
38. **COVID-19 driven care changes in high risk patients from an outpatient to a community setting.** *Pflege* 2020; 33:219-227Daly ML, Zimmer A, Stickling J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811324>
39. **A GAS-POWERED, PATIENT-RESPONSIVE AUTOMATIC RESUSCITATOR FOR USE IN ACUTE RESPIRATORY FAILURE: A BENCH AND EXPERIMENTAL STUDY.** *Respir. Care* 2020; Jonkman AH, Katira BH, Schreiber A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817445>
40. **Chest physiotherapy: an important adjuvant in critically ill mechanically ventilated patients with COVID-19.** *Respir. Physiol. Neurobiol.* 2020:103529Battaglini D, Robba C, Caiffa S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818606>
41. **Sexual and gender minority adolescents must be prioritised during the global COVID-19 public health response.** *Sex Reprod Health Matters* 2020; 28:1804717DeMulder J, Kraus-Perrotta C, Zaidi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799759>
42. **Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review.** *Strahlenther. Onkol.* 2020; Del Castillo R, Martinez D, Sarria GJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816059>
43. **Anti Xa activity after high dose LMWH thrombolysis in covid 19 patients at the intensive care unit.** *Thromb Res* 2020; 196:1-3Vlot EA, Van den Dool EJ, Hackeng CM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805623>
44. **Risk of Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 by Transfusion: A Literature Review.** *Transfusion* 2020; Leblanc JF, Germain M, Delage G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798237>
45. **Efficacy of dexamethasone treatment for patients with the acute respiratory distress syndrome caused by COVID-19: study protocol for a randomized controlled superiority trial.** *Trials* 2020; 21:717Villar J, Añón JM, Ferrando C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799933>
46. **The holistic way of tackling the COVID-19 pandemic: the one health approach.** *Trop Med Health* 2020; 48:69Mushi V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818020>
47. **[COVID-19: treatment strategies of German-speaking pediatric rheumatologists : Results of an online survey].** *Z. Rheumatol.* 2020:1-8Janda A, Schuetz C, Heeg M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809050>
48. **COVID-19 Pandemic in Germany: The Current Situation in Thoracic Surgery.** *Zentralbl. Chir.* 2020; Dziodzio T, Hillebrandt KH, Knitter S *et al.*

Mental – public health (65 articles)

1. **Public Health Strategies Contain and Mitigate COVID-19: A Tale of Two Democracies.** *Am. J. Med.* 2020; Solano JJ, Maki DG, Adirim TA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810463>
2. **Australian College of Critical Care Nurses and Australasian College for Infection Prevention and Control position statement on facilitating next-of-kin presence for patients dying from coronavirus disease 2019 (COVID-19) in the intensive care unit.** *Aust. Crit. Care* 2020; Bloomer MJ, Bouchoucha S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826150>
3. **Mathematical Parameters of the COVID-19 Epidemic in Brazil and Evaluation of the Impact of Different Public Health Measures.** *Biology (Basel)* 2020; 9Cotta RM, Naveira-Cotta CP, Magal P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806613>
4. **Impact of the COVID-19 pandemic and initial period of lockdown on the mental health and well-being of adults in the UK.** *BJPsych Open* 2020; 6:e90White RG, Van Der Boor C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799958>
5. **Psychological Impacts of the COVID-19 Pandemic on the Public in Egypt.** *Community Ment. Health J.* 2020; Arafa A, Mohamed A, Saleh L, Senosy S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803445>

6. **Prevention Knowledge and Its Practice Towards COVID-19 Among General Population of Saudi Arabia: A Gender-based Perspective.** *Curr. Pharm. Des.* 2020; Alshammary F, Siddiqui AA, Amin J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811408>
7. **Mental Health Care Goes Online: Practitioners' Experiences of Providing Mental Health Care During the COVID-19 Pandemic.** *Cyberpsychol Behav Soc Netw* 2020; Feijt M, de Kort Y, Bongers I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815742>
8. **Subjective burden and perspectives of German healthcare workers during the COVID-19 pandemic.** *Eur. Arch. Psychiatry Clin. Neurosci.* 2020; Kramer V, Papazova I, Thoma A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815019>
9. **Migrant workers in China need emergency psychological interventions during the COVID-19 outbreak.** *Global Health* 2020; 16:75Liu ZH, Zhao YJ, Feng Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814575>
10. **Covid-19 and social stigma: Role of scientific community.** *Indian J. Tuberc.* 2020; 67:284-285Chopra KK, Arora VK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825854>
11. **Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.** *Indian Pacing Electrophysiol J* 2020; Pranata R, Huang I, Raharjo SB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814094>
12. **How the COVID-19 Pandemic is Changing Mental Health Disease Management: The Growing Need of Telecounseling in Italy.** *Innov. Clin. Neurosci.* 2020; 17:16-17De Luca R, Calabrò RS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802587>
13. **COVID-19 Lockdown: Housing Built Environment's Effects on Mental Health.** *Int J Environ Res Public Health* 2020; 17Amerio A, Brambilla A, Morganti A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824594>
14. **Tendency to Worry and Fear of Mental Health during Italy's COVID-19 Lockdown.** *Int J Environ Res Public Health* 2020; 17Baiano C, Zappullo I, The Lab NG, Conson M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824152>
15. **Analysis of the Impact of the Confinement Resulting from COVID-19 on the Lifestyle and Psychological Wellbeing of Spanish Pregnant Women: An Internet-Based Cross-Sectional Survey.** *Int J Environ Res Public Health* 2020; 17Biviá-Roig G, La Rosa VL, Gómez-Tébar M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824191>
16. **Predicting Psychological Distress Amid the COVID-19 Pandemic by Machine Learning: Discrimination and Coping Mechanisms of Korean Immigrants in the U.S.** *Int J Environ Res Public Health* 2020; 17Choi S, Hong JY, Kim YJ, Park H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825349>
17. **The Contagion of Sentiments during the COVID-19 Pandemic Crisis: The Case of Isolation in Spain.** *Int J Environ Res Public Health* 2020; 17Iglesias-Sánchez PP, Vaccaro Witt GF, Cabrera FE, Jambrino-Maldonado C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824110>
18. **Anxiety About the Risk of Death of Their Patients in Health Professionals in Spain: Analysis at the Peak of the COVID-19 Pandemic.** *Int J Environ Res Public Health* 2020; 17Lázaro-Pérez C, Martínez-López J, Gómez-Galán J, López-Meneses E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824258>
19. **Social Policy Responses to the Covid-19 Crisis in China in 2020.** *Int J Environ Res Public Health* 2020; 17Lu Q, Cai Z, Chen B, Liu T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823833>
20. **Multilevel Analysis of the Relationship between Ownership Structure and Technical Efficiency Frontier in the Spanish National Health System Hospitals.** *Int J Environ Res Public Health* 2020; 17Ortega-Díaz MI, Ocaña-Riola R, Pérez-Romero C, Martín-Martín JJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823922>
21. **Assessment of Mental Health Factors among Health Professionals Depending on Their Contact with COVID-19 Patients.** *Int J Environ Res Public Health* 2020; 17Wańkowicz P, Szylińska A, Rotter I. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806699>
22. **Attitudes and collateral psychological effects of COVID-19 in pregnant women in Colombia.** *Int J Gynaecol Obstet* 2020; Parra-Saavedra M, Villa-Villa I, Pérez-Olivo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799318>
23. **Mental health response to the COVID-19 pandemic in Kenya: a review.** *Int J Ment Health Syst* 2020; 14:68Jaguga F, Kwobah E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821271>
24. **Caring for the caregiver during COVID-19 outbreak: Does inclusive leadership improve psychological safety and curb psychological distress? A cross-sectional study.** *Int. J. Nurs. Stud.* 2020; 110:103725Zhao F, Ahmed F, Faraz NA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810720>
25. **COVID pandemic as an opportunity for improving mental health treatments of the homeless people.** *Int J Soc Psychiatry* 2020:20764020950770Martin C, Andrés P, Bullón A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820986>
26. **Psychedelic Science in Post-Covid Psychiatry.** *Ir. J. Psychol. Med.* 2020:1-18Kelly JR, Crockett MT, Alexander L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811575>
27. **Psychiatrists and Covid-19: What is our role during this unprecedented time?** *Ir. J. Psychol. Med.* 2020:1-19Scriven M, Geary E, Kelly BD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811576>
28. **Psychological distress associated with COVID-19 quarantine: Latent profile analysis, outcome prediction and mediation analysis.** *J. Affect. Disord.* 2020; 277:75-84Fernández RS, Crivelli L, Guimet NM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799107>
29. **The impact of COVID-19 pandemic on mental health & wellbeing among home-quarantined Bangladeshi students: A cross-sectional pilot study.** *J. Affect. Disord.* 2020; 277:121-128Khan AH, Sultana MS, Hossain S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818775>
30. **Psychological distress related to COVID-19 - The contribution of continuous traumatic stress.** *J. Affect. Disord.* 2020; 277:12316Lahav Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818776>
31. **Prevalence and factors for anxiety during the coronavirus disease 2019 (COVID-19) epidemic among the teachers in China.** *J. Affect. Disord.* 2020; 277:153-158Li Q, Miao Y, Zeng X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32828002>
32. **Reactions to COVID-19: Differential predictors of distress, avoidance, and disregard for social distancing.** *J. Affect. Disord.* 2020; 277:94-98Taylor S, Landry CA, Paluszek MM, Asmundson GJG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799109>
33. **Impact of COVID-19 pandemic on mental health in the general population: A systematic review.** *J. Affect. Disord.* 2020; 277:55-64Xiong J, Lipsitz O, Nasri F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799105>

34. **Facing new fears during the COVID-19 pandemic: The State of America's mental health.** *J. Anxiety Disord.* 2020; 75:102291 Fitzpatrick KM, Drawve G, Harris C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827869>
35. **The prospective influence of COVID-19 affective risk assessments and intolerance of uncertainty on later dimensions of health anxiety.** *J. Anxiety Disord.* 2020; 75:102290 Tull MT, Barbano AC, Scamaldo KM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823216>
36. **Including Children with Developmental Disabilities in the Equation During this COVID-19 Pandemic.** *J. Autism Dev. Disord.* 2020; Aishworiya R, Kang YQ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816170>
37. **The Interrelation of Neurological and Psychological Symptoms of COVID-19: Risks and Remedies.** *J Clin Med* 2020; 9 Nami M, Gadad BS, Chong L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823540>
38. **Nurses' experiences regarding shift patterns in isolation wards during the COVID-19 pandemic in China: A qualitative study.** *J. Clin. Nurs.* 2020; Gao X, Jiang L, Hu Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810919>
39. **Public Health Student Response to COVID-19.** *J. Community Health* 2020; 1-6 Burns KF, Strickland CJ, Horney JA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813136>
40. **Days of worry: Emotional intelligence and social support mediate worry in the COVID-19 pandemic.** *J Health Psychol* 2020; 1359105320949935 Zysberg L, Zisberg A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811195>
41. **The emotional impact of the COVID-19 pandemic on individuals with progressive multiple sclerosis.** *J. Neurol.* 2020; 1-10 Chiaravalloti ND, Amato MP, Bricchetto G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813051>
42. **The COVID-19 Crisis: A Mental Health Perspective and Response Using Telemedicine.** *J Patient Exp* 2020; 7:295-301 Sullivan AB, Kane A, Roth AJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821785>
43. **Over the Rainbow: Navigating the COVID-19 Pandemic While Living With PTSD.** *J Patient Exp* 2020; 7:293-294 Vigouroux M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821784>
44. **Letter to the Editor: New onset psychosis and mania following COVID-19 infection.** *J. Psychiatr. Res.* 2020; 130:177-179 Noone R, Cabassa JA, Gardner L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823051>
45. **Psychological status of healthcare workers during the civil war and COVID-19 pandemic: A cross-sectional study.** *J. Psychosom. Res.* 2020; 137:110221 Elhadi M, Msherghi A, Elgzairi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827801>
46. **Role and importance of consultation-liaison psychiatry during the Covid-19 epidemic.** *J. Psychosom. Res.* 2020; 137:110214 Horn M, Granon B, Vaiva G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798833>
47. **The Dead with No Wake, Grieving with No Closure: Illness and Death in the Days of Coronavirus in Spain.** *J Relig Health* 2020; Fernández Ó, González-González M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816226>
48. **Does Sars-Cov-2 threaten our dreams? Effect of quarantine on sleep quality and body mass index.** *J Transl Med* 2020; 18:318 Barrea L, Pugliese G, Framondi L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811530>
49. **COVID-19 Is a Multifaceted Challenging Pandemic Which Needs Urgent Public Health Interventions.** *Microorganisms* 2020; 8 Contini C, Caselli E, Martini F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806657>
50. **Acutely altered mental status as the main clinical presentation of multiple strokes in critically ill patients with COVID-19.** *Neurol Sci* 2020; 1-4 Díaz-Pérez C, Ramos C, López-Cruz A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808174>
51. **Public Behavior Change, Perceptions, Depression, and Anxiety in Relation to the COVID-19 Outbreak.** *Open Forum Infect Dis* 2020; 7:ofaa273 Huang J, Liu F, Teng Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817845>
52. **[Impact of the COVID-19 pandemic on emergency department: Early findings from a hospital in Madrid].** *An Pediatr (Barc)* 2020; Molina Gutiérrez M, Ruiz Domínguez JA, Bueno Barriocanal M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800720>
53. **Nursing students' views on the COVID-19 pandemic and their perceived stress levels.** *Perspect. Psychiatr. Care* 2020; Aslan H, Pekince H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808314>
54. **Impact of Social Isolation due to the COVID-19 Pandemic in Patients with Pediatric Disorders: Rehabilitation Perspectives From a Developing Country.** *Phys Ther* 2020; Meireles ALF, de Meireles LCF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805029>
55. **Social and behavioral consequences of mask policies during the COVID-19 pandemic.** *Proc Natl Acad Sci U S A* 2020; Betsch C, Korn L, Sprengholz P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820078>
56. **Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review.** *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2020; 110070 Mallet J, Dubertret C, Le Strat Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800868>
57. **Psychological effects of the COVID-2019 pandemic: Perceived stress and coping strategies among healthcare professionals.** *Psychiatry Res* 2020; 293:113366 Babore A, Lombardi L, Viceconti ML *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798932>
58. **Psychological factors associated with substance use initiation during the COVID-19 pandemic.** *Psychiatry Res* 2020; 293:113407 Rogers AH, Shepherd JM, Garey L, Zvolensky MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827993>
59. **COVID-19 in Portugal: exploring the immediate psychological impact on the general population.** *Psychol Health Med* 2020; 1-12 Paulino M, Dumas-Diniz R, Brissos S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809853>
60. **Impact of COVID-19 on Public Mental Health and the Buffering Effect of a Sense of Coherence.** *Psychother Psychosom* 2020; 1-7 Schäfer SK, Sopp MR, Schanz CG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810855>
61. **Socioeconomic restrictions slowdown COVID-19 far more effectively than favorable weather-evidence from the satellite.** *Sci Total Environ* 2020; 748:141401 Shen X, Cai C, Li H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798876>

62. **Sexual and gender minority adolescents must be prioritised during the global COVID-19 public health response.** *Sex Reprod Health Matters* 2020; 28:1804717DeMulder J, Kraus-Perrotta C, Zaidi H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799759>
63. **Early impacts of the COVID-19 pandemic on mental health care and on people with mental health conditions: framework synthesis of international experiences and responses.** *Soc. Psychiatry Psychiatr. Epidemiol.* 2020; Sheridan Rains L, Johnson S, Barnett P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804258>
64. **Penetrating trauma during a global pandemic: Changing patterns in interpersonal violence, self-harm and domestic violence in the Covid-19 outbreak.** *Surgeon* 2020; Olding J, Zisman S, Olding C, Fan K. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826157>
65. **Lockdown and adolescent mental health: reflections from a child and adolescent psychotherapist.** *Wellcome Open Res* 2020; 5:132Catty J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802965>

Meta-analyses - systematic reviews (13 articles)

1. **Diabetes Mellitus is Associated with Severe Infection and Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis.** *Arch Med Res* 2020; Shang L, Shao M, Guo Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811670>
2. **Is there any potential management against COVID-19? A systematic review and meta-analysis.** *Daru* 2020:1-13Talaie H, Hosseini SM, Nazari M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812187>
3. **Anemia and iron metabolism in COVID-19: a systematic review and meta-analysis.** *Eur. J. Epidemiol.* 2020; Taneri PE, Gómez-Ochoa SA, Llanaj E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816244>
4. **Incidence and impact of cardiac arrhythmias in coronavirus disease 2019 (COVID-19): A systematic review and meta-analysis.** *Indian Pacing Electrophysiol J* 2020; Pranata R, Huang I, Raharjo SB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814094>
5. **The epidemiological burden of and overall distribution of chronic comorbidities in coronavirus disease-2019 among 202,005 infected patients: evidence from a systematic review and meta-analysis.** *Infection* 2020:1-21Mahumud RA, Kamara JK, Renzaho AMN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813220>
6. **The Age-Related Risk of Severe Outcomes Due to COVID-19 Infection: A Rapid Review, Meta-Analysis, and Meta-Regression.** *Int J Environ Res Public Health* 2020; 17Romero Starke K, Petereit-Haack G, Schubert M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824596>
7. **A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19.** *Int J Infect Dis* 2020; Lu YF, Pan LY, Zhang WW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798659>
8. **Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis.** *Int J Infect Dis* 2020; Ortolan A, Lorenzin M, Felicetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800858>
9. **Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular Toxicity of Hydroxychloroquine.** *J Med Internet Res* 2020; 22:e20007Michelson M, Chow T, Martin NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804086>
10. **Hydroxychloroquine for treatment of non-severe COVID-19 patients; systematic review and meta-analysis of controlled clinical trials.** *J Med Virol* 2020; Elsawah HK, Elsokary MA, Elrazzaz MG, ElShafey AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808712>
11. **Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis.** *J Med Virol* 2020; Jiang Y, Chen D, Cai D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813283>
12. **The add-on effect of Chinese herbal medicine on COVID-19: A systematic review and meta-analysis.** *Phytotherapy* 2020:153282Luo X, Ni X, Lin J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800699>
13. **Effect of Remdesivir on Patients with COVID-19: A Network Meta-Analysis of Randomized Control Trials.** *Virus Res.* 2020; 288:198137Yokoyama Y, Briasoulis A, Takagi H, Kuno T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827627>

Mortality (18 articles)

1. **[Letter to the Editor Regarding the Article "Excess Mortality Estimation During the COVID-19 Pandemic: Preliminary Data from Portugal"].** *Acta Med Port* 2020; Silva CF. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814012>
2. **A fatal case of COVID-19 in a patient with common variable immunodeficiency.** *Ann. Allergy. Asthma. Immunol.* 2020; Mullur J, Wang A, Feldweg A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818593>
3. **Diabetes Mellitus is Associated with Severe Infection and Mortality in Patients with COVID-19: A Systematic Review and Meta-analysis.** *Arch Med Res* 2020; Shang L, Shao M, Guo Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811670>
4. **Australian College of Critical Care Nurses and Australasian College for Infection Prevention and Control position statement on facilitating next-of-kin presence for patients dying from coronavirus disease 2019 (COVID-19) in the intensive care unit.** *Aust. Crit. Care* 2020; Bloomer MJ, Bouchoucha S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826150>
5. **Clinical characteristics and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance database analysis.** *Bjog* 2020; Takemoto MLS, Menezes MO, Andreucci CB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799381>
6. **Clinical characteristics, management and in-hospital mortality of patients with COVID-19 In Genoa, Italy.** *Clin Microbiol Infect* 2020; Vena A, Giacobbe DR, Di Biagio A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810610>
7. **COVID-19 prevalence and fatality rates in association with air pollution emission concentrations and emission sources.** *Environ Pollut* 2020; 265:115126Hendryx M, Luo J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806422>

8. **Mortality Attributed to COVID-19 in High-Altitude Populations.** *High. Alt. Med. Biol.* 2020; Woolcott OO, Bergman RN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815745>
9. **Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.** *Int J Infect Dis* 2020; Klopfenstein T, Zayet S, Lohse A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798660>
10. **Mortality and Pre-Hospitalization use of Renin-Angiotensin System Inhibitors in Hypertensive COVID-19 Patients.** *J Am Heart Assoc* 2020:e017736Chen C, Wang F, Chen P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807002>
11. **Quantification of Death Risk in Relation to Sex, Pre-Existing Cardiovascular Diseases and Risk Factors in COVID-19 Patients: Let's Take Stock and See Where We Are.** *J Clin Med* 2020; 9Moula AI, Micali LR, Matteucci F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825068>
12. **Real-time naive case fatality rates can reflect timeliness of case confirmation during pandemics.** *J Infect Public Health* 2020; Qi R, Chen C, Hu XB, Yu XJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798184>
13. **COVID-19 and maternal, fetal and neonatal mortality: a systematic review.** *J Matern Fetal Neonatal Med* 2020:1-6Hessami K, Homayoon N, Hashemi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799712>
14. **Special considerations in the assessment of catastrophic brain injury and determination of brain death in patients with SARS-CoV-2.** *J Neurol Sci* 2020; 417:117087Valdes E, Agarwal S, Carroll E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798855>
15. **Critically ill COVID-19 patients: Does remdesivir have an influence on mortality?** *MMW-Fortschritte der Medizin* 2020; 162:62Schumacher B.
16. **Demographic perspectives on the mortality of COVID-19 and other epidemics.** *Proc Natl Acad Sci U S A* 2020; Goldstein JR, Lee RD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820077>
17. **Lung Ultrasound Findings Are Associated with Mortality and Need for Intensive Care Admission in COVID-19 Patients Evaluated in the Emergency Department.** *Ultrasound Med. Biol.* 2020; Bonadia N, Carnicelli A, Piano A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798003>
18. **Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage.** *Virchows Arch.* 2020; Skok K, Stelzl E, Trauner M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815036>

Online – IT – Apps (36 articles)

1. **Virtual Geriatric Clinics and the COVID-19 Catalyst: A Rapid Review.** *Age Ageing* 2020; Murphy RP, Dennehy KA, Costello MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821909>
2. **Virtual Imaging Trials for Coronavirus Disease (COVID-19).** *AJR Am J Roentgenol* 2020:1-7Abadi E, Paul Segars W, Chalian H, Samei E. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822224>
3. **Misinformation dissemination in Twitter in the COVID-19 era.** *Am. J. Med.* 2020; Krittanawong C, Narasimhan B, Virk HUH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805227>
4. **Feasibility and acceptability of telemedicine to substitute outpatient rehabilitation services in the COVID-19 emergency in Italy: an observational everyday clinical-life study.** *Arch. Phys. Med. Rehabil.* 2020; Negrini S, Donzelli S, Negrini A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800748>
5. **COVID-19-related issues on tele-counseling helpline in Bangladesh.** *Asia Pac Psychiatry* 2020:e124071qbal Y, Jahan R, Yesmin S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808472>
6. **Following COVID-19 clinicians now overwhelmingly accept virtual clinics in Oral and Maxillofacial Surgery.** *Br. J. Oral Maxillofac. Surg.* 2020; Al-Izzi T, Breeze J, Elledge R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798104>
7. **Covid-19 and the 'new normal': are remote video consultations here to stay?** *Br. Med. Bull.* 2020; Bidmead E, Marshall A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827250>
8. **Teleconsultation in a coloproctology unit during the COVID-19 pandemic. Preliminary results.** *Cir Esp* 2020; Muñoz-Duyos A, Abarca-Alvarado N, Lagares-Tena L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811680>
9. **Mental Health Care Goes Online: Practitioners' Experiences of Providing Mental Health Care During the COVID-19 Pandemic.** *Cyberpsychol Behav Soc Netw* 2020; Feijt M, de Kort Y, Bongers I *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815742>
10. **Webinars as a mode of e-discussion by Indian dermatologists during the COVID-19 era: A boon or a bane?** *Dermatol Ther* 2020; Sarkar R, Bhargava S, Chander R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820852>
11. **Counseling of people with epilepsy via telemedicine: Experiences at a German tertiary epilepsy center during the COVID-19 pandemic.** *Epilepsy Behav.* 2020; 112:107298von Wrede R, Moskau-Hartmann S, Baumgartner T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801068>
12. **Telemedicine in ophthalmology in view of the emerging COVID-19 outbreak.** *Graefes Arch Clin Exp Ophthalmol* 2020:1-12Sommer AC, Blumenthal EZ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813110>
13. **Nigeria media framing of coronavirus pandemic and audience response.** *Health Promot Perspect* 2020; 10:192-199Nwakpu ES, Ezema VO, Ogbodo JN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802755>
14. **Communicating health crisis: a content analysis of global media framing of COVID-19.** *Health Promot Perspect* 2020; 10:257-269Ogbodo JN, Onwe EC, Chukwu J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802763>
15. **Prediction of COVID-19 Outbreaks Using Google Trends in India: A Retrospective Analysis.** *Healthc Inform Res* 2020; 26:175-184Venkatesh U, Gandhi PA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819035>
16. **Simulated Video Consultations as a Learning Tool in Undergraduate Nursing: Students' Perceptions.** *Healthcare (Base)* 2020; 8Jiménez-Rodríguez D, Arrogante O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825269>
17. **How the COVID-19 Pandemic is Changing Mental Health Disease Management: The Growing Need of Telecounseling in Italy.** *Innov. Clin. Neurosci.* 2020; 17:16-17De Luca R, Calabrò RS. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802587>

18. **Prognostic machine learning models for COVID-19 to facilitate decision making.** *Int J Clin Pract* 2020:e13685Subudhi S, Verma A, A BP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810316>
19. **Fake News and Covid-19 in Italy: Results of a Quantitative Observational Study.** *Int J Environ Res Public Health* 2020; 17Moscadelli A, Albora G, Biamonte MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806772>
20. **Telemedicine Center of Korean Medicine for treating patients with COVID-19: a retrospective analysis.** *Integr Med Res* 2020; 9:100492Kim DS, Chu H, Min BK *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802745>
21. **Bridging the Needs of Adolescent Diabetes Care During Coronavirus Disease 2019: A Nurse-Led Telehealth Initiative.** *J. Adolesc. Health* 2020; Lim ST, Yap F, Chin X. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798101>
22. **COVID-19 impact and virtual medical education.** *J Adv Med Educ Prof* 2020; 8:140-143Tabatabai S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802908>
23. **Special Article: Mitigating Misinformation and Changing the Social Narrative.** *J Allergy Clin Immunol Pract* 2020; Abrams EM, Greenhawt M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822920>
24. **Ethical Issues Related to the Virtual Interviews Process Faced by Applicants and Programs.** *J Am Acad Dermatol* 2020; Alvarado S, Grant-Kels JM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798573>
25. **Diseases with health disparities as drivers of COVID-19 outcome.** *J Cell Mol Med* 2020; Moore JT, Pilkington W, Kumar D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816409>
26. **Resuming of endodontic practices in COVID-19 hardest-hit area of China: A Web-based Survey.** *J Endod* 2020; Yu J, Hua F, Shen Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818564>
27. **Creating Virtual Presence During a Pandemic.** *J Patient Exp* 2020; 7:285-286Millstein JH, Chaiyachati KH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821781>
28. **Leveraging media and health communication strategies to overcome the COVID-19 infodemic.** *J Public Health Policy* 2020:1-11Mheidly N, Fares J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826935>
29. **Optimising telemedicine in ophthalmology during the COVID-19 pandemic.** *J Telemed Telecare* 2020:1357633x20949796Patel S, Hamdan S, Donahue S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799736>
30. **Telehealth in cancer care during the COVID-19 pandemic.** *Med. J. Aust.* 2020; Wong ZW, Cross HL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803783>
31. **Quality of online information for the general public on COVID-19.** *Patient Educ. Couns.* 2020; Jayasinghe R, Ranasinghe S, Jayarajah U, Seneviratne S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800422>
32. **Pflege in Zeiten von COVID-19: Onlinebefragung von Führungskräften zu Herausforderungen, Belastungen und Bewältigungsstrategien.** *Pflege* 2020; 33:207-218Hower KI, Pfaff H, Pfortner TK. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811325>
33. **Health Inequalities in the Use of Telehealth in the United States in the Lens of COVID-19.** *Popul Health Manag* 2020; Jaffe DH, Lee L, Huynh S, Haskell TP. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816644>
34. **The effect of big-city news on rural America during the COVID-19 pandemic.** *Proc Natl Acad Sci U S A* 2020; Kim E, Shepherd ME, Clinton JD. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820075>
35. **Telehealth Beyond COVID-19.** *Psychiatr. Serv.* 2020:appis202000368Haque SN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811284>
36. **Delivery of urological services (telemedicine and urgent surgery) during COVID-19 lockdown: experience and lessons learnt from a university hospital in United Kingdom.** *Scott. Med. J.* 2020:36933020951932Somani BK, Pietropaolo A, Coulter P, Smith J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819219>

Other – Miscellaneous (37 articles)

1. **World Sepsis Day - A Global Agenda to Target a Leading Cause of Morbidity and Mortality.** *Am J Physiol Lung Cell Mol Physiol* 2020; Schlapbach LJ, Kisson N, Alhawsawi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812788>
2. **Was child abuse underdetected during the COVID-19 lockdown?** *Arch. Pediatr.* 2020; Caron F, Plancq MC, Tourneux P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807622>
3. **Impact of the COVID-19 pandemic on sports and exercise.** *Asia Pac J Sports Med Arthrosc Rehabil Technol* 2020; 22:39-44Wong AY, Ling SK, Louie LH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821648>
4. **COVID-19 in Light of Seasonal Respiratory Infections.** *Biology (Basel)* 2020; 9Kiseleva I, Grigorieva E, Larionova N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825427>
5. **Inverted Covariate Effects for First versus Mutated Second Wave Covid-19: High Temperature Spread Biased for Young.** *Biology (Basel)* 2020; 9Seligmann H, Iggui S, Rachdi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823981>
6. **Screen rhytides: the cosmetic legacy of COVID-19.** *Dermatol Ther* 2020; Searle T, Ali FR, Al-Niaimi F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820855>
7. **Current ethical challenges in intensive care in the face of the corona pandemic.** *Deutsche medizinische Wochenschrift (1946)* 2020; 145:1152-1156Janssens U.
8. **Asymptomatic Transmission of SARS-CoV-2 on Evacuation Flight.** *Emerg Infect Dis* 2020; 26Bae SH, Shin H, Koo HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822289>
9. **COVID-19 prevalence and fatality rates in association with air pollution emission concentrations and emission sources.** *Environ Pollut* 2020; 265:115126Hendryx M, Luo J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806422>
10. **Impact of climate and ambient air pollution on the epidemic growth during COVID-19 outbreak in Japan.** *Environ. Res.* 2020:110042Azuma K, Kagi N, Kim H, Hayashi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800895>
11. **SARS-CoV-2 in soils.** *Environ. Res.* 2020; 190:110045Núñez-Delgado A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800893>
12. **Effects of climatological parameters on the outbreak spread of COVID-19 in highly affected regions of Spain.** *Environ. Sci. Pollut. Res. Int.* 2020:1-10Shahzad K, Shahzad U, Iqbal N *et al.*

- <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827296>
13. **The Under-Reported Role of Toxic Substance Exposures in the COVID-19 Pandemic.** *Food Chem. Toxicol.* 2020;111687Kostoff RN, Briggs MB, Porter AL *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805343>
 14. **LATENT/Missing: On Missing Values, Narrative Power, and Data Politics in Discourse of COVID-19.** *Health Educ. Behav.* 2020;1090198120950194Petteway RJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806932>
 15. **Indoor air quality at school and students' performance: Recommendations of the UNESCO Chair on Health Education and Sustainable Development & the Italian Society of Environmental Medicine (SIMA).** *Health Promot Perspect* 2020; 10:169-174Pulimeno M, Piscitelli P, Colazzo S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802752>
 16. **COVID-19, SARS-CoV-2, and Export Controls.** *Health Secur* 2020; 18:329-334Millett P, Rutten P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816590>
 17. **No "back to normal" after COVID-19 for our failed drug policies.** *Int. J. Drug Policy* 2020;102901Del Pozo B, Beletsky L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807624>
 18. **Understanding COVID-19: From Origin to Potential Therapeutics.** *Int J Environ Res Public Health* 2020; 17Moazzam M, Sajid MI, Shahid H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823901>
 19. **The Condition of Air Pollution in Kraków, Poland, in 2005-2020, with Health Risk Assessment.** *Int J Environ Res Public Health* 2020; 17Traczyk P, Gruszecka-Kosowska A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825405>
 20. **COVID-19 Pandemic Brings a Sedentary Lifestyle in Young Adults: A Cross-Sectional and Longitudinal Study.** *Int J Environ Res Public Health* 2020; 17Zheng C, Huang WY, Sheridan S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825092>
 21. **Welfare Chauvinism, Populist Radical Right Parties and Health Inequalities Comment on "A Scoping Review of Populist Radical Right Parties' Influence on Welfare Policy and its Implications for Population Health in Europe".** *Int J Health Policy Manag* 2020; Bambra C, Lynch J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801220>
 22. **COVID-19: in the uncertainty, do not try this at home.** *Intern Emerg Med* 2020; Lupia T, Corcione S, De Rosa FG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803631>
 23. **Impact of COVID-19 outbreak on physical activity of patients with implantable cardioverter defibrillators.** *J. Card. Fail.* 2020; Malanchini G, Malacrida M, Ferrari P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827643>
 24. **Diseases with health disparities as drivers of COVID-19 outcome.** *J Cell Mol Med* 2020; Moore JT, Pilkington W, Kumar D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816409>
 25. **The effect of small versus large clog size on emergency response time: A randomized controlled trial.** *J Crit Care* 2020; 60:116-119Elbers PWG, de Grooth HJ, Girbes ARJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799180>
 26. **Scabies outbreak during home confinement due to the SARS-CoV-2 pandemic.** *J Eur Acad Dermatol Venereol* 2020; Martínez-Pallás I, Aldea-Manrique B, Ramírez-Lluch M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810303>
 27. **Turned Upside Down: The Role of New York Patient Experience Leaders During COVID-19.** *J Patient Exp* 2020; 7:287-290Gierlinger S, Barden A, Giammarinaro N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821782>
 28. **Communication for Equity in the Service of Patient Experience: Health Justice and the COVID-19 Pandemic.** *J Patient Exp* 2020; 7:279-281Cordero DM, Davis DL. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821779>
 29. **Safe Villages during the 1918-1919 influenza pandemic in Spain and Portugal.** *J. Prev. Med. Hyg.* 2020; 61:E137-e142Erkoreka A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802996>
 30. **Songbirds Must Sing: How Artistic Voice Users Perceive Their Voice in Times of COVID-19.** *J. Voice* 2020; Primov-Fever A, Roziner I, Amir O. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826119>
 31. **Susceptibility to SARS, MERS, and COVID-19 from animal health perspective.** *Open Vet J* 2020; 10:164-177Gautam A, Kaphle K, Shrestha B, Phuyal S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821661>
 32. **[The patterns of seasonal outbreaks of acute respiratory diseases].** *Probl Sotsialnoi Gig Zdravookhranennii i Istor Med* 2020; 28:507-511Gundarov IA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827360>
 33. **Impact of the COVID-19 pandemic and control measures on air quality and aerosol light absorption in Southwestern China.** *Sci Total Environ* 2020; 749:141419Chen Y, Zhang S, Peng C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822916>
 34. **Unlocking challenges and opportunities presented by COVID-19 pandemic for cross-cutting disruption in agri-food and green deal innovations: Quo Vadis?** *Sci Total Environ* 2020; 748:141362Rowan NJ, Galanakis CM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823223>
 35. **To avoid the noncausal association between environmental factor and COVID-19 when using aggregated data: Simulation-based counterexamples for demonstration.** *Sci Total Environ* 2020; 748:141590Zhao S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798858>
 36. **Fractured aluminum nasopharyngeal swab during drive-through testing for COVID-19: radiographic detection of a retained foreign body.** *Skeletal Radiol.* 2020;1-5Azar A, Wessell DE, Janus JR, Simon LV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827082>
 37. **Detection of SARS-CoV-2 in pets living with COVID-19 owners diagnosed during the COVID-19 lockdown in Spain: A case of an asymptomatic cat with SARS-CoV-2 in Europe.** *Transbound Emerg Dis* 2020; Ruiz-Arrodo I, Portillo A, Palomar AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810370>

Pathology (6 articles)

1. **The Spectrum of Histopathologic Findings in Lungs of Patients with Fatal COVID-19 Infection.** *Arch Pathol Lab Med* 2020; Roden AC, Bois MC, Johnson TF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821902>

2. **Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) - anatomic pathology perspective on current knowledge.** *Diagn. Pathol.* 2020; 15:103Mohanty SK, Satapathy A, Naidu MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799894>
3. **Clinicopathological Features and Outcomes of Acute Kidney Injury in Critically Ill COVID-19 with Prolonged Disease Course: A Retrospective Cohort.** *J Am Soc Nephrol* 2020; Xia P, Wen Y, Duan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826326>
4. **A review of the management and safe handling of bodies in cases involving COVID-19.** *Med. Sci. Law* 2020;25802420949044Rani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799740>
5. **Pathologic features of COVID-19: A concise review.** *Pathol. Res. Pract.* 2020; 216:153097Tabary M, Khanmohammadi S, Araghi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825963>
6. **Post-mortem viral dynamics and tropism in COVID-19 patients in correlation with organ damage.** *Virchows Arch.* 2020; Skok K, Stelzl E, Trauner M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815036>

Protection (40 articles)

1. **Strategic implementation of dental infection control in resource-poor jurisdictions during COVID-19 pandemic: a perspective from South Africa.** *Acta Odontol. Scand.* 2020;1-4Blignaut E, Nematandani S, Samaranyake L. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809910>
2. **Novel Insights into the Transmission of SARS-CoV-2 Through the Ocular Surface and its Detection in Tears and Conjunctival Secretions: A Review.** *Adv Ther* 2020;1-10Güemes-Villahoz N, Burgos-Blasco B, Vidal-Villegas B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809211>
3. **Inactivation of SARS-CoV-2 by commercially available alcohol-based hand sanitizers.** *Am. J. Infect. Control* 2020; Leslie RA, Zhou SS, Macinga DR. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818578>
4. **Impact of Extended Use and Decontamination with Vaporized Hydrogen Peroxide on N95 Respirator Fit.** *Am. J. Infect. Control* 2020; Lieu A, Mah J, Zanichelli V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805321>
5. **The Impact of COVID-19 Pandemic on Hand Hygiene Performance in Hospitals.** *Am. J. Infect. Control* 2020; Moore LD, Robbins G, Quinn J, Arbogast JW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818577>
6. **COVID-19 Intubation Safety: A Multidisciplinary, Rapid-Cycle Model of Improvement.** *Am. J. Med. Qual.* 2020;1062860620949141Tronnier A, Mulcahy CF, Pierce A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806935>
7. **Occupational safety in the treatment of COVID-19 patients: Relevant laws and regulations for the treating personnel.** *Anaesthetist* 2020; Mayr NP, Sernetz S, Heitzer F *et al.*
8. **Selecting Controls for Minimizing SARS-CoV-2 Aerosol Transmission in Workplaces and Conserving Respiratory Protective Equipment Supplies.** *Ann Work Expo Health* 2020; Brosseau LM, Rosen J, Harrison R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820333>
9. **Guidance on infection control and plume management with Laser and Energy-Based Devices taking into consideration COVID-19.** *Australas. J. Dermatol.* 2020; Sullivan JR, Rademaker M, Goodman G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815148>
10. **Safety considerations in the bioanalytical laboratories handling specimens from coronavirus disease 2019 patients.** *Bioanalysis* 2020; Chen Z, Sikorski TW. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820941>
11. **Coronavirus 2019 (COVID-19) Infections Among Healthcare Workers, Los Angeles County, February - May 2020.** *Clin Infect Dis* 2020; Hartmann S, Rubin Z, Sato H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803237>
12. **Proactive screening approach for SARS-CoV-2 among healthcare workers.** *Clin Microbiol Infect* 2020; Oster Y, Wolf DG, Olshtain-Pops K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822884>
13. **Asymptomatic Transmission of SARS-CoV-2 on Evacuation Flight.** *Emerg Infect Dis* 2020; 26Bae SH, Shin H, Koo HY *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822289>
14. **Aerosol transmission of SARS-CoV-2? Evidence, prevention and control.** *Environ Int* 2020; 144:106039Tang S, Mao Y, Jones RM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822927>
15. **Promoting safe and effective use of aerosol devices in COVID-19: Risks and suggestions for viral transmission.** *Expert Opin Drug Deliv* 2020; Ari A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799579>
16. **MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale.** *Expert Rev Anti Infect Ther.* 2020;1-7Marik PE, Kory P, Varon J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809870>
17. **On the Optimal Indoor Air Conditions for SARS-CoV-2 Inactivation. An Enthalpy-Based Approach.** *Int J Environ Res Public Health* 2020; 17Spena A, Palombi L, Corcione M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825607>
18. **Environmental contamination of SARS-CoV-2 on surfaces, air-conditioner and ventilation systems.** *Int J Hyg Environ Health* 2020; 230:113599Mouchtouri VA, Koureas M, Kyritsi M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823069>
19. **Surfaces and equipment contamination by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the emergency department at a university hospital.** *Int J Hyg Environ Health* 2020; 230:113600Peyrony O, Ellouze S, Fontaine JP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799101>
20. **Could nasal irrigation and oral rinse reduce the risk for COVID-19 infection?** *Int. J. Immunopathol. Pharmacol.* 2020; 34:2058738420941757Casale M, Rinaldi V, Sabatino L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799596>
21. **Estimating the impact of physical distancing measures in containing COVID-19: an empirical analysis.** *Int J Infect Dis* 2020; Koh WC, Naing L, Wong J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800859>
22. **Simple solutions for fogging of spectacles on wearing surgical masks.** *J Am Acad Dermatol* 2020; Bhardwaj A, Sharma C, Rajan MB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805291>
23. **Minimizing endoscopic facial exposure to droplets: optimal patient-endoscopist distance and use of a barrier device.** *J Gastroenterol Hepatol* 2020; Suzuki S, Gotoda T, Ikehara H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808303>
24. **Efficacy and Safety of Disinfectants for Decontamination of N95 and SN95 Filtering Facepiece Respirators: A Systematic Review.** *J Hosp Infect* 2020; O'Hearn K, Gertsman S, Webster R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800824>

25. **Wearing of face masks by healthcare workers during covid-19 lockdown: what did the public observe through the French media?** *J Hosp Infect* 2020; Picard J, Cornec G, Baron R, Saliou P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798641>
26. **Protecting healthcare workers during COVID-19 pandemic with nanotechnology: A protocol for a new device from Egypt.** *J Infect Public Health* 2020; Ahmed MK, Afifi M, Uskoković V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798183>
27. **Operating Room Setup: How to Improve Health Care Professionals Safety During Pandemic COVID-19-A Quality Improvement Study.** *J. Laparoendosc. Adv. Surg. Tech. A* 2020; Perrone G, Giuffrida M, Bellini V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804047>
28. **Operating Room Protocols in OMFS During Corona virus (Covid-19) Pandemic.** *J. Maxillofac. Oral Surg.* 2020; 19:327-331 Datarkar A, Purohit S, Tayal S, Bhawalkar A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801523>
29. **Unprotected stroke management in an undiagnosed case of Severe Acute Respiratory Syndrome Coronavirus 2 infection.** *J. Stroke Cerebrovasc. Dis.* 2020; 29:104981 Papi C, Spagni G, Alexandre A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807416>
30. **Bedside vascular access procedures for COVID-19 patients.** *J Vasc Access* 2020; 1129729820951000 Arrichiello A, Angileri SA, Ierardi AM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815482>
31. **Reducing Aerosolised Particles and Droplet Spread in Endoscopic Sinus Surgery during COVID-19.** *Laryngoscope* 2020; Jones HA, Salib RJ, Harries PG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798323>
32. **Could masks curtail the post-lockdown resurgence of COVID-19 in the US?** *Math. Biosci.* 2020; 108452 Ngonghala CN, Iboi E, Gumel AB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818515>
33. **A review of the management and safe handling of bodies in cases involving COVID-19.** *Med. Sci. Law* 2020; 25802420949044 Rani S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799740>
34. **Droplet Exposure Risk to Providers From In-Office Flexible Laryngoscopy: A COVID-19 Simulation.** *Otolaryngol Head Neck Surg* 2020; 194599820952800 Ye MJ, Sharma D, Rubel KE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808872>
35. **A smartphone microscopic method for rapid screening of cloth facemask fabrics during pandemics.** *PeerJ* 2020; 8:e9647 Neupane BB, Chaudhary RK, Sharma A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821549>
36. **COVID-19-Schutzmaßnahmen in der stationären Altenpflege.** *Pflege* 2020; 33:199-206 Fischer F, Raiber L, Boscher C, Winter MH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811330>
37. **A modelling framework to assess the likely effectiveness of facemasks in combination with 'lock-down' in managing the COVID-19 pandemic.** *Proc Math Phys Eng Sci* 2020; 476:20200376 Stutt R, Retkute R, Bradley M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821237>
38. **Social and behavioral consequences of mask policies during the COVID-19 pandemic.** *Proc Natl Acad Sci U S A* 2020; Betsch C, Korn L, Sprengholz P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820078>
39. **Hospital indoor air quality monitoring for the detection of SARS-CoV-2 (COVID-19) virus.** *Sci Total Environ* 2020; 748:141324 Kenarkoohi A, Noorimotlagh Z, Falahi S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805566>
40. **Understanding air and water borne transmission and survival of coronavirus: Insights and way forward for SARS-CoV-2.** *Sci Total Environ* 2020; 749:141486 Wathore R, Gupta A, Bherwani H, Labhasetwar N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827813>

Pulmonary disease (12 articles)

1. **Spontaneous pneumomediastinum in a male adult with COVID-19 pneumonia.** *Am J Emerg Med* 2020; Janssen J, Kamps MJA, Joosten TMB, Barten DG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800430>
2. **Spontaneous hemopneumothorax in a patient with COVID-19: A case report.** *Am J Emerg Med* 2020; Long A, Grimaldo F. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800431>
3. **Bubble Trouble in COVID-19.** *Am J Respir Crit Care Med* 2020; DuBrock HM, Krowka MJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822239>
4. **Acute Kidney Injury in COVID-19 Pneumonia: A Single-Center Experience in Bahrain.** *Cureus* 2020; 12:e9693 Taher A, Alalwan AA, Naser N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802627>
5. **COVID-19: A Pneumological Point of View - Long-Term Sequelae of COVID-19 - Implications for Follow-up in Respiratory Medicine.** *Deutsche Medizinische Wochenschrift* 2020; 145:1086-1092 Leo F, Wormanns D, Grohé C.
6. **CT abnormalities evocative of lung infection are associated with lower (18)F-FDG uptake in confirmed COVID-19 patients.** *Eur J Nucl Med Mol Imaging* 2020; 1-5 Bahloul A, Boursier C, Jeulin H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808079>
7. **Difference in Biomarkers Between COVID-19 Patients and Other Pulmonary Infection Patients.** *Infect Drug Resist* 2020; 13:2609-2615 Dai J, Du Y, Gao J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801798>
8. **Pediatric Asthma Healthcare Utilization, Viral Testing, and Air Pollution Changes during the COVID-19 Pandemic.** *J Allergy Clin Immunol Pract* 2020; Taquechel K, Diwadkar AR, Sayed S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827728>
9. **Letter to the Editor: Pulmonary Artery Pressure Monitoring during the COVID-19 Pandemic in New York City.** *J. Card. Fail.* 2020; Oliveros E, Mahmood K, Mitter S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805377>
10. **Usefulness of bronchoalveolar lavage in suspect covid-19 repeatedly negative swab test and interstitial lung disease.** *J Glob Antimicrob Resist* 2020; Vannucci J, Ruberto F, Diso D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810641>
11. **Gesundheitsverhalten und Bedürfnisse von Menschen mit COPD während der COVID-19-Pandemie.** *Pflege* 2020; 33:237-245 Hübsch C, Clarenbach CF, Petry H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811328>

12. **Practical considerations for spirometry during the COVID-19 outbreak: Literature review and insights.** *Pulmonology* 2020; Crimi C, Impellizzeri P, Campisi R *et al.*
<http://www.ncbi.nlm.nih.gov/pubmed/?term=32800783>

Renal disease (11 articles)

1. **Peritoneal Dialysis for Acute Kidney Injury during the COVID-19 Pandemic.** *Clin J Am Soc Nephrol* 2020; Shimonov D, Srivatana V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801119>
2. **COVID-19: The Perspective of Nephrology.** *Deutsche Medizinische Wochenschrift* 2020; 145:1068-1073 Kann M, Benzing T.
3. **The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis.** *Eur. J. Pharmacol.* 2020:173487 Habibzadeh P, Mofatteh M, Ghavami S, Roozbeh J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805256>
4. **Perspectives on COVID-19 from Singapore: Impact on ESKD Care and Medical Education.** *J Am Soc Nephrol* 2020; Coffman TM, Chan CM, Choong LH *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817117>
5. **Racial and Ethnic Disparities in Seasonal Influenza Vaccination among Dialysis Facilities in the United States.** *J Am Soc Nephrol* 2020; Danziger J, Weinhandl E, Friedman D, Mukamal KJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817310>
6. **Clinicopathological Features and Outcomes of Acute Kidney Injury in Critically Ill COVID-19 with Prolonged Disease Course: A Retrospective Cohort.** *J Am Soc Nephrol* 2020; Xia P, Wen Y, Duan Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32826326>
7. **Clinical Profiles in Renal Patients with COVID-19.** *J Clin Med* 2020; 9 Arenas MD, Crespo M, Pérez-Sáez MJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824683>
8. **COVID-19-related stigma and perceived stress among dialysis staff.** *J Nephrol* 2020; Uvais NA, Aziz F, Hafeeq B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804354>
9. **COVID Era "Essential Surgery" Dialysis Access Management Considerations.** *J. Vasc. Surg.* 2020; Kirksey L, Vacharajani T, Droz NM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798572>
10. **Outcomes of patients with end-stage kidney disease hospitalized with COVID-19.** *Kidney Int* 2020; Ng JH, Hirsch JS, Wanchoo R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810523>
11. **Successful recovery from COVID-19 in three kidney transplant recipients who received convalescent plasma therapy.** *Transpl Infect Dis* 2020:e13451 Naem S, Gohh R, Bayliss G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815238>

Reviews (36 articles)

1. **Novel Insights into the Transmission of SARS-CoV-2 Through the Ocular Surface and its Detection in Tears and Conjunctival Secretions: A Review.** *Adv Ther* 2020:1-10 Güemes-Villahoz N, Burgos-Blasco B, Vidal-Villegas B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809211>
2. **Virtual Geriatric Clinics and the COVID-19 Catalyst: A Rapid Review.** *Age Ageing* 2020; Murphy RP, Dennehy KA, Costello MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821909>
3. **The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature.** *Am. J. Hum. Genet.* 2020; LoPresti M, Beck DB, Duggal P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814065>
4. **Cardiovascular involvement during COVID-19 and clinical implications in elderly patients. A review.** *Ann Med Surg (Lond)* 2020; 57:236-243 Napoli C, Tritto I, Benincasa G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802325>
5. **COVID-19 and the central nervous system.** *Clin. Neurol. Neurosurg.* 2020; 198:106116 Alomari SO, Abou-Mrad Z, Bydon A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32828027>
6. **Incidence of ARDS and outcomes in hospitalized patients with COVID-19: a global literature survey.** *Crit Care* 2020; 24:516 Tzotzos SJ, Fischer B, Fischer H, Zeitlinger M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825837>
7. **COVID-19 Induced Acute Pancreatitis: A Case Report and Literature Review.** *Cureus* 2020; 12:e9169 Kataria S, Sharif A, Ur Rehman A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802606>
8. **Severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) and coronavirus disease 19 (COVID-19) - anatomic pathology perspective on current knowledge.** *Diagn. Pathol.* 2020; 15:103 Mohanty SK, Satapathy A, Naidu MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799894>
9. **A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.** *Drug Des. Devel. Ther.* 2020; 14:3215-3222 Hashemian SM, Farhadi T, Velayati AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821086>
10. **Cardiac manifestations in SARS-CoV-2-associated multisystem inflammatory syndrome in children: a comprehensive review and proposed clinical approach.** *Eur. J. Pediatr.* 2020; Sperotto F, Friedman KG, Son MBF *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803422>
11. **Emerging therapeutics for the management of COVID 19.** *Expert Opin Emerg Drugs* 2020; Debnath S, Srivastava R, Omri A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799566>
12. **Investigating and evaluating evidence of the behavioural determinants of adherence to social distancing measures - A protocol for a scoping review of COVID-19 research.** *HRB Open Res* 2020; 3:46 Noone C, Warner N, Byrne M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803123>
13. **The Coronavirus Disease 2019 (COVID-19) in Children: A Study in an Iranian Children's Referral Hospital.** *Infect Drug Resist* 2020; 13:2649-2655 Mahmoudi S, Mehdizadeh M, Shervin Badv R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801803>
14. **Current Status of Laboratory Diagnosis for COVID-19: A Narrative Review.** *Infect Drug Resist* 2020; 13:2657-2665 Russo A, Minichini C, Starace M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801804>
15. **From SARS to SARS-CoV-2, insights on structure, pathogenicity and immunity aspects of pandemic human coronaviruses.** *Infect Genet Evol* 2020:104502 Kirtipal N, Bharadwaj S, Kang SG. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798769>

16. **A Review on Currently Available Potential Therapeutic Options for COVID-19.** *Int. J. Gen. Med.* 2020; 13:443-467 Oadian Moghadam S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801840>
17. **Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: a systematic review.** *Int J Gynaecol Obstet* 2020; Turan O, Hakim A, Dashraath P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816307>
18. **Vitamin D can be effective on the prevention of COVID-19 complications: A narrative review on molecular aspects.** *Int. J. Vitam. Nutr. Res.* 2020;1-13 Shiravi AA, Saadatkish M, Abdollahi Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811354>
19. **COVID-19 in Liver Transplant Patients: Report of 2 Cases and Review of the Literature.** *Int Med Case Rep J* 2020; 13:317-321 Niknam R, Malek-Hosseini SA, Hashemieh SS, Dehghani M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801943>
20. **Persian medicine recommendations for the prevention of pandemics related to the respiratory system: a narrative literature review.** *Integr Med Res* 2021; 10:100483 Iranzadasl M, Karimi Y, Moadeli F, Pasalar M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802742>
21. **A Narrative Review of COVID-19: The New Pandemic Disease.** *Iran J Med Sci* 2020; 45:233-249 Shirani K, Sheikhbahaei E, Torkpour Z *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801413>
22. **Anticoagulant treatment in COVID-19: a narrative review.** *J. Thromb. Thrombolysis* 2020;1-7 Carfora V, Spiniello G, Ricciolino R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809158>
23. **Utilizing drug repurposing against COVID-19 - Efficacy, limitations, and challenges.** *Life Sci* 2020;118275 Parvathaneni V, Gupta V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818545>
24. **Novel Antiviral Strategies in the Treatment of COVID-19: A Review.** *Microorganisms* 2020; 8:Chen SJ, Wang SC, Chen YC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825283>
25. **Not just antibodies: B cells and T cells mediate immunity to COVID-19.** *Nat. Rev. Immunol.* 2020; Cox RJ, Brokstad KA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32839569>
26. **COVID-19 - What does a paediatrician need to know?** *Paediatr. Respir. Rev.* 2020; Robinson J, Freire D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798115>
27. **Pathologic features of COVID-19: A concise review.** *Pathol. Res. Pract.* 2020; 216:153097 Tabary M, Khanmohammadi S, Araghi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825963>
28. **Addictions in the COVID-19 era: Current evidence, future perspectives a comprehensive review.** *Prog. Neuropsychopharmacol. Biol. Psychiatry* 2020;110070 Mallet J, Dubertret C, Le Strat Y. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800868>
29. **Past Epidemics, Natural Disasters, COVID19, and Mental Health: Learning from History as we Deal with the Present and Prepare for the Future.** *Psychiatr. Q.* 2020; Esterwood E, Saeed SA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803472>
30. **Practical considerations for spirometry during the COVID-19 outbreak: Literature review and insights.** *Pulmonology* 2020; Crimi C, Impellizzeri P, Campisi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800783>
31. **ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review.** *Rep Biochem Mol Biol* 2020; 9:97-105 Mostafa-Hedeab G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821757>
32. **SARS-CoV: Lessons learned; opportunities missed for SARS-CoV-2.** *Rev Med Virol* 2020:e2152 Davis IM. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808446>
33. **Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review.** *Strahlenther. Onkol.* 2020; Del Castillo R, Martinez D, Sarria GJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816059>
34. **Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.** *Ther Adv Infect Dis* 2020; 7:2049936120947517 Acharya Y, Sayed A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821381>
35. **Risk of Transmission of Severe Acute Respiratory Syndrome Coronavirus-2 by Transfusion: A Literature Review.** *Transfusion* 2020; Leblanc JF, Germain M, Delage G *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798237>
36. **Male Fertility and the COVID-19 Pandemic: Systematic Review of the Literature.** *World J Mens Health* 2020; Khalili MA, Leisegang K, Majzoub A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814369>

Risk factors (35 articles)

1. **The relationship between diabetes and clinical outcomes in COVID-19: a single-center retrospective analysis.** *Acta Diabetol* 2020; Fox T, Ruddiman K, Lo KB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804317>
2. **Risk factors for severe cases of COVID-19: a retrospective cohort study.** *Aging (Albany NY)* 2020; 12:He F, Luo Q, Lei M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805730>
3. **Elevated Lactate Dehydrogenase (LDH) level as an independent risk factor for the severity and mortality of COVID-19.** *Aging (Albany NY)* 2020; 12:Li C, Ye J, Chen Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805722>
4. **Atopic status protects from severe complications of COVID-19.** *Allergy* 2020; Scala E, Abeni D, Tedeschi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799364>
5. **The Role of Host Genetic Factors in Coronavirus Susceptibility: Review of Animal and Systematic Review of Human Literature.** *Am. J. Hum. Genet.* 2020; LoPresti M, Beck DB, Duggal P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814065>
6. **A fatal case of COVID-19 in a patient with common variable immunodeficiency.** *Ann. Allergy. Asthma. Immunol.* 2020; Mullur J, Wang A, Feldweg A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818593>
7. **Predicting Disease Severity and Outcome in COVID-19 Patients: A Review of Multiple Biomarkers.** *Arch Pathol Lab Med* 2020; Tjendra Y, Al Mana AF, Espejo AP *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818235>
8. **Mechanistic insights into SARS-CoV-2 epidemic via revealing the features of SARS-CoV-2 coding proteins and host responses upon its infection.** *Bioinformatics* 2020; Qin S, Xia X, Shi X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805023>
9. **Clinical characteristics and risk factors for mortality in obstetric patients with severe COVID-19 in Brazil: a surveillance database analysis.** *Bjog* 2020; Takemoto MLS, Menezes MO, Andreucci CB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799381>

10. **Implications of ABO blood group in hypertensive patients with covid-19.** *BMC Cardiovasc. Disord.* 2020; 20:373Sardu C, Marfella R, Maggi P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799852>
11. **Low Incidence of SARS-CoV-2 in Patients with Solid Tumours on Active Treatment: An Observational Study at a Tertiary Cancer Centre in Lombardy, Italy.** *Cancers (Basel)* 2020; 12Bertuzzi AF, Marrari A, Gennaro N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825295>
12. **Factors determining COVID-19 pneumonia severity in a country with routine BCG vaccination.** *Clin. Exp. Immunol.* 2020; Aksu K, Naziroğlu T, Özkan P. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813879>
13. **Prediction of respiratory decompensation in Covid-19 patients using machine learning: The READY trial.** *Comput. Biol. Med.* 2020; 124:103949Burdick H, Lam C, Mataraso S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798922>
14. **COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study.** *Immun. Ageing* 2020; 17:22Jurado A, Martín MC, Abad-Molina C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802142>
15. **Poor outcomes in patients with cirrhosis and Corona Virus Disease-19.** *Indian J. Gastroenterol.* 2020; Shalimar, Elhence A, Vaishnav M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803716>
16. **Previous and active tuberculosis increases risk of death and prolongs recovery in patients with COVID-19.** *Infect Dis (Lond)* 2020:1-6Sy KTL, Haw NJL, Uy J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808838>
17. **Analysis of Risk Factors on Readmission Cases of COVID-19 in the Republic of Korea: Using Nationwide Health Claims Data.** *Int J Environ Res Public Health* 2020; 17Jeon WH, Seon JY, Park SY, Oh IH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806775>
18. **Risk factors for positive and negative COVID-19 tests: a cautious and in-depth analysis of UK biobank data.** *Int J Epidemiol* 2020; Chadeau-Hyam M, Bodinier B, Elliott J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814959>
19. **Unspoken inequality: how COVID-19 has exacerbated existing vulnerabilities of asylum-seekers, refugees, and undocumented migrants in South Africa.** *Int J Equity Health* 2020; 19:141Mukumbang FC, Ambe AN, Adebisi BO. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819364>
20. **Does gender influence clinical expression and disease outcomes in COVID-19? A systematic review and meta-analysis.** *Int J Infect Dis* 2020; Ortolan A, Lorenzin M, Felicetti M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800858>
21. **Obesity and COVID-19: Molecular Mechanisms Linking Both Pandemics.** *Int J Mol Sci* 2020; 21Ritter A, Kreis NN, Louwen F, Yuan J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806722>
22. **Utilization of machine-learning models to accurately predict the risk for critical COVID-19.** *Intern Emerg Med* 2020:1-9Assaf D, Gutman Y, Neuman Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812204>
23. **Resilience of Alzheimer's Disease to COVID-19.** *J. Alzheimers Dis.* 2020; Li J, Long X, Huang H *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804094>
24. **Clinical Characteristics and Risk Factors of Cardiac Involvement in COVID-19.** *J Am Heart Assoc* 2020:e016807Xu H, Hou K, Xu R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806998>
25. **Quantification of Death Risk in Relation to Sex, Pre-Existing Cardiovascular Diseases and Risk Factors in COVID-19 Patients: Let's Take Stock and See Where We Are.** *J Clin Med* 2020; 9Moula AI, Micali LR, Matteucci F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825068>
26. **Comment on "ApoE e4e4 genotype and mortality with COVID-19 in UK Biobank" by Kuo et al.** *J Gerontol A Biol Sci Med Sci* 2020; Nikogosov DA, Shevlyakov AD, Baranova AV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803253>
27. **Circulating Endothelial Cells as a Marker of Endothelial Injury in Severe COVID -19.** *J Infect Dis* 2020; Guervilly C, Burtsey S, Sabatier F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812049>
28. **Anaemia is associated with severe illness in COVID-19: a retrospective cohort study.** *J Med Virol* 2020; Tao Z, Xu J, Chen W *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813298>
29. **Infection and thrombosis associated with COVID-19: Possible role of the ABO blood group.** *Med Clin (Barc)* 2020; Zalba Marcos S, Antelo ML, Galbete A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814635>
30. **Vitamin D Insufficiency and Deficiency and Mortality from Respiratory Diseases in a Cohort of Older Adults: Potential for Limiting the Death Toll during and beyond the COVID-19 Pandemic?** *Nutrients* 2020; 12Brenner H, Holleczeck B, Schöttker B. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824839>
31. **Is growth hormone insufficiency the missing link between obesity, male gender, age and COVID-19 severity?** *Obesity (Silver Spring)* 2020; Lubrano C, Masi D, Risi R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808459>
32. **Brady-arrhythmias in Patients with COVID-19: Marker of Poor Prognosis?** *Pacing Clin. Electrophysiol.* 2020; Chinitz JS, Goyal R, Harding M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820823>
33. **COVID-19 severity scoring systems in radiological imaging - a review.** *Pol J Radiol* 2020; 85:e361-e368Wasilewski PG, Mruk B, Mazur S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817769>
34. **Are people with uncontrolled diabetes mellitus at high risk of reinfections with COVID-19?** *Prim. Care Diabetes* 2020; Pal R, Banerjee M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800450>
35. **Socioeconomic restrictions slowdown COVID-19 far more effectively than favorable weather-evidence from the satellite.** *Sci Total Environ* 2020; 748:141401Shen X, Cai C, Li H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798876>

Safety (10 articles)

1. **Effect of common medications on the expression of SARS-CoV-2 entry receptors in liver tissue.** *Arch. Toxicol.* 2020:1-5Saheb Sharif-Askari N, Saheb Sharif-Askari F, Mdkhana B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808185>
2. **Sex Hormones and Hormone Therapy during COVID-19 Pandemic: Implications for Patients with Cancer.** *Cancers (Basel)* 2020; 12Cattrini C, Bersanelli M, Latocca MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824674>
3. **Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.** *Circ Arrhythm Electrophysiol* 2020; 13:e008798Beyls C, Martin N, Hermida A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809882>

4. **Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular Toxicity of Hydroxychloroquine.** *J Med Internet Res* 2020; 22:e20007 Michelson M, Chow T, Martin NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804086>
5. **Einnahme von immunsupprimierenden Medikamenten.** *Kliniker* 2020; 49:274.
6. **Does activation of the protective Renin-Angiotensin System have therapeutic potential in COVID-19?** *Mol. Med.* 2020; 26:80 Namsolleck P, Moll GN. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807075>
7. **Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae.** *Psychosomatics* 2020; Hamm BS, Rosenthal LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800347>
8. **Heparin-induced thrombocytopenia and thrombosis in a patient with Covid-19.** *Thromb Res* 2020; 196:11-14 Huang CT, Hsu SY, Chang KW *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810772>

Treatment options (58 articles)

1. **Enhanced Binding of SARS-CoV-2 Spike Protein to Receptor by Distal Polybasic Cleavage Sites.** *ACS Nano* 2020; Qiao B, Olvera de la Cruz M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32806067>
2. **Could Spectral CT Have a Potential Benefit in Coronavirus Disease (COVID-19)?** *AJR Am J Roentgenol* 2020;1-6 Daoud B, Cazejust J, Tavolaro S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822225>
3. **Prescribing in COVID-19 patients: Should we take into account inflammation?** *Br. J. Clin. Pharmacol.* 2020; Marzolini C, Battagay M, Sendi P, Back DJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820554>
4. **Lopinavir-Ritonavir Treatment for COVID-19 Infection in Intensive Care Unit: Risk of Bradycardia.** *Circ Arrhythm Electrophysiol* 2020; 13:e008798 Beyls C, Martin N, Hermida A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809882>
5. **Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials against COVID-19: An in-silico Evaluation.** *Comb. Chem. High Throughput Screen.* 2020; Gorla US, Rao GK, Kulandaivelu US *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32819226>
6. **Potential Leads from Liquorice against SARS-CoV-2 Main Protease using Molecular Docking Simulation Studies.** *Comb. Chem. High Throughput Screen.* 2020; Sinha SK, Prasad SK, Islam MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807047>
7. **Molecular Docking and Virtual Screening based prediction of drugs for COVID-19.** *Comb. Chem. High Throughput Screen.* 2020; Talluri S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798373>
8. **Clinical Outcomes of Early Treatment With Doxycycline for 89 High-Risk COVID-19 Patients in Long-Term Care Facilities in New York.** *Cureus* 2020; 12:e9658 Alam MM, Mahmud S, Rahman MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802622>
9. **Early Use of Tocilizumab May Prevent Clinical Deterioration in Select COVID-19 Patients: A Case Series.** *Cureus* 2020; 12:e9187 Hitawala A, Kumar S, Gopalakrishna KV. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32818119>
10. **The application of direct viral cytopathic hypothesis to design drug trials in the battle against COVID-19.** *Daru* 2020; Ashraf MA, Sherafat A, Pourdast A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32803688>
11. **Data on chloroquine/hydroxychloroquine content in compounded oral suspension after filtration and centrifugation.** *Data Brief* 2020; 32:106116 Musazzi UM, Zanon D, Gennari CMG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802924>
12. **Evaluation of the Usefulness of CO-RADS for Chest CT in Patients Suspected of Having COVID-19.** *Diagnostics (Basel)* 2020; 10Fujioka T, Takahashi M, Mori M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825060>
13. **A Review on Remdesivir: A Possible Promising Agent for the Treatment of COVID-19.** *Drug Des. Devel. Ther.* 2020; 14:3215-3222 Hashemian SM, Farhadi T, Velayati AA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821086>
14. **Potent inhibitors of SARS-CoV-2 3C-like protease derived from N-substituted isatin compounds.** *Eur. J. Med. Chem.* 2020; 206:112702 Liu P, Liu H, Sun Q *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798789>
15. **The potential effectiveness of acetazolamide in the prevention of acute kidney injury in COVID-19: A hypothesis.** *Eur. J. Pharmacol.* 2020:173487 Habibzadeh P, Mofatteh M, Ghavami S, Roozbeh J. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805256>
16. **Emerging therapeutics for the management of COVID 19.** *Expert Opin Emerg Drugs* 2020; Debnath S, Srivastava R, Omri A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799566>
17. **MATH+ protocol for the treatment of SARS-CoV-2 infection: the scientific rationale.** *Expert Rev. Anti Infect. Ther.* 2020:1-7 Marik PE, Kory P, Varon J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809870>
18. **Potential chimeric peptides to block the SARS-CoV-2 spike receptor-binding domain.** *F1000Res* 2020; 9:576 Barh D, Tiwari S, Silva Andrade B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802318>
19. **Tocilizumab improves oxidative stress and endothelial glycocalyx: A mechanism that may explain the effects of biological treatment on COVID-19.** *Food Chem. Toxicol.* 2020; 145:111694 Ikonomidis I, Pavlidis G, Katsimbri P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32822775>
20. **Study of the structural, chemical descriptors and optoelectronic properties of the drugs Hydroxychloroquine and Azithromycin.** *Heliyon* 2020; 6:e04647 Ejuh GW, Fonkem C, Tadjouteu Assatse Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802983>
21. **Virtual screening, molecular docking studies and DFT calculations of FDA approved compounds similar to the non-nucleoside reverse transcriptase inhibitor (NNRTI) efavirenz.** *Heliyon* 2020; 6:e04642 Jordaan MA, Ebenezer O, Damoyi N, Shapi M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802982>
22. **Predicting novel drugs for SARS-CoV-2 using machine learning from a >10 million chemical space.** *Heliyon* 2020; 6:e04639 Kowalewski J, Ray A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802980>
23. **Searching potential antiviral candidates for the treatment of the 2019 novel coronavirus based on DFT calculations and molecular docking.** *Heliyon* 2020; 6:e04640 Sagaama A, Brandan SA, Ben Issa T, Issaoui N. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802981>
24. **A Review on Currently Available Potential Therapeutic Options for COVID-19.** *Int. J. Gen. Med.* 2020; 13:443-467 Ohadian Moghadam S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801840>

25. **Antimalarial artemisinin-based combination therapies (ACT) and COVID-19 in Africa: In vitro inhibition of SARS-CoV-2 replication by mefloquine-artesunate.** *Int J Infect Dis* 2020; Gendrot M, Duflot I, Boxberger M *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805422>
26. **Impact of Tocilizumab on mortality and/or invasive mechanical ventilation requirement in a cohort of 206 COVID-19 patients.** *Int J Infect Dis* 2020; Klopfenstein T, Zayet S, Lohse A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798660>
27. **Low Dose Radiation Therapy and Convalescent Plasma: How a Hybrid Method May Maximize Benefits for COVID-19 Patients.** *J Biomed Phys Eng* 2020; 10:387-394H A, I S, J JB *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802787>
28. **In silico molecular investigations of pyridine N-Oxide compounds as potential inhibitors of SARS-CoV-2: 3D QSAR, molecular docking modeling, and ADMET screening.** *J Biomol Struct Dyn* 2020:1-11Ghaleb A, Aoudate A, Ayouchia HBE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799761>
29. **Baricitinib restrains the immune dysregulation in severe COVID-19 patients.** *J. Clin. Invest.* 2020; Bronte V, Ugel S, Tinazzi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809969>
30. **Plasma from recovered COVID-19 subjects inhibits spike protein binding to ACE2 in a microsphere-based inhibition assay.** *J Infect Dis* 2020; Gniffke EP, Harrington WE, Dambrasuskas N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798222>
31. **Could Sumac Be Effective on COVID-19 Treatment?** *J. Med. Food* 2020; Korkmaz H. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816615>
32. **Artificial Intelligence for Rapid Meta-Analysis: Case Study on Ocular Toxicity of Hydroxychloroquine.** *J Med Internet Res* 2020; 22:e20007Michelson M, Chow T, Martin NA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804086>
33. **Hydroxychloroquine for treatment of non-severe COVID-19 patients; systematic review and meta-analysis of controlled clinical trials.** *J Med Virol* 2020; Elsayah HK, Elsokary MA, Elrazzaz MG, ElShafey AH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808712>
34. **Effectiveness of remdesivir for the treatment of hospitalized Covid-19 persons: a network meta-analysis.** *J Med Virol* 2020; Jiang Y, Chen D, Cai D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32813283>
35. **Einnahme von immunsupprimierenden Medikamenten.** *Klinikerzt* 2020; 49:274.
36. **A novel biparatopic hybrid antibody-ACE2 fusion that blocks SARS-CoV-2 infection: implications for therapy.** *MAbs* 2020; 12:1804241Miao X, Luo Y, Huang X *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32804015>
37. **GRL-0920, an Indole Chloropyridinyl Ester, Completely Blocks SARS-CoV-2 Infection.** *mBio* 2020; 11Hattori SI, Higshi-Kuwata N, Raghavaiah J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820005>
38. **The therapeutic potential of colchicine in the complications of COVID19. Could the immunometabolic properties of an old and cheap drug help?** *Metabol Open* 2020; 7:100045Ribeiro SA, Lopes C, Amaral R, Amaral A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808940>
39. **Novel Antiviral Strategies in the Treatment of COVID-19: A Review.** *Microorganisms* 2020; 8Chen SJ, Wang SC, Chen YC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825283>
40. **Critically ill COVID-19 patients: Does remdesivir have an influence on mortality?** *MMW-Fortschritte der Medizin* 2020; 162:62Schumacher B.
41. **Genome-wide computational prediction of miRNAs in severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) revealed target genes involved in pulmonary vasculature and antiviral innate immunity.** *Mol Biol Res Commun* 2020; 9:83-91Saini S, Saini A, Thakur CJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802902>
42. **Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection.** *Mol. Neurobiol.* 2020:1-22Bhatti JS, Bhatti GK, Khullar N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808122>
43. **Antiviral Potential of Nanoparticles-Can Nanoparticles Fight Against Coronaviruses?** *Nanomaterials (Basel)* 2020; 10Gurunathan S, Qasim M, Choi Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32825737>
44. **Recommendations for therapy in pandemic times: Acting (and treating) correctly under pressure to act.** *Notfall und Rettungsmedizin* 2020; 23:382-384Trentzsch H, Flake F, Häske D *et al.*
45. **Pharmacological treatments of COVID-19.** *Pharmacol. Rep.* 2020; Sahebnasagh A, Avan R, Saghafi F *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816200>
46. **The add-on effect of Chinese herbal medicine on COVID-19: A systematic review and meta-analysis.** *Phytomedicine* 2020:153282Luo X, Ni X, Lin J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800699>
47. **Antiviral properties of placental growth factors: A novel therapeutic approach for COVID-19 treatment.** *Placenta* 2020; 99:117-130Joshi MG, Kshersagar J, Desai SR, Sharma S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798764>
48. **Psychiatric Aspects of Chloroquine and Hydroxychloroquine Treatment in the Wake of Coronavirus Disease-2019: Psychopharmacological Interactions and Neuropsychiatric Sequelae.** *Psychosomatics* 2020; Hamm BS, Rosenthal LJ. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800347>
49. **ACE2 as Drug Target of COVID-19 Virus Treatment, Simplified Updated Review.** *Rep Biochem Mol Biol* 2020; 9:97-105Mostafa-Hedeab G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821757>
50. **Bringing into Focus Treatment Limitation and DNACPR Decisions: How COVID-19 has Changed Practice.** *Resuscitation* 2020; Coleman JJ, A HB, Marson EJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827587>
51. **Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.** *Scott. Med. J.* 2020:36933020949219Megaly M, Glogoza M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807019>
52. **Treatment of severe COVID-19 with human umbilical cord mesenchymal stem cells.** *Stem Cell. Res. Ther.* 2020; 11:361Shu L, Niu C, Li R *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811531>
53. **Mesenchymal stromal cells for sepsis and septic shock: Lessons for treatment of COVID-19.** *Stem Cells Transl Med* 2020; Laroye C, Gibot S, Huselstein C, Bensoussan D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808462>
54. **Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review.** *Strahlenther. Onkol.* 2020; Del Castillo R, Martinez D, Sarria GJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816059>

55. **Chloroquine and hydroxychloroquine as a repurposed agent against COVID-19: a narrative review.** *Ther Adv Infect Dis* 2020; 7:2049936120947517 Acharya Y, Sayed A. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821381>
56. **Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:724 Busani S, Tosi M, Mighali P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807241>
57. **A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial.** *Trials* 2020; 21:718 Hinks TSC, Barber VS, Black J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807209>
58. **Effect of Remdesivir on Patients with COVID-19: A Network Meta-Analysis of Randomized Control Trials.** *Virus Res* 2020; 288:198137 Yokoyama Y, Briasoulis A, Takagi H, Kuno T. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827627>

Trials (12 articles)

1. **Prediction of respiratory decompensation in Covid-19 patients using machine learning: The READY trial.** *Comput. Biol. Med.* 2020; 124:103949 Burdick H, Lam C, Mataraso S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798922>
2. **Clinical Outcomes of Early Treatment With Doxycycline for 89 High-Risk COVID-19 Patients in Long-Term Care Facilities in New York.** *Cureus* 2020; 12:e9658 Alam MM, Mahmud S, Rahman MM *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802622>
3. **Considerations for stakeholder engagement and COVID-19 related clinical trials' conduct in sub-Saharan Africa.** *Dev World Bioeth* 2020; Folayan MO, Brown B, Haire B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798320>
4. **COVID-19: age, Interleukin-6, C-reactive protein, and lymphocytes as key clues from a multicentre retrospective study.** *Immun. Ageing* 2020; 17:22 Jurado A, Martín MC, Abad-Molina C *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802142>
5. **Baricitinib restrains the immune dysregulation in severe COVID-19 patients.** *J. Clin. Invest.* 2020; Bronte V, Ugel S, Tinazzi E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809969>
6. **Immune response to SARS-CoV-2 in health care workers following a COVID-19 outbreak: A prospective longitudinal study.** *J Clin Virol* 2020; 130:104575 Fill Malfertheiner S, Brandstetter S, Roth S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805631>
7. **Meta-trial of awake prone positioning with nasal high flow therapy: Invitation to join a pandemic collaborative research effort.** *J Crit Care* 2020; 60:140-142 Li J, Pavlov I, Laffey JG *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799184>
8. **Managing Preterm Infants Born to COVID-19 Mothers: Evidence from a Retrospective Cohort Study in Wuhan, China.** *Neonatology* 2020:1-7 Hu X, Gao J, Wei Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799197>
9. **Renin-angiotensin system antagonists are associated with lower mortality in hypertensive patients with COVID-19.** *Scott. Med. J.* 2020:36933020949219 Megaly M, Glogoza M. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807019>
10. **Low-dose radiotherapy for COVID-19 pneumonia treatment: case report, procedure, and literature review.** *Strahlenther. Onkol.* 2020; Del Castillo R, Martinez D, Sarria GJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816059>
11. **Multi-centre, three arm, randomized controlled trial on the use of methylprednisolone and unfractionated heparin in critically ill ventilated patients with pneumonia from SARS-CoV-2 infection: A structured summary of a study protocol for a randomised controlled trial.** *Trials* 2020; 21:724 Busani S, Tosi M, Mighali P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807241>
12. **A multi-centre open-label two-arm randomised superiority clinical trial of azithromycin versus usual care in ambulatory COVID-19: study protocol for the ATOMIC2 trial.** *Trials* 2020; 21:718 Hinks TSC, Barber VS, Black J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32807209>

Vaccines (16 articles)

1. **Strong homology between SARS-CoV-2 envelope protein and a Mycobacterium sp. antigen allows rapid diagnosis of Mycobacterial infections and may provide specific anti-SARS-CoV-2 immunity via the BCG vaccine.** *Ann. Diagn. Pathol.* 2020; 48:151600 Nuovo G, Tili E, Suster D *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805515>
2. **Replication-Competent Vesicular Stomatitis Virus Vaccine Vector Protects against SARS-CoV-2-Mediated Pathogenesis in Mice.** *Cell Host Microbe* 2020; Case JB, Rothlauf PW, Chen RE *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798445>
3. **Approaches and Challenges in SARS-CoV-2 Vaccine Development.** *Cell Host Microbe* 2020; Dagotto G, Yu J, Barouch DH. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798444>
4. **Immunoinformatics-guided design of an epitope-based vaccine against severe acute respiratory syndrome coronavirus 2 spike glycoprotein.** *Comput. Biol. Med.* 2020; 124:103967 Rakib A, Sami SA, Mimi NJ *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32828069>
5. **Mistrust in biomedical research and vaccine hesitancy: the forefront challenge in the battle against COVID-19 in Italy.** *Eur. J. Epidemiol.* 2020:1-4 Palamenghi L, Barello S, Boccia S, Graffigna G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808095>
6. **Lipid-based nano delivery of Tat-peptide conjugated drug or vaccine-promising therapeutic strategy for SARS-CoV-2 treatment.** *Expert Opin Drug Deliv* 2020; Ansari MA, Almatroudi A, Alzohairy MA *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32820694>
7. **Key Guidelines in Developing a Pre-Emptive COVID-19 Vaccination Uptake Promotion Strategy.** *Int J Environ Res Public Health* 2020; 17 French J, Deshpande S, Evans W, Obregon R. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32823775>

8. **Convergence between global BCG vaccination and COVID-19 pandemic.** *J Med Virol* 2020; Islam MZ, MK EZ, Al-Bari MAA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32827313>
9. **Paediatric activities and adherence to vaccinations during the COVID-19 epidemic period in Tuscany, Italy: a survey of paediatricians.** *J. Prev. Med. Hyg.* 2020; 61:E125-e129Bechini A, Garamella G, Giammarco B *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32802994>
10. **On Occasion of the COVID-19 Pandemic - One of the Most Important Dilemma: Vaccinate or Not?** *Med Arch* 2020; 74:164-167Masic I, Gerc V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32801428>
11. **Progress in Developing Inhibitors of SARS-CoV-2 3C-Like Protease.** *Microorganisms* 2020; 8Li Q, Kang C. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32824639>
12. **Therapeutic Strategies in the Development of Anti-viral Drugs and Vaccines Against SARS-CoV-2 Infection.** *Mol. Neurobiol.* 2020:1-22Bhatti JS, Bhatti GK, Khullar N *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32808122>
13. **COVID-19: Underpinning Research for Detection, Therapeutics, and Vaccines Development.** *Pharm Nanotechnol* 2020; Aljabali AAA, Bakshi HA, Satija S *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811406>
14. **Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development.** *Transbound Emerg Dis* 2020; Begum J, Mir NA, Dev K *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32815655>
15. **The effect of Bacillus Calmette-Guérin (BCG) vaccination in preventing severe infectious respiratory diseases other than TB: Implications for the COVID-19 pandemic.** *Vaccine* 2020; Yitbarek K, Abraham G, Girma T *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32798142>
16. **COVID-19 Vaccine: A comprehensive status report.** *Virus Res.* 2020:198114Kaur SP, Gupta V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800805>

Women – pregnancy (16 articles)

1. **First follow-up of art pregnancies in the context of the COVID-19 outbreak.** *Eur. J. Obstet. Gynecol. Reprod. Biol.* 2020; 253:71-75Mayeur A, Binois O, Gallot V *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32805629>
2. **COVID-19 During Pregnancy and Puerperium - A Review by the Austrian Society of Gynaecology and Obstetrics (OEGGG).** *Geburtshilfe Frauenheilkd.* 2020; 80:813-819Klaritsch P, Ciresa-König A, Pristauz-Telsnigg G. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32817988>
3. **A picture of medically assisted reproduction activities during the COVID-19 pandemic in Europe.** *Hum Reprod Open* 2020; 2020:hoaa035Vermeulen N, Ata B, Gianaroli L *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821857>
4. **Women's perspective on the COVID-19 pandemic: Walking into a post-peak phase.** *Int J Cardiol* 2020; Sabatino J, Moscatelli S, Rustamova Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32800917>
5. **Attitudes and collateral psychological effects of COVID-19 in pregnant women in Colombia.** *Int J Gynaecol Obstet* 2020; Parra-Saavedra M, Villa-Villa I, Pérez-Olivo J *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799318>
6. **Restructuring fetal medicine services in a low-resource setting during the COVID-19 pandemic: Experience from a tertiary care fetal medicine center.** *Int J Gynaecol Obstet* 2020; Rana A, A KS, Dadhwal V. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32810903>
7. **Clinical characteristics, prognostic factors, and maternal and neonatal outcomes of SARS-CoV-2 infection among hospitalized pregnant women: a systematic review.** *Int J Gynaecol Obstet* 2020; Turan O, Hakim A, Dashraath P *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32816307>
8. **COVID-19 and maternal, fetal and neonatal mortality: a systematic review.** *J Matern Fetal Neonatal Med* 2020:1-6Hessami K, Homayoon N, Hashemi A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799712>
9. **COVID-19 in pregnancy: possible mechanisms not to be discounted.** *J Matern Fetal Neonatal Med* 2020:1-4Zelop CM, Bonney EA. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32811230>
10. **Medical Abortion Care During a Pandemic.** *J Patient Exp* 2020; 7:291-292Baill IC. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32821783>
11. **COVID-19 in pregnancy: creating an outpatient surveillance model in a public hospital system.** *J. Perinat. Med.* 2020; Trostle ME, Silverstein JS, Tubridy E *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32809968>
12. **The level of anxiety in infertile women whose ART cycles are postponed due to the COVID-19 outbreak.** *J. Psychosom. Obstet. Gynaecol.* 2020:1-8Tokgoz VY, Kaya Y, Tekin AB. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32812477>
13. **Managing Preterm Infants Born to COVID-19 Mothers: Evidence from a Retrospective Cohort Study in Wuhan, China.** *Neonatology* 2020:1-7Hu X, Gao J, Wei Y *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32799197>
14. **Practical recommendations in the obstetrical patient with a COVID-19 infection.** *Rev. Esp. Anesthesiol. Reanim.* 2020; Guasch E, Brogly N, Manrique S. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814634>
15. **Consolidation of obstetric services in a public health emergency.** *Semin. Perinatol.* 2020:151281Campbell KH, Pettker CM, Goffman D. <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814629>
16. **Male Fertility and the COVID-19 Pandemic: Systematic Review of the Literature.** *World J Mens Health* 2020; Khalili MA, Leisegang K, Majzoub A *et al.* <http://www.ncbi.nlm.nih.gov/pubmed/?term=32814369>

to subscribe click [here](#)
